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Abstract 
The ovarian follicle is the major site of sex steroid production in females, hormones that are 
crucially required for normal ovarian function and female reproduction. The biosynthesis and 
metabolism of androgens by individual follicles throughout development has been difficult to 
study because androgens and androgen precursors are structurally similar molecules present in 
low concentrations. Androgens have dual dose-dependent effects on folliculogenesis, with 
reduced or exaggerated levels of androgens being deleterious for follicle development. Few 
studies have shown the whole spectrum of androgen action using a single experimental model.  
 
Here we employed tandem mass spectrometry to measure sex steroid production by murine 
follicles, cultured in an alginate encapsulated, 3-dimensional model. We showed developmental 
stage-dependant FSH-stimulated androgen and oestrogen secretion. When follicles were 
cultured in the presence of non-aromatisable  5a-dihydrotestosterone, endogenous androgen 
production decreased. Following exposure to the universal sex steroid precursor 
dehydroepiandrosterone, high androgen generation was achieved by immature follicles. We 
described androgen receptor-mediated growth-promoting effects of androgen supplementation 
in developing follicles. However, when androgen exposure was gradually increased, we first 
observed suppression of oocyte development, followed by stagnation of follicle growth.  
 
These data provide the rationale for androgen treatment in women with low ovarian reserve, 
but call for caution as over-replacement might cause harm to oocyte quality. Furthermore, this 
study describes mechanisms which might contribute to the follicular developmental arrest that 
is observed in androgen excess conditions such as polycystic ovary syndrome. 
 
 
         Acknowledgements 
 III 
Acknowledgements 
I would like to express my sincere gratitude to my supervisors, Prof. Wiebke Arlt and Prof. 
Teresa Woodruff, for their support, guidance and mentorship throughout this thesis. Their 
global vision and attention for detail have learned me a lot. Thank you to my co-supervisor Dr. 
Jackson Kirkman-Brown for his encouragement and availability.  
 
I am very grateful for the wonderful opportunity I was given to train in the United States before 
conducting my research in the United Kingdom. The nine months spend in the Woodruff Lab 
in Chicago, and the participation in the Frontiers in Reproduction course have allowed me to 
engage with an exciting reproductive research community and to meet new friends. Moving 
with our family helped us to develop independence, maturity and adaptability. A great 
experience we will never forget! 
 
I would like to dedicate this thesis to my husband Charles-Emmanuel and to our sons Augustin, 
Baudouin, Grégoire, Ambroise and Adrien. Without Charles-Emmanuel’s love and support, his 
enthusiasm and confidence in this work, none of this would have been possible!   
 
           Table of Content 
 
 IV 
1 Table of Contents 
1	 General	Introduction	.............................................................................................................	1	
1.1	 Androgen	synthesis	and	metabolism	in	females	.............................................................	2	1.1.1	 Androgen	biosynthesis	..........................................................................................................................	2	1.1.2	 Androgen	metabolism	in	peripheral	target	tissues	...................................................................	8	1.1.3	 Measuring	androgen	levels	................................................................................................................	11	1.1.4	 The	role	of	androgens	in	women	.....................................................................................................	15	
1.2	 Androgen	signaling	..................................................................................................................	19	1.2.1	 The	androgen	receptor	........................................................................................................................	19	1.2.2	 Non-genomic	androgen	signaling	...................................................................................................	20	1.2.3	 Antiandrogens	.........................................................................................................................................	21	
1.3	 Physiology	of	the	ovary	...........................................................................................................	22	1.3.1	 Function	and	structure	of	the	ovary	..............................................................................................	22	1.3.2	 Folliculogenesis	and	oogenesis	in	vivo	..........................................................................................	24	1.3.3	 Reproductive	cycle	................................................................................................................................	35	1.3.4	 Folliculogenesis	and	oogenesis	in	vitro	........................................................................................	39	
1.4	 Effect	of	androgens	on	the	on	the	different	stages	of	follicular	development	.....	44	1.4.1	 Pharmacological	studies	.....................................................................................................................	44	1.4.2	 Genetic	studies	........................................................................................................................................	48	
1.5	 Androgen	excess	and	polycystic	ovary	syndrome	(PCOS)	..........................................	49	1.5.1	 Introduction	to	PCOS	............................................................................................................................	49	1.5.2	 Etiology	and	pathophysiology	of	PCOS	.........................................................................................	49	1.5.3	 Diagnostic	criteria	..................................................................................................................................	52	1.5.4	 Genetics	of	PCOS	.....................................................................................................................................	54	1.5.5	 Clinical	signs	and	symptoms	of	PCOS	............................................................................................	55	1.5.6	 Ovarian	manifestations	of	PCOS	......................................................................................................	61	
           Table of Content 
 
 V 
1.5.7	 Animal	models	of	female	androgen	excess	.................................................................................	68	
1.6	 Reproductive	dysfunction	in	androgen	deficiency	syndromes	................................	73	1.6.1	 Adrenal	androgen	deficiency	............................................................................................................	73	1.6.2	 Physiological	androgen	deficiency	.................................................................................................	77	
1.7	 Research	hypothesis	and	aims	of	the	study	.....................................................................	81	1.7.1	 The	endogenous	sex	steroid	production	by	follicles	in	physiological	conditions	......	81	1.7.2	 The	effect	of	exogenous	androgens	on	endogenous	follicular	steroid	production	...	82	1.7.3	 The	androgen	receptor-mediated	effects	of	androgens	on	follicle	development	......	83	1.7.4	 The	effects	of	increasing	androgen	provision	to	the	growing	follicle	.............................	83	
2	 Methods	...................................................................................................................................	85	
2.1	 Murine	Encapsulated	In	Vitro	Follicle	Culture	...............................................................	86	2.1.1	 Animals	.......................................................................................................................................................	86	2.1.2	 Follicle	isolation	procedure	...............................................................................................................	86	2.1.3	 Follicle	encapsulation	...........................................................................................................................	87	2.1.4	 Follicle	plating	and	imaging	...............................................................................................................	90	
2.2	 In	vitro	follicle	maturation	....................................................................................................	92	2.2.1	 Removal	of	follicles	from	alginate	beads	.....................................................................................	92	2.2.2	 Follicle	maturation	medium	..............................................................................................................	92	2.2.3	 Oocyte	quality	and	maturation	status	...........................................................................................	93	
2.3	 Neonatal	mouse	ovarian	culture	.........................................................................................	94	
2.4	 Ovarian	histology	and	follicle	counting	............................................................................	95	
2.5	 Steroid	analysis	by	Liquid	Chromatography	Mass	Spectrometry	............................	96	
2.6	 Gene	expression	studies	.........................................................................................................	97	2.6.1	 RNA	extraction	........................................................................................................................................	97	2.6.2	 RNA	quality	examination	....................................................................................................................	98	2.6.3	 Complementary	DNA	(cDNA)	generation	and	reverse	transcription	.............................	99	2.6.4	 Real-time	Polymerase	Chain	Reaction	(RT-PCR)	..................................................................	100	
           Table of Content 
 
 VI 
2.7	 Statistical	Analysis	................................................................................................................	102	
3	 In	vitro	folliculogenesis,	oogenesis	and	steroidogenesis	under	physiological	
conditions	......................................................................................................................................	103	
3.1	 Introduction	............................................................................................................................	104	
3.2	 Methods	.....................................................................................................................................	108	3.2.1	 Research	strategy	................................................................................................................................	108	3.2.2	 Murine	encapsulated	in	vitro	follicle	growth	(eIVFG)	.........................................................	108	3.2.3	 In	vitro	follicle	maturation	..............................................................................................................	109	3.2.4	 RNA	extraction,	reverse	transcription	and	real-time	PCR	................................................	109	3.2.5	 Follicle	culture	steroid	extraction	and	LC-MS/MS	analysis	..............................................	110	3.2.6	 Statistical	analysis	...............................................................................................................................	111	
3.3	 Results	.......................................................................................................................................	111	3.3.1	 Physiological	follicle	development	in	the	alginate	encapsulated	in	vitro	follicle	growth	system	(eIVFG)	.....................................................................................................................................	111	3.3.2	 Endogenous	steroid	synthesis	under	physiological	culture	conditions	......................	117	
3.4	 Discussion	................................................................................................................................	121	
4	 Effects	of	exogenous	androgen	exposure	and	antagonism	on	the	developing	
follicle	.............................................................................................................................................	125	
4.1	 Introduction	............................................................................................................................	126	
4.2	 Methods	.....................................................................................................................................	127	4.2.1	 Research	strategy	................................................................................................................................	127	4.2.2	 Follicle	treatments	..............................................................................................................................	128	4.2.3	 In	vitro	follicle	culture	and	oocyte	maturation	.......................................................................	128	4.2.4	 Real-time	qPCR	analysis	of	target	genes	...................................................................................	129	4.2.5	 LC-MS/MS	analysis	of	steroid	hormones	..................................................................................	130	4.2.6	 Peptide	hormone	measurement	...................................................................................................	130	4.2.7	 Statistical	analysis	...............................................................................................................................	130	
           Table of Content 
 
 VII 
4.3	 Results	.......................................................................................................................................	131	4.3.1	 Follicle	growth,	survival	and	oocyte	maturation	..................................................................	131	4.3.2	 Exogenous	androgen	exposure	and	antagonism	reveals	an	androgen	receptor-mediated	autocrine	feedback	loop	in	the	follicle	..................................................................................	137	
4.4	 Discussion	................................................................................................................................	141	
5	 Effects	of	increasing	concentrations	of	exogenous	androgens	and	oestrogens	
on	follicular	development	.......................................................................................................	145	
5.1	 Introduction	............................................................................................................................	146	
5.2	 Methods	.....................................................................................................................................	148	5.2.1	 Research	strategy	................................................................................................................................	148	5.2.2	 Follicle	treatments	..............................................................................................................................	148	5.2.3	 In	vitro	follicle	culture	and	oocyte	maturation	.......................................................................	149	5.2.4	 Neonatal	mouse	ovarian	culture	..................................................................................................	150	5.2.5	 Realtime	qPCR	analysis	....................................................................................................................	150	5.2.6	 LC-MS/MS	steroid	hormone	analysis	.........................................................................................	150	5.2.7	 Inhibin	B	measurement	....................................................................................................................	151	5.2.8	 Statistical	analysis	...............................................................................................................................	151	
5.3	 Results	.......................................................................................................................................	152	5.3.1	 The	androgen	precursor	DHEA	is	converted	to	active	sex	steroids	in	the	developing	follicle	 ……………………………………………………………………………………………………………………...152	5.3.2	 Effects	of	increasing	concentrations	of	exogenous	androgens	and	oestrogens	on	follicular	growth	and	survival	.......................................................................................................................	158	5.3.3	 Effects	of	increasing	concentrations	of	exogenous	androgens	and	oestrogens	on	oocyte	development	and	quality	..................................................................................................................	161	5.3.4	 The	impact	of	increasing	androgen	administration	on	ovarian	follicular	dynamics	in	
vitro	 ……………………………………………………………………………………………………………………….164	
5.4	 Discussion	................................................................................................................................	167	
           Table of Content 
 
 VIII 
6	 Final	conclusions	and	future	directions	.....................................................................	171	
6.1	 Final	conclusions	...................................................................................................................	172	6.1.1	 Endogenous	steroid	production	and	androgen	metabolism	in	the	developing	follicle	in	culture	.................................................................................................................................................................	172	6.1.2	 Effect	of	increasing	androgen	supplementation	on	follicle	development	and	oocyte	maturation	.............................................................................................................................................................	174	
6.2	 Future	directions	...................................................................................................................	175	6.2.1	 Steroid	analysis	in	murine	target	tissues	of	sex	steroid	hormones	..............................	175	6.2.2	 Steroid	profiling	in	human	follicles	during	in	vitro	alginate	encapsulated	growth	176	
7	 References	............................................................................................................................	177	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           List of Figures  
 IX 
List of figures 
Figure 1-1 Steroidogenesis in the adrenal glands, divided in the zona glomerulosa (green), 
fasciculata (yellow), and reticularis (blue), with synthesis of mineralocorticoids, 
glucocorticoids and adrenal androgens respectively. DHEA is taken up by peripheral 
tissues, and metabolised to active androgens (dark blue) and oestrogens (pink). Reprinted 
with kind permission of Prof. Wiebke Arlt, University of Birmingham ........................... 3	
Figure 1-2 Two cell, two gonadotropin concept of oestrogen synthesis in the follicle focusing 
on steroidogenic enzyme expression in granulosa and theca cells: steroidogenic acute 
regulatory protein (StAR), cholesterol side-chain cleavage cytochrome P450 (CYP11A1), 
17-hydroxylase (CYP17A1), 3b-hydroxysteroid dehydrogenase (HSD3B2) and 17b-
hydroxysteroid dehydrogenase (17HSD1). CYP17A1 expression is induced solely in theca 
cells under the influence of LH and CYP19A1 (aromatase) expression is found uniquely 
in granulosa cells, stimulated by FSH. ............................................................................... 6	
Figure 1-3 Two cell, two gonadotrophin hypothesis and neuro-endocrine axis. Pituitary LH 
stimulates theca cells to produce androstenedione, that diffuses to the granulosa cells for 
conversion to estradiol under FSH-stimulation. The sex steroids feedback to the 
hypothalamo-pituitary unit to regulate gonadotrophin releasing hormone (GnRH) and LH 
secretion. ............................................................................................................................ 7	
Figure 1-4 Concentrations of DHEAS as function of age. Derived from data in Orentreich et al, 
1984. Reprinted from Miller and Auchus with kind permission of Endocrine Society, 
Copyright 2011. ................................................................................................................. 8	
Figure 1-5 Peripheral sex steroid metabolism. Circulatory DHEA is taken up by peripheral 
tissues and converted to androstenedione, which can be either converted to testosterone or 
aromatized to estrone (E1). Testosterone can be metabolized to the more potent 
           List of Figures  
 X 
dihydrotestoserone (DHT) or aromatized to estradiol (E2). The enzymes responsible for 
these reactions are mentioned in red. ................................................................................. 9	
Figure 1-6 HSDs interconvert inactive and active steroids. The direction of the reaction in vivo 
depends mainly on the availability of the pyridine nucleodide NAD(P)H/NAD(P)+ 
cofactor. ........................................................................................................................... 10	
Figure 1-7 Mechanism of action of Enzalutamide (MDV). DHT binds the AR and induces the 
formation of a co-activator binding platform (AF1), nuclear translocation and transcription 
of AR-responsive genes. Enzalutamide (Enz) inhibits the formation of AF1 and prevents 
nuclear translocation, making it a potent antiandrogen. Adapted from Helsen et al, with 
kind permission of BioScientifica Limited. Copyright 2014. .......................................... 22	
Figure 1-8 Schematic overview of the ovary, showing the main cell types and follicle stages. 
The follicle consists of an oocyte or ovum surrounded by granulosa cells and theca cells. 
Preovulatory follicles contain a central fluid-fuild space called an antrum. After ovulation, 
the somatic cells differentate in a corpus luteum. The central area of the ovary is the 
medulla, the outer layer the cortex, surrounded by the ovarian surface epithelium. 
Reprinted from Sexual bodies: anatomy and physiology, by Marcus Tye with kind 
permission of Flat World Knowledge. ............................................................................. 23	
Figure 1-9 Prenatal and early postnatal ovarian follicle development in the mouse. Primordial 
germ cells increase in number and migrate to the bipotential gonad, where they 
differentiate to oocytes. Closely after birth, clusters or syncytia of germ cells break down 
to form primordial follicles. Adapted and reprinted from Richards et al, with kind 
permission of American Society for Clinical Investigation, Copyright 2010. ................ 26	
Figure 1-10 Presumed roles of intra-oocyte phosphoinoside 3-kinase (PI3K) signaling in 
controlling the fate of the primordial follicle pool. An optimal PI3K balance maintains 
follicle survival during dormancy, elevated PI3K signaling leads to follicle activation, 
           List of Figures  
 XI 
while suppressed PI3K signaling leads to follicle loss. Adapted and reprinted from Zheng 
et al, with kind permission of Elsevier, Copyright 2012. ................................................ 27	
Figure 1-11 Schematic overview of the different stages of folliculogenesis. AMH, Inhibin B 
and Estradiol secretion and interaction with hypothalamo-pituitary axis. Reprinted from 
Visser et al, with kind permission from Macmillan Publishers Ltd: Nature Reviews. 
Copyright 2012. ............................................................................................................... 31	
Figure 1-12 Schematic overview of molecular and cellular development of human oocytes. 
Oocyte development is initiated by oocyte growth in small follicles. Competence to 
resume meiosis is reached shortly before ovulation. Transcription becomes silenced after 
resumption of meiosis. Protein synthesis increases to a plateau when the oocyte is fully 
grown. Adapted and reprinted from Gosden and Lee with kind permission from the 
American Society for Clinical Investigation. Copyright 2010. ....................................... 33	
Figure 1-13 Schematic image of oocyte maturation and chromosome configuration. Following 
germinal vesicle envelope breakdown, the spindle assembles and moves to the surface of 
the oocyte. Half of the homologous chromosomes segregates and is extruded in the polar 
body. Around the remaining chromosomes a spindle assembles. The egg arrests in 
metaphase II until fertilization. Adapted from Clift and Schuh, with kind permission from 
Nature Publishing Group. Copyright 2013. ..................................................................... 34	
Figure 1-14 The menstrual cycle, with circulating levels of gonadotrophins (LH and FSH), 
ovarian steroid hormones (estradiol, progesterone) and cyclical endometrial changes, 
during the follicular and luteal phase. Adapted and reprinted with kind permission from 
UpToDate. ........................................................................................................................ 37	
Figure 1-15 (a) Secondary mouse follicle encapsulated in an alginate bead (edge of bead 
indicated by arrows). (b) Follicles stained for viability 1 day after encapsulation are 
healthy. (c,d) Follicles cultured in alginate beads (c) maintain their morphology at day 4 
of culture, while follicles cultured on 2D substrates (d) have a disrupted follicular 
           List of Figures  
 XII 
architecture. Scale bar = 30 µm. Reprinted from Kreeger et al, with kind permission of 
Pergamon, Copyright 2006. ............................................................................................. 41	
Figure 1-16 Alginate is a polysaccharide, derived from seaweed, that crosslinkes in the presence 
of calcium to form a solid gel, used to encapsulate ovarian follicles. Courtesy to the 
Woodruff Lab. .................................................................................................................. 41	
Figure 1-17 (A) After 8 days of culture, immature follicle reached the pre-ovulatory stage (B) 
an outer theca cell layer indicated by 3b-hydroxysteroid dehydrogenase staining. (C) 
Meiotically arrested cultured oocytes (D) Resumption of meiosis after exogenous HCG 
stimulation. (E) Metaphase II oocytes fertilized in vitro, and (F) resulting in live offspring 
after transfer into the oviduct of pseudopregnant mouse. Bar 1⁄4 100 mm (A, B), 50 mm 
(C–E). Reprinted from Xu et al, with kind permission of Mary Ann Liebert INC 
Publishers, Copyright 2006. ............................................................................................. 42	
Figure 1-18 Current understanding of PCOS pathophysiology. Androgen excess and insulin 
resistance perpetuate the vicious cycle of increased ovarian and extra-ovarian androgen 
production and adipose tissue oestrogen generation. The latter results in deficient 
gonadotropin secretion, contributing to the ovarian hyperandrogenenism and the deficient 
dominant follicle selection, leading to chronic anovulation. Obesity reinforces the vicious 
cycle. ................................................................................................................................ 52	
Figure 1-19 Modified Ferriman-Gallwey score. Terminal hair growth is scored from 1 
(minimally present) to 4 (equivalent to hairy male), in 9 body areas: upper lip, chin, chest, 
arm, upper and lower abdomen, lower back and tights. If no terminal hair is present in a 
specific area, the score is 0. A sum of scores > 8, is considered as clinically relevant 
hirsutism. Reprinted from Yildiz, with kind permission of Oxford University Press, 
Copyright 2010. ............................................................................................................... 57	
Figure 1-20 Working model for follicular-stromal interactions in the pathogenesis of PCOS. 
Follicular arrest results from the imbalance between androgens, FSH and AMH. 
           List of Figures  
 XIII 
Circulating FSH-levels are inappropriately low and dominant follicle selection fails. The 
PCOS cortex shows signs of remodeling, partly mediated by increased local androgen 
concentrations, and maintained by increased cortical blood flow. Reprinted and adapted 
from Lebbe et al, with kind permission of Oxford University Press. Copyright 2013. ... 66 
Figure 2-1 Mouse ovarian dissection; excision of the female reproductive tract, followed by 
removal of the ovary from its bursa under the dissection scope. Courtesy of the laboratory 
of Dr.T.K. Woodruff, Northwestern University Chicago (Follicle handbook_2014). .... 87	
Figure 2-2 Schematic of a mouthpipette. Courtesy of the laboratory of Dr. T.K.Woodruff 
(follicle handbook_2014). ................................................................................................ 89	
Figure 2-3 Follicle growth and development during the 6-days of alginate-encapsulated culture. 
Antrum formation start around day 4 in basal conditions. Scale-bar 100 µm ................. 92	
Figure 2-4 Oocyte quality and nuclear maturation following in vitro maturation at the end of 
culture. Completion of the first meiotic division is visualised by the presence of the first 
polar body in the perivitilline space (white arrow).Scale bar 100 µm. ............................ 94 
Figure 3-1 Androgen and oestrogen synthesis throughout the different stages of follicle 
development. Androgens production occurs in the theca cells, from the secondary stage 
onward, and conversion to oestrogens occurs in the granulosa cells via aromatase 
(CYP19A1) activity in the antral follicle. Reprinted and adapted from Lebbe and 
Woodruff, with kind permission of Oxford University Press, copyright 2013. ............ 105	
Figure 3-2 Estradiol, androstenedione and progesterone production by two-layered (A-C) and 
multilayered (D-F) secondary follicles during in vitro alginate encapsulated culture, with 
3%, 1.5%, 0.7%, oxidated and irradiated alginate . Steroids are measured by 
immunoassays in culture medium. Reprinted from (West et al., 2007) with kind permission 
from Pergamon, copyright 2007. ................................................................................... 107	
           List of Figures  
 XIV 
Figure 3-3 Light-microscopic representative image of a multi-layered secondary follicle at the 
start of culture, containing an oocyte, several layers of granulosa cells, and some attached 
ovarian stroma cells; scale-bar:50 µm. .......................................................................... 112	
Figure 3-4 Follicle growth of follicles during eIVFG in basal conditions. Data are expressed as 
mean ± SD. Follicle numbers are outlined in Table 3-2. ............................................... 113	
Figure 3-5 Representative light-microscopic images of small (left) and large (right) antral 
follicles, grown in alginate beads allowing for 3-dimensional growth expansion and 
maintenance of in vivo follicle architecture. The antrum is the dark area that first displaces 
the ovary, and later fills the entire follicle centre, hiding the oocyte for the sight. Scale-
bar: 50 µm ...................................................................................................................... 114	
Figure 3-6 Follicle survival at day 0, 2, 4 and 6 of culture, in basal condition. Data are expressed 
as mean (SD). ................................................................................................................. 115	
Figure 3-7 Oocyte meiotic maturation in standard conditions (n=26). Mature oocytes have 
extruded a polar body, while immature oocytes are healthy gametes arrested in Meiosis I. 
Dead or shrunken oocytes are considered degenerated.Data are expressed as mean (SD)
........................................................................................................................................ 116	
Figure 3-8 Steroid hormone production by the cultured follicles in physiological conditions, 
measured by LC-MS/MS, in pooled follicle culture medium (72-105 follicles) at day 2, 4 
and 6 of culture, and normalised to 100 follicles. Data are expressed as mean ± SD (A) 
Schematic showing the steroidogenic pathway, with colour coding of the different steroids 
assessed in culture medium: Progesterone (Prog), Dehydroepiandrosterone (DHEA), 
Androstenedione (A’dione), Testosterone, Dehydrotestosterone (DHT), Estrone (E1) and 
Estradiol (E2). (B) Endogenous steroid production in basal conditions. ....................... 119	
Figure 3-9 Schematic representation of steroidogenic pathway in the follicle with indication of 
enzymes which gene-expression was upregulated during in vitro follicle development 
           List of Figures  
 XV 
(indicated by an asterix), ensuring increasing active sex steroid and progesterone synthesis 
with ongoing follicle maturation. ................................................................................... 121 
Figure 4-1 Representative light-microscopic images of control follicles, DHT- and MDV-
treated follicles at day 0, 2, 4 and 6 of culture. DHT-treated follicles exhibited increased 
growth, and MDV-treated follicles decreased growth compared with control follicles. 132	
Figure 4-2 Follicle diameters at the start, and at day 2, 4 and 6 of culture for control follicles 
(dotted line), follicles treated with 25 nM DHT, and follicles exposed to enzalutamide 
(MDV). DHT-exposed follicles had an overall increased follicle growth, while MDV-
treated follicles exhibited overall growth restriction, to a similar extent. Data are expressed 
as mean ± SD for 89-156 follicles. ................................................................................ 132	
Figure 4-3 Inhibin-B concentrations, measured by ELISA, in DHT-, MDV- and untreated 
follicles, on day 2,4, and 6 of culture. Data represent mean ± SD for 6 follicles for each 
treatment condition. ....................................................................................................... 133	
Figure 4-4 Antrum formation in control follicles (dotted line), DHT 25 nM and MDV-follicles. 
DHT follicles achieve earlier and more complete antrum formation, compared with 
controls, and MDV-treated follicles have delayed antrum formation. Data are expressed 
as mean ± SD for 7-10 experiments. * <0.05, ***<0.001, ****< 0.0001 for comparison of 
control to DHT and MDV respectively ......................................................................... 134	
Figure 4-5 Follicle survival at the end of culture, in control follicles, follicles treated with 25 
nM DHT, and follicles exposed to the AR-antagonist enzalutamide (MDV). DHT-exposed 
follicles have increased follicle survival (P<0.05). Data are expressed as mean ± SD for 7-
10 independent experiments.* ≤0.01 ............................................................................. 135	
Figure 4-6 Oocyte status in control follicles, follicles treated with 25 nM DHT and follicles 
treated with MDV, with regard to size (left) and nuclear maturation (right). No difference 
were observed in either conditions. Data are expressed as mean ± SD for nuclear 
           List of Figures  
 XVI 
maturation, oocyte size is presented in box and whisker plots with boxes representative of 
the interquartile range and whiskers of the 5th and 95th centile, respectively, for at least 3 
experiments, 14-30 oocytes per group. .......................................................................... 135	
Figure 4-7 Steroid profile in control follicles, and follicles treated DHT 25 nM ± androgen-
receptor antagonist MDV (enzalutamide) at day 2, day 4 and day 6 of culture, measured 
by LC-MS/MS in pooled conditioned medium from 32-97 follicles. Data are normalized 
to 100 follicles, and expressed as mean ± SD (n=3 measurements for control and DHT, 2 
experiments for DHT+MDV condition). The color coding refers to Figure 3-9: 
Progesterone (yellow), DHEA (light green-blue), Androstenedione (dark green-blue), 
Testosterone (light blue), Dehydrotestosterone (dark blue), Estrone (light pink) and 
Estradiol (dark pink). ..................................................................................................... 140 
Figure 5-1 Steroid hormone profile of follicle cultured with supplementation of 100 nM DHEA, 
measured by LC-MS/MS, in pooled follicle culture medium (32-41 follicles) at day 2, 4 
and 6 of culture, and normalised to 100 follicles. Data are expressed as mean ± SD (2 
measurements). Upper panel: Schematic showing the steroidogenic pathway, with colour 
coding of the different steroids assessed in culture medium: Progesterone (Prog), 
Dehydroepiandrosterone (DHEA) (exogenous addition), Androstenedione (A’dione), 
Testosterone, Dehydrotestosterone (DHT), Estrone (E1) and Estradiol (E2). .............. 153	
Figure 5-2 Effect of increasing DHEA supplementation (100, 200 and 500nM) on follicular 
steroid hormone production, compared with control conditions. Steroids were measured 
LC-MS/MS, in pooled follicle culture medium (32-83 follicles), and normalised to 100 
follicles. Data are expressed as mean ± SD (3 measurements for control and DHEA 200 
nM and 2 measurements for DHEA 100 and 500 nM conditions. The color coding refers 
to Figure 5-1. .................................................................................................................. 155	
Figure 5-3 Androgen/oestrogen ratio on day 6, for follicles treated with 100, 200 and 500 nM 
DHEA compared with untreated follicle; * p<0.05, ** p<0.01 ..................................... 156	
           List of Figures  
 XVII 
Figure 5-4 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus control (dotted lines) on follicle size at day 0, 2, 
4 and 6 of culture. Data (n=31-156 follicles/condition) are expressed as mean ± SD for 
follicle diameter; **** p< 0.0001. ................................................................................. 159	
Figure 5-5 Inhibin-B levels measured by ELISA in follicles treated with DHEA (100 and 
500nM), DHT (25 and 50 nM) and E2 (25nM) at day 2, 4 and 6. Data are represented by 
mean ± SD for n=6 follicles per condition. .................................................................... 160	
Figure 5-6 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus control (dotted lines) on antrum formation rates 
at day 0, 2, 4 and 6 of culture. Data (n=31-156 follicles/condition) are expressed as mean 
± SD; ***p< 0.001, **** p< 0.0001. ............................................................................. 160	
Figure 5-7 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus control (dotted lines) on follicle survival rates at 
day 0, 2, 4 and 6 of culture. Data (n=31-156 follicles/condition) are expressed as mean ± 
SD, * p<0.05, ** p<0.01. ............................................................................................... 161	
Figure 5-8 Oocyte status in control follicles, follicles treated with 100 nM or 200 nM DHEA, 
with regard to (A) oocyte size and (B) oocyte nuclear maturation, for 24-48 oocytes per 
condition. Data are expressed as mean ± SD for nuclear maturation, oocyte size is 
presented in box and whisker plots with boxes representative of the interquartile range and 
whiskers of the 5th and 95th centile, respectively, for at least 3 experiments, 24-48 oocytes 
per group. *** p <0.001, **** p<0.0001 ....................................................................... 162	
Figure 5-9 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus untreated follicles on oocyte size following in 
vitro maturation at day 6 of culture. Data are expressed as mean ± SD for nuclear 
maturation, oocyte size is presented in box and whisker plots with boxes representative of 
           List of Figures  
 XVIII 
the interquartile range and whiskers of the 5th and 95th centile, respectively, for at least 3 
experiment, 24-48 oocytes/condition, * p<0.05, **** p<0.0001. ................................. 163	
Figure 5-10 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus untreated follicles on oocyte nuclear maturation 
following in vitro maturation at day 6 of culture. Data (n=24-48 oocytes/condition) are 
expressed as mean ± SD for meiosis II rate , * p<0.05, *** p<0.001, **** p<0.0001. 163	
Figure 5-11 Morphology of untreated and DHT-treated ovaries at the end of culture. (A) 
Brightfield microscope image of a control ovary at magnification 40 ,and  (B) of a 10-7M 
DHT-treated ovary. (C) Haematoxylin-eosin (HE) stained section of a control ovary and 
(D) of a 10-7M DHT-treated ovary at magnification 40. Scale bar = 100 µm. The number 
of primordial follicles and total number of growing follicles was similar between both 
groups. ............................................................................................................................ 165	
Figure 5-12 Follicle counts in ovaries in untreated ovaries, and ovaries cultured in presence of  
10-7 or 10-8M DHT. The number of different follicle classes was counted per ovary, and 
expressed as % of total follicles. Data represent mean ± SD (n=3 ovaries per treatment 
group). No significant differences were observed between groups for the different follicle 
classes, except for secondary follicles, which were decreased in 10-7 M DHT ovaries and 
increased in 10-8M ovaries. ............................................................................................ 166	
Figure 5-13 Follicle dynamics in the growing follicle pool. Primary, secondary and atretic 
follicles, expressed as percentage of total growing follicles, for untreated ovaries and 
ovaries cultured in the presence of 10-8 and 10-7M DHT. Ovaries exposed to the lower 
concentrations of DHT, have a decreased amount of atretic follicles compared with 
controls, while exposure to higher concentrations of DHT decreased the number of 
secondary follicles compared with controls and lower doses of DHT. ......................... 166 
           List of Tables 
 XIX 
	
 
List of tables 
Table 1-1 Characteristics of human and mouse 3b-HSD involved in active biosynthesis of 
steroid hormones .............................................................................................................. 10	
Table 1-2 Characteristics of the mouse estrous cycle, with regard to vaginal smear cytology and 
levels of pituitary and ovarian hormones (based on (Caligioni, 2009)) .......................... 38	
Table 1-3 Diagnostic criteria for PCOS, to be employed after exclusion of other causes of 
androgen excess or related disorders ............................................................................... 53	
Table 1-4 Ovarian and extra-ovarian phenotype in rodent PCOS models, generated by 
administration of pre-natal or postnatal testosterone (T) or dihydrotestosterone (DHT). 
Abreviations: estradiol (E2), progesterone (P4), luteinizing hormone (LH). .................. 68	
Table 1-5 Ovarian and systemic characteristics on primate models of PCOS, generated by 
prenatal or postnatal administration of testosterone (T) or dihydrotestosterone (DHT). 
Abbreviations: progesterone (P4), luteinizing hormone (LH) and Western Style Diet 
(WSD). ............................................................................................................................. 71	
Table 1-6 Clinical presentation of primary and secondary adrenal insufficiency, with symptoms 
related to deficient production of glucocorticoid, mineralocorticoid and adrenal androgen 
synthesis. .......................................................................................................................... 74	
Table 2-1Sample calibration series for follicle culture media steroid measurement ............... 96	
Table 2-2TaqMan Gene Expression Assays used (purchased from Life Technologies, Thermo 
Fisher Scientific) ............................................................................................................ 101	
Table 3-1 Baseline characteristics of follicles cultured in control conditions ....................... 111	
Table 3-2 Growth characteristics of follicles cultured in control conditions ......................... 112	
           List of Tables 
 XX 
Table 3-3 Relative mRNA expression of target genes of follicle development, expressed as DCT 
values (normalized against 18S ribosomal RNA) ± SD (for each triplicate experiment from 
30 follicles from each group pooled prior to RNA extraction), in follicles at day 0 and 6 
of follicle culture in basal conditions. ............................................................................ 117	
Table 3-4 Steroid hormone production by the cultured follicles, measured by LC-MS/MS, in 
pooled follicle culture medium (72-105 follicles) at day 2, 4 and 6 of culture, and 
normalised to 100 follicles. Data are expressed as mean ± SD (n=3 measurements). .. 118	
Table 3-5 Relative mRNA expression of target genes of steroidogenesis, expressed as DCT 
values (normalized against 18S ribosomal RNA) ± SD (for each triplicate experiment from 
30 follicles from each pooled prior to RNA extraction), in follicles at day 0 and 6 of follicle 
culture in basal conditions. ............................................................................................ 120	
Table 4-1 Relative mRNA expression of target genes of steroidogenesis and follicle 
development, expressed as DCT values (normalized against 18S ribosomal RNA) ± SD 
(for each triplicate experiment from 21-28 follicles from each treatment group pooled prior 
to RNA extraction), in follicles treated with 25 nM DHT or MDV at day 6 of culture. P 
values reflect differential expression between DHT and MDV conditions. .................. 136	
Table 4-2 Steroid hormone production by the cultured follicles, exposed to 25 nM DHT 
throughout culture. Steroids are measured by LC-MS/MS, in pooled follicle culture 
medium from 63-97 follicle incubations at day 2, 4 and 6 of culture, and normalised to 
100 follicles. Data are expressed as mean ± SD (n=3 measurements). ......................... 137	
Table 4-3  Steroid hormone production by the cultured follicles, exposed to 25 nM DHT + 
MDV throughout culture. Steroids are measured by LC-MS/MS, in pooled follicle culture 
medium from 32-50 follicle incubations at day 2, 4 and 6 of culture, and normalised to 
100 follicles. Data are expressed as mean ± SD (n=2 measurements). ......................... 138	
           List of Tables 
 XXI 
Table 4-4 Relative mRNA expression of target genes of steroidogenesis and follicle 
development, expressed as DCT values (normalized against 18S ribosomal RNA) ± SD 
(for each triplicate experiment from 21-28 follicles from each treatment group pooled prior 
to RNA extraction), in follicles treated with 25 nM DHT or MDV at day 6 of culture. P 
values reflect differential expression between DHT and MDV conditions. .................. 140	
Table 5-1 Steroid hormone production by the follicles,cultured in the presence of 100, 200 or 
500 nM DHEA measured by LC-MS/MS, in pooled follicle culture medium (32-83 
follicles) at day 2, 4 and 6 of culture, and normalised to 100 follicles. Data are expressed 
as mean ± SD (n=3 measurements for DHEA 200 nM , duplicates for DHEA 100 and 500 
nM conditions). .............................................................................................................. 154	
Table 5-2 Relative mRNA expression of steroidogenic enzymes, androgen receptor and 
gonadotrophin receptors, expressed as DCT values (normalized against 18S ribosomal 
RNA) ± SD (for each triplicate experiment from 18-30 follicles from each treatment group 
pooled prior to RNA extraction). ................................................................................... 157	
Table 5-3 Follicle classes in untreated ovaries, and ovaries cultured in presence of 10-8 or 10-7 
M DHT. The number of different follicle classes was counted per ovary, and expressed as 
% of total follicles. Data represent mean ± SD (n=3 ovaries per treatment group).** p<0.01 
compared with control. .................................................................................................. 165		
 
  XXII 
Abbreviations 
17β-HSD  17β-hydroxysteroid dehydrogenase  
3β-HSD   3β-hydroxysteroid dehydrogenase  
2D    2-dimensional  
3D    3-dimensional 
ACTH   adrenocorticotrophic hormone 
A’dione   androstenedione 
AKR1C3  aldoketoreductase type 3 
AMH   anti-Müllerian hormone 
AMH-R2  anti-Müllerian hormone receptor 2 
APS   autoimmune polyendocrine syndrome 
AR    androgen receptor 
ART   assisted reproductive techniques 
ARE   androgen response elements 
ARKO   androgen receptor knock-out 
ATP   adenosine triphosphate 
BMP15   bone morphogenetic factor 15 
cDNA   complementary deoxyribonucleic acid 
CO2   carbondioxide 
CRP   c-reactive protein 
CYP11A1  cytochrome P450 11A1 
CYP17A1   cytochrome P450 17A1 
CYP19A1  cytochrome P450 17A1 or placental aromatase 
DHEA   dehydroepiandrosterone 
DHEAS   dehydroepiandrosterone sulfate 
DHT   5a-dihydrotestosterone 
DNA   deoxyribonucleic acid 
E1    oestrone 
E2    oestradiol 
EGF   epidermal growth factor 
eIVFG   encapsulated in vitro follicle growth 
FGF   fibroblast growth factor 
FOXO3   forkhead box O3 
FSH   follicle-stimulating hormone 
FSH-R   follicle-stimulating hormone receptor 
GC-MS   gas chromatography mass spectrometry 
GDF9   growth differentiation factor 9 
GnRH   gonadotrophin-releasing hormone 
HCG   human chorionic gonadotrophin 
HDL   high-density lipoprotein 
HPLC   high performance liquid chromatography 
HSD   hydroxyl steroid dehydrogenases 
IBMX   phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine 
ICSI   intracytoplasmatic sperm injection 
IGF-1   insulin-like growth factor-1    
IVF   in vitro fertilization 
IVM   in vitro maturation 
LC-MS/MS  liquid chromatography tandem mass spectrometry 
LDL   low-density lipoprotein 
LH    luteinising hormone 
LH-R    luteinising hormone receptor 
LOR   low ovarian reserve 
mRNA   messenger ribonucleic acid 
MTBE   tert-butyl-methyl-ether 
NADPH   nicotinamide adenine dinucleotide phosphate 
OC    oral contraceptive 
OHSS   ovarian hyperstimulation syndrome 
P4    progesterone 
  XXIII 
P450scc   cholesterol side-chain cleavage enzyme 
PAI   primary adrenal insufficiency 
PCO   polycystic ovaries 
PCOS   polycystic ovary syndrome 
PCR   polymerase chain reaction 
PI3K   phosphoinositide 3-kinase 
PMSG   pregnant mare serum gonadotrophin 
POMC   proopiomelanocortin 
POF   premature ovarian failure 
Prog   progesterone 
PTEN   phosphatase and tension homolog 
rFSH   recombinant follicle-stimulating hormone 
RIA   radioimmunoassay 
RNA   ribonucleic acid 
RT-PCR   reverse transcription PCR 
SD    standard deviation 
SF1   steroidogenic factor 1 
SHBG   sex hormone binding globulin 
StAR   steroidogenesis acute regulatory protein 
STS   steroid sulfatase deficiency 
SULT   sulfotransferase 
T    testosterone 
TGF   tumor growth factor 
VEGF   vascular endothelial growth factor 
WSD   Western-style diet 
Δct    delta cycle threshold 
 
 
  
1 General Introduction 
 
 
 
 
 
 
 
 
 
Parts of this chapter have been published as: 
 
Androgen Replacement Therapy in Women  
M.Lebbe, D.Hughes, N.Reisch, W.Arlt. 
Expert Review of Endocrinology and Metabolism, 2012, 7(5): 415-529. 
 
Involvement of androgens in ovarian health and disease 
M.Lebbe, T.K.Woodruff. 
Molecular Human Reproduction, 2013, 19(12): 828-837. 
 
 
 
 
  2 
1.1 Androgen synthesis and metabolism in females 
1.1.1 Androgen biosynthesis 
In women, circulating androgens are mainly derived from the adrenal glands and the 
ovary. The universal sex steroid precursor dehydroepiandrosterone (DHEA) and its sulphated 
ester DHEAS originate mostly from the adrenal gland (Arlt, 2006). The conjugated DHEAS, 
the inactive storage form, is the most abundant steroid hormone in the human circulation 
(Labrie, 2010). In the adrenal, ovary and peripheral target cells, DHEA is downstream 
metabolized to androstenedione and testosterone, and both can be aromatized into oestrogens 
(Longcope, 1996). Testosterone can further be converted to the much more potent 5a-
dihydrotestosterone (DHT) by the enzyme 5a-reductase (Arlt, 2006). The increased androgenic 
potency of DHT is attributed to its stronger interaction with the androgen receptor (AR), 
compared with testosterone (Grino et al., 1990). The peripheral target cells of sex steroid action, 
such as skin, liver, fat, muscle, breast and brain cells, readily take up non-conjugated, lipophilic 
DHEA (Labrie, 2010). The tissue-specific downstream metabolism of DHEA depends on the 
intracellular availability and activity of steroidogenic enzymes (Arlt et al., 1998). This means 
that circulating levels of androgens and their precursors do not necessarily reflect target cell 
concentrations (Lebbe M et al, 2012). 
 
1.1.1.1 Adrenal androgen synthesis   
The adrenals are small yellowish glands located at the upper pole of the kidneys. The 
adrenal gland consists of an outer cortex and an inner medulla and is responsible for secretion 
of the adrenocortical steroids and catecholamines respectively (Nussey and Whitehead, 2001). 
The adrenal cortex is divided in three separate zones, from outside to inside: the zona 
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glomerulosa, producing mineralocorticoids (principally aldosterone), the zona fasciculata, 
producing glucocorticoids (dominantly cortisol in humans, corticosterone in rodents) and the 
zona reticularis, the site of adrenal androgen synthesis in humans (mainly DHEA) (Figure 1-1).  
 
 
Figure 1-1 Steroidogenesis in the adrenal glands, divided in the zona glomerulosa (green), 
fasciculata (yellow), and reticularis (blue), with synthesis of mineralocorticoids, 
glucocorticoids and adrenal androgens respectively. DHEA is taken up by peripheral tissues, 
and metabolised to active androgens (dark blue) and oestrogens (pink). Reprinted with kind 
permission of Prof. Wiebke Arlt, University of Birmingham  
 
All biologically active steroids are derived from cholesterol, that is delivered to the inner 
compartment of the mitochondria by steroidogenic acute regulatory protein (StAR), enabling 
CYP11A1 (Cytochrome P450 enzyme 11A1) or P450scc (cholesterol side-chain cleavage 
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enzyme)-mediated conversion to pregnenolone in a first rate-limiting step (Miller and Auchus, 
2011) (Figure 1-1). The P450 enzymes, members of the heme-containing protein superfamily, 
and contributing to steroid hormone production are membrane-bound to the mitochondria 
(CYP11A) or the endoplasmatic reticulum (CYP17A1 and CYP19A1) (Payne and Hales, 
2004). The CYP enzymes catalyze selective irreversible reactions in steroidogenic cells, by 
hydroxylation and cleavage of the steroid substrate, utilizing nicotinamide adenine dinucleotide 
phosphate (NADPH) as electron donor. The weak precursor hormones are stepwise converted 
to potent bioactive hormones via CYP enzymes, which catalyze unidirectional reactions, or 
hydroxysteroid dehydrogenases (HSD), which can act in a bidirectional way. HSD and 5a- 
reductase are found in peripheral target tissues of steroid action (Miller and Auchus, 2011).  
In humans, the adrenal zona reticularis has a pronounced CYP17A1 activity, and 
abundant DHEA is produced, most of it being sulfated to DHEAS by SULT2A1 
(sulfotransferase 2A1), and small amounts converted to androstenedione by 3b-HSD2 
(Idkowiak et al., 2011) (Figure 1-1) In contrast, the mouse adrenal gland does not express 
CYP17A1 (Perkins and Payne, 1988), and does not produce DHEA; corticosterone is the main 
glucocorticoid in rodents (Brock and Waterman, 1999). 
 
1.1.1.2 Ovarian steroidogenesis  
The ovaries are bilateral, white, oval-shaped glands, localized in the posterior wall of 
the broad ligament in the supra-pelvic peritoneal cavity (Nussey and Whitehead, 2001). The 
ovarian follicle, the basic structure of the ovary, contains an oocyte surrounded by specialized 
endocrine cells (inner granulosa and outer theca cells, separated by a basal membrane) and is 
the other main site of androgen production in women. Androgens are the mandatory precursors 
of oestrogen synthesis, the main sex steroid in females. Ovarian steroid hormone secretion 
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occurs in a cyclical pattern, with estradiol secretion during the follicular phase and progesterone 
production during the luteal phase of the menstrual cycle. Testosterone levels modestly increase 
at midcycle in women (Braunstein et al., 2011) 
From the 1960s onward, the idea arose that follicular oestrogen secretion results from a 
collaboration between granulosa and theca cells, named as ‘two cell, two gonadotropin’ theory 
(Bjersing and Carstensen, 1967). In this concept of follicular steroidogenesis, the theca cells 
produce androgens, under stimulation of Luteinizing Hormone (LH), which induces the crucial 
androgen-synthetizing enzyme CYP17A1, that is solely expressed in theca cells (Fortune and 
Armstrong, 1977, Liu and Hsueh, 1986) (Figure 1-2). The main androgen produced in women 
is androstenedione, from which small amounts are converted to testosterone in the theca cells 
via 17b-HSD1 (Figure 1-2). Most of the androstenedione diffuse across the basal lamina to the 
granulosa cells, which express Follicle Stimulating Hormone (FSH) receptors on the cell 
membrane, inducing aromatase enzyme (CYP19A1) expression (Figure 1-2). Aromatase 
converts both androstenedione to estrone, and testosterone to estadiol (Dorrington et al., 1975, 
Makris and Ryan, 1977). Estone is converted to estradiol, the main oestrogen in the circulation, 
via 17b-HSD1 (Figure 1-2). During follicle maturation, theca and granulosa cells become 
progressively more active in the production of steroid hormones, under the influence of FSH 
and LH. Circulating androgens and oestrogens, in turn, provide feedback regulation to the 
hypothalamic-pituitary axis, thereby adjusting hypothalamic gonadotrophin-releasing hormone 
(GnRH) production and pituitary LH and FSH release, allowing for continuous monitoring of 
sex steroid hormone concentrations (Figure 1-3).  
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Figure 1-2 Two cell, two gonadotropin concept of oestrogen synthesis in the follicle focusing 
on steroidogenic enzyme expression in granulosa and theca cells: steroidogenic acute 
regulatory protein (StAR), cholesterol side-chain cleavage cytochrome P450 (CYP11A1), 17-
hydroxylase (CYP17A1), 3b-hydroxysteroid dehydrogenase (HSD3B2) and 17b-
hydroxysteroid dehydrogenase (17HSD1). CYP17A1 expression is induced solely in theca cells 
under the influence of LH and CYP19A1 (aromatase) expression is found uniquely in granulosa 
cells, stimulated by FSH. 
 
 
  7 
Figure 1-3 Two cell, two gonadotrophin hypothesis and neuro-endocrine axis. Pituitary LH 
stimulates theca cells to produce androstenedione, that diffuses to the granulosa cells for 
conversion to estradiol under FSH-stimulation. The sex steroids feedback to the hypothalamo-
pituitary unit to regulate gonadotrophin releasing hormone (GnRH) and LH secretion.  
 
1.1.1.3 Androgen levels in the female lifespan 
Circulating androgen levels fluctuate with age. Immediately after birth, levels of DHEA 
and DHEAS show a transient peak, reflecting fetal adrenal androgen production, that rapidly 
disappears (Arlt, 2004). Around the age of 8 years, DHEA is increasingly produced in the 
adrenal gland, and converted to active androgens in androgen-responsive hair follicles, 
progressively manifesting with appearance of pubic hair, a phenomenon called adrenarche 
(Idkowiak et al., 2011). Serum levels of DHEAS, androstenedione and testosterone increase 
and peak in the early reproductive years, followed by a progressive decline with advancing age, 
as illustrated by a cross-sectional study of 1423 healthy women (Davison et al., 2005). The high 
inter-individual variations in circulating DHEAS levels and their decrease over time reflect a 
genetic component in androgen synthesis (Orentreich et al., 1984). (Figure 1-4). A large study 
of serum testosterone and DHT, measured by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) in 985 women in the third to ninth decade, showed overall lower values for 
testosterone compared with previous measurements by immunoassays, especially for the lower 
concentrations (Shiraishi et al., 2008) Androstenedione levels also decrease with advancing 
reproductive age, as shown in a recent study measuring these androgen levels by LC-MS/MS 
in a cohort of 995 women aged 20-80 years (Haring et al., 2012) Menopause refers to the 
cessation of oestrogen production by the ovary, but the postmenopausal ovary continues to 
secrete androgens, as a result of the increased LH drive (Adashi, 1994). This means that 
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menopause does not significantly affect circulating androgen levels (Burger et al., 2000). At 
the end of life, circulating DHEAS levels have dropped to 10-20% of young adult levels, a 
phenomenon sometimes called ‘adrenopause’, which only refers to the decline in adrenal 
androgen secretion, as glucocorticoid and mineralocorticoid secretion are maintained with 
advancing age (Lebbe M et al, 2012). 
 
 
Figure 1-4 Concentrations of DHEAS as function of age. Derived from data in Orentreich et 
al, 1984. Reprinted from Miller and Auchus with kind permission of Endocrine Society, 
Copyright 2011. 
 
1.1.2 Androgen metabolism in peripheral target tissues 
Androgen metabolism refers to the tissue-specific generation of androgens, derived 
from circulatory DHEA, and depending on the expression and the activity of peripheral 
steroidogenic enzymes, including isoforms of 3b-HSD, 17b-HSD and 5a-reductase, in the 
specific target tissue (Labrie, 2010) (Figure 1-5). 
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Figure 1-5 Peripheral sex steroid metabolism. Circulatory DHEA is taken up by peripheral 
tissues and converted to androstenedione, which can be either converted to testosterone or 
aromatized to estrone (E1). Testosterone can be metabolized to the more potent 
dihydrotestoserone (DHT) or aromatized to estradiol (E2). The enzymes responsible for these 
reactions are mentioned in red.  
  
 The HSD enzymes include the 3b-HSDs and 17b-HSDs and belong to the 
dehydrogenase reductase superfamily. They regulate steroid potency by catalyzing the 
conversion of keto- and hydroxysteroid pairs using the pyridine nucleotide cofactors 
NAD(P)H/NAD(P)+ (Miller and Auchus, 2011) (Figure 1-6). Their physiological role is the 
biosynthesis versus inactivation of androgens and oestrogens in peripheral tissues.  
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Figure 1-6 HSDs interconvert inactive and active steroids. The direction of the reaction in vivo 
depends mainly on the availability of the pyridine nucleodide NAD(P)H/NAD(P)+ cofactor. 
 
3b-HSD/isomerases are bound to mitochondrial or microsomal membranes, depending 
on the cell type in which they are expressed (Payne and Hales, 2004). Multiple isoforms of 3b-
HSD have been isolated in human (Simard et al., 1996) and mouse (Payne et al., 1997). The 
different isoforms are chronologically numbered, which means that the same number in a 
different species is not orthologous (Payne and Hales, 2004, Rasmussen et al., 2013). Six 
isoforms of 3b-HSD are discovered in mouse and 5 in humans. Human 3b-HSD I and II and 
mouse 3b-HSD I and VI are involved in the biosynthesis of active sex steroid hormones, and 
some of their characteristics have been outlined in Table 1-1 (based on (Payne and Hales, 
2004)).   
 
Table 1-1 Characteristics of human and mouse 3b-HSD involved in active biosynthesis of 
steroid hormones  
Human 
Gene 
Mouse 
Gene 
Human 
Protein 
Mouse 
Protein 
Reaction catalyzed Tissue 
distribution 
HSD3B1 Hsd3b6 3b-HSD I 3b-HSD 
VI 
Preg -> Prog 
DHEA ->A’dione 
Placenta, Uterus 
Skin 
HSD3B2 Hsd3b1 3b-HSD II 3b-HSD I Preg -> Prog 
DHEA ->A’dione 
Ovary,Testis, 
Adrenal 
Abbreviations: Preg (pregnenolone), Prog (progesterone), DHEA (dehydroepiandrosterone), 
A’dione (androstenedione). 
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17b-HSD are membrane bound or soluble enzymes, catalyzing the final step in sex 
steroid biosynthesis by interconverting androstenedione and testosterone, and estrone and 
estradiol. Multiple 17b-HSD isoforms are identified, and the nomenclature for these enzymes 
has assigned orthologs for the same number among species (Adamski and Jakob, 2001). 17b-
HSD isoforms 1, 3 and 7 are predominant in gonadal tissue. Human 17b-HSD1 has substrate 
specificity for estrone, while mouse 17b-HSD1 also efficiently converts androstenedione to 
testosterone (Puranen et al., 1997). 17b-HSD5 account for most of the extra-gonadal peripheral 
reduction of androstenedione, and is also called AKR1C3 (aldoketoreductase 1C3) (Miller and 
Auchus, 2011).  
5a-reductases perform irreversible transformations, and activate testosterone to DHT, 
which is the most active androgen in skin, vulva and clitoris (Arlt et al., 1998). Type 1 5a-
reductase is found in skin, liver, adrenal and ovaries while the type 2 isoform is confined to 
genital skin and prostate (Jenkins et al., 1992). 
 
1.1.3 Measuring androgen levels 
 The access to a sensitive, specific and reproducible assay for the measurement of 
androgen levels is challenging, particularly in the case of low sample concentrations and in the 
presence of other steroids with closely related structures which may cross-react the assay 
(Rosner et al., 2010). For the past five decades, immunoassay has been the routine assessment 
for androgen concentrations, and for steroid hormones in general. A great deal of our 
knowledge about the role of sex steroid hormones in normal cycling women through the 
reproductive lifespan (puberty, menstrual cycle, pregnancy, menopause) and endocrine-related 
diseases is based on studies using these techniques (Lebbe M et al, 2012). Mass spectrometry-
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based assay methods have been used since 1960 for the measurement of steroid hormones, and 
have recently started to replace immunoassays for steroid quantification in larger clinical and 
research laboratories (Rosner et al., 2007). This section aims to introduce both assays, and 
discuss the main applications, advantages and disadvantages. 
 
1.1.3.1 Immunoassays for steroid hormone measurements 
Antibodies were first developed for large proteins, such as insulin, growth hormone, LH 
and FSH, which provoke immunogenic reactions when administered to experimental animals, 
f.ex. rabbits or mice (Yalow and Berson, 1959). Steroids are smaller molecules, and require 
coupling to a protein, such as albumin or thyroglobulin, to evoke antibody generation 
(Abraham, 1969). Steroid hormone measurement using immunoassays are subject to different 
issues, which might have negative effects on the sensitivity and specificity of the assay. Steroids 
have low affinity for the employed antibodies, and are generally present in low concentration 
in biological samples. Moreover, the presence of steroid molecules with similar structure 
induces risks of cross-reactivity (Taylor et al., 2015). The immunoassays utilizing pre-
assessment extraction with organic solvent (liquid-liquid extraction) and chromatographic 
fractioning have shown to perform with good sensitivity and specificity (Janse et al., 2011). 
The more recent ‘direct’ assays have suppressed the sample purification steps, and run on 
automated platforms, using chemiluminescence, fluorescence or enzymatic color reactions as 
detection methods (Taylor et al., 2015). Although the development of monoclonal antibodies 
has improved the analytical performance, a lower sensitivity and specificity is often achieved. 
(Stanczyk, 2006). The advantages of the automated assays are their wide availability, reduced 
cost and ease of use. Standardization of specific assays is difficult, because of differences in 
antibodies and kit formulations purchased from different suppliers (Taylor et al., 2015). 
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1.1.3.2 Mass spectrometry-based steroid hormone measurement 
The mass spectrometer is a device that measures the mass-charge ratio of charged 
particles (m/Q). It is composed of a sample inlet device, an ionization source, an analyzer and 
an ion detector. The initial steroid mixture is first separated using chromatography, either gas 
chromatography (GC) or liquid chromatography (LC).   
GC-MS is employed to analyze the metabolites of steroid hormones and precursors. GC 
vaporizes liquid analytes, and separates them in a heated column based on different speed 
resulting from different interactions with the liquid medium in the column. Since steroid 
metabolites present as glucuronide and sulfate conjugates, these charged are removed by 
chemical derivatization, making them less polar and more volatile and stable in order to 
improve chromatographic resolution (McDonald et al., 2011). GC-MS is the method of 
reference for urinary steroid profiling, and remains at the forefront for identifying and studying 
steroid metabolic disorders (Krone et al., 2010)  
LC-MS requires less sample preparation, and does not rely on chemical derivatization 
of steroid analytes. LC and High performance LC (HPLC), retain steroids in the column based 
on polarity of the mobile phase versus the stationary phase. The introduction of tandem mass  
spectrometry (MS/MS), utilizing quadrupole mass analyzers, which fragment the sample inside 
the instrument and analyze the generated products, have modernized the MS-field considerably 
(Shackleton, 2010). LC-MS/MS is the method of choice in routine clinical laboratories, because 
of its superior sensitivity and specificity with regard to immunoassays, the possibility to 
measure several different steroids simultaneously and the high throughput capacity (Grebe and 
Singh, 2011). The LC-MS/MS methods require thorough, standardized validation and 
appropriate technical training to optimize their analytical performance (Taylor et al., 2015). 
Importantly, the employed assay requires calibration against approved standards (Wierman et 
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al., 2014a). Kushnir et al. published a standardized sample preparation technique using for the 
quantification of steroid hormones, and made available reference ranges for testosterone in pre- 
and post-menopausal women (Kushnir et al., 2010).  
 
1.1.3.3 Which method to choose? 
Choosing the correct assay for research or clinical purposes might be a difficult, and 
will depend on the specific scientific or diagnostic question, the expected steroid concentration 
in the biological sample, the availability of the technique, costs and technical and analytical 
training (Taylor et al., 2015)  A Sex Steroid Assay Reporting Task Force, issued by the 
Endocrine Society, has recently highlighted the requirements for analytical validity and quality 
of the steroid hormone assay, with regard to accuracy, sensitivity, specificity, and 
reproducibility (Wierman et al., 2014b). This statement arises following a vigorous debate, 
provoked by an editorial promoting MS assays for reporting steroid hormone measurement 
(Handelsman and Wartofsky, 2013) and indicates a place for both immunoassay and MS in the 
current state of steroid hormone measurements, although MS will eventually take the lead in 
the future. 
For testosterone assays, the sensitivity of immunoassays is sufficient to detect 
circulating levels in male subjects, but inaccurate to test samples from women or children, in 
which case MS is recommended (Rosner et al., 2007). Another problem for androgen 
measurement by immunoassay is the high level of cross-reactivity between structurally similar 
molecules, the most abundant circulating steroid DHEAS, present in µM concentrations, will 
compete and interfere with low testosterone levels (<10 nM) for antibody binding (Taylor et 
al., 2015). 
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The Endocrine Society position on estradiol assays states that good quality 
immunoassays and validated MS methods are both convenient for measuring levels present in 
normal or high concentrations (such as in in vitro fertilization or IVF settings), but inaccurate 
for determining very low levels, as present in non-reproductive tissues or in male patients 
(Rosner et al., 2013). With both immunoassays and MS-based methods, current analytical 
performance for estradiol measuring needs improvement (Vesper et al., 2014), and in particular 
sensitivity in the low pM range. Both techniques have reported ultrasensitive methods, but the 
availability of these techniques is extremely limited (Klein et al., 1994, Owen et al., 2014). 
 
1.1.3.4 Free testosterone levels  
Sex hormone binding globulin (SHBG) and albumin are the main binding proteins for 
testosterone in the circulation. Free fractions of testosterone are calculated using total 
testosterone, concentrations of binding proteins and dissociation coefficients between 
testosterone and SHBG and testosterone and albumin (Sodergard et al., 1982). A commonly 
used calculation of free androgen index is total testosterone X 100/SHBG blood level 
(Vermeulen et al., 1999). The most accurate way of measuring free testosterone levels are done 
by equilibrium dialysis, but this technique is not routinely used in clinical practice (Vermeulen 
et al., 1999). 
 
1.1.4 The role of androgens in women 
1.1.4.1 Adrenarche and gonadarche 
The human adrenal zona reticularis starts to mature and becomes steroidogenically 
active around the age of 6-8 years in both boys and girls. Its regulation is still poorly understood. 
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This developmental process is termed adrenarche, and manifests with increasing circulatory 
levels of DHEA, DHEAS and androstenedione (Idkowiak et al., 2011). DHEA is converted to 
testosterone and DHT in target cells of androgen actions, including androgen-responsive skin 
and bone cells, resulting in the appearance of pubic and axillary hair, oily skin, a transient 
growth spurt and bone maturation. In parallel, increased estrone and estradiol levels can be 
observed in pre-pubertal girls, and might be derived from androstenedione through peripheral 
tissue-specific aromatization (such as in adipose tissue) (Biro et al., 2014).  
The onset of steroidogenesis in the gonads, ovary and testicles, is called gonadarche, 
and is triggered by increasing gonadotropin releasing hormone (GnRH) pulse frequency and 
amplitude with subsequent LH release from the pituitary gland. It manifests with breast 
development and menarche in girls, and testicular and scrotal enlargement in boys. Adrenarche 
is usually observed before gonadarche, but it remains unclear if and how both events are related 
(Idkowiak et al., 2011).  
 
1.1.4.2 Androgens and female sexuality  
 Androgens are important drivers of female sexual desire, increasing interest in sexual 
activity and response to sexual stimulation (Bancroft, 2002) Female Androgen Deficiency 
Syndrome is defined by self-reported symptoms of decreased well-being and libido occurring 
in women with testosterone levels in the lower quartile of normal and adequate estradiol levels 
(Bachmann et al., 2002). This definition, provided by the Princeton statement, has been widely 
criticized, because of the imprecise clinical symptoms, the heterogeneity in androgen assays, 
and the lack of normative age-related testosterone levels in females (Wierman et al., 2006). The 
diagnosis has been revised, and the American Psychiatric Association states that Hypoactive 
Sexual Desire Disorder is defined by deficiency or absence in sexual desire causing marked 
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personal distress or relational difficulties, and associated with decreased or absent physical 
arousal (Diagnostic and Statistical Manual of Mental Disease) (Association, 2013). In the latest 
guidelines of the Endocrine Society for androgen therapy in women, a 3-6 months trial of 
testosterone for postmenopausal women with diagnosed hypoactive sexual desire disorder is 
suggested, after exclusion of contraindications, and with the aim of restoring midnormal 
premenstrual testosterone levels (Wierman et al., 2014a). This suggestion is based on evidence 
suggesting an increased sexual satisfaction in postmenopausal women receiving 300 µg/d 
transdermal testosterone, alone (Davis et al., 2008) or with associated estradiol therapy (Shifren 
et al., 2000, Simon et al., 2005, Buster et al., 2005, Shifren et al., 2006)  
 
1.1.4.3 Androgens and bone metabolism 
Bone mass in women is critically dependent on bioavailable oestrogen. In 
premenopausal women, bone mineral density is not correlated with sex steroid levels, but in 
postmenopausal women >60 years, an association between bioavailable oestrogen and 
testosterone with cortical and trabecular bone mineral density was observed (Khosla et al., 
2005) . Randomized controlled studies on combined testosterone and oestrogen replacement in 
surgically menopausal women show increased bone mineral density in the combined treatment 
group versus estradiol alone  (Barrett-Connor et al., 1999, Watts et al., 1995)  In naturally 
menopausal women, the effect of addition of testosterone to oestrogen replacement is 
controversial, either positive (Garnett et al., 1992) or insignificant (Miller et al., 2000). 
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1.1.4.4 Androgens and body composition 
The relation between endogenous testosterone levels and lean body mass in women 
depends on menopausal status. Casson et al reported that increased circulating androgen levels 
in naturally postmenopausal women is associated with reduced body fat, increased aerobic 
capacity and increased insulin sensitivity (Casson et al., 2010). The same group found that in 
healthy premenopausal women without hyperandrogenism, circulating testosterone is a 
predictor of increased fat mass, but not visceral adiposity, and no association is found with 
resting energy or substrate metabolism (Keller et al., 2011) 
1.1.4.5 Androgens and cardiovascular health 
A prospective population-based study of 639 postmenopausal women found age-
adjusted increased risk for coronary heart disease in women with total and free testosterone 
levels in the highest and lowest quintiles (Laughlin et al., 2010). These data suggest a U-shaped 
association of bioavailable testosterone and incidence of cardiovascular disease (Laughlin et 
al., 2010). In younger women with polycystic ovary syndrome (PCOS), a condition 
characterized by increased circulating androgen levels, no increase of coronary heart disease 
was observed during long-term follow-up, despite the presence of a higher incidence of 
cardiovascular risk factors, such as diabetes mellitus, hypertension, hyperlipidaemia and 
obesity (Wild et al., 2000a, Wild et al., 2000b). Low levels of SHBG, associated with obesity 
and resulting in increased free testosterone but without change in total testosterone 
concentrations, were associated with impaired cardiovascular outcome (Guthrie et al., 2004).
 The described effects of postmenopausal testosterone replacement on lipid metabolism 
in women is conflicting. Some randomized controlled studies showed beneficial effects of 
combined estradiol and testosterone administration, leading to decreased triglycerides levels 
(Chiuve et al., 2004, Watts et al., 1995), increased HDL-cholesterol (Barrett-Connor et al., 
  19 
1999), decreased LDL (Davis et al., 1995) and total cholesterol (Davis et al., 2000) compared 
with estradiol only. Other studies failed to prove any effect of testosterone on lipid parameters 
(El-Hage et al., 2007, Nathorst-Boos et al., 2006), or reported detrimentally decreased HDL-
cholesterol levels (Penotti et al., 2001, Shafighi et al., 2012, Raisz et al., 1996, Watts et al., 
1995). The long-term effects of these altered lipoprotein concentrations induced by oral 
testosterone have not been investigated in these studies.  
 
1.2 Androgen signaling  
1.2.1 The androgen receptor 
Androgens exert their action mainly through the androgen receptor (AR). The AR is a 
member of the steroid and nuclear receptor superfamily. The AR gene is located on the X 
chromosome (Xp11-12) and contains 8 exons (Gelmann, 2002). AR protein contains 919 amino 
acids and contains 3 major functional domains: a N-terminal modulatory domain with 
activation function 1, a DNA-binding domain containing a nuclear localization signal and a C-
terminal ligand-binding domain with activation function 2. There is also a small hinge region, 
localized between the DNA and ligand-binding domain (Gao et al., 2005).  
The unbound AR is associated with a heat-shock protein complex and usually resides 
in the cytoplasm. Upon ligand-binding, the heat-shock protein dissociates from the AR protein, 
that will further undergo dimerization and phosphorylation before translocating to the nucleus. 
The DNA-binding domain is directed to androgen-response elements in the promotor or 
enhancer region of androgen-responsive genes. The AR-DNA complex further necessitate the 
presence of co-activators or co-repressors to ensure AR-related gene expression (Gao et al., 
2005).  
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The human and rodent AR structure and function are quite similar (Lubahn et al., 1988). 
In females, AR is expressed in the ovary, breast, liver, bone, muscle, adipose tissue, 
brain and skin (De Gendt and Verhoeven, 2012). In the ovarian follicle, ARs are identified in 
the oocyte, granulosa, and theca cells (Sen and Hammes, 2010). In cattle, non-human primates 
and women, AR is expressed in ovarian cortical stroma cells (Weil et al., 1998, Horie et al., 
1992, Yang and Fortune, 2006). In rodents, bovine, primates and human, AR are detected in 
granulosa cells from the primary stage onward, and their concentration peaks in the antral 
follicle stage (Sen and Hammes, 2010, Yang and Fortune, 2006, Weil et al., 1998, Rice et al., 
2007). The expression of AR decreases as the follicle reaches the preovulatory stage (Prizant 
et al., 2014).  
 
1.2.2 Non-genomic androgen signaling 
As for other steroids, it is now commonly accepted that many effects of androgens 
depend on other complex signaling pathways, including rapid non-genomic signaling. The 
reported non-genomic effects related to physiological concentrations of testosterone appear to 
involve the classical AR, with downstream activation of the MAPK-ERK pathways (Kousteni 
et al., 2001). Further evidence points toward increased AR transcriptional activation following 
rapid non-genomic signaling, with creation of an  autocrine stimulatory loop between AR and 
its ligand (Heinlein and Chang, 2002b, Heinlein and Chang, 2002a).  
Evidence for non-genomic androgen actions in ovarian tissue is elegantly described in 
the frog Xenopus laevis oocyte, where progesterone and testosterone are capable of promoting 
oocyte maturation in vitro (Lutz et al., 2001). Inhibitory signals maintain high intracellular 
cAMP levels within the frog oocyte, keeping it in meiotic arrest. Testosterone has the ability to 
overcome and release these inhibitory signals, via transcription-independent activation of 
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MAPK-pathways, and permit meiosis to progress (Lutz et al., 2003).  The same group has 
further demonstrated that testosterone-induced maturation equally occurs in mouse oocytes 
(Gill et al., 2004). In the frog as well as the mouse oocytes, androgen-triggered maturation was 
found attenuated in the presence of the AR antagonist flutamide, indicating that classical AR in 
the oocytes are involved in the non-genomic signaling cascade (Lutz et al., 2001, Gill et al., 
2004). Transcription-independent upregulation of FSH-R protein following androgen-
treatment was also described in mouse ovaries (Sen et al., 2014). Increasing attention focuses 
on extra-nuclear non-genomic androgen signaling pathways, including the activation of the 
scaffold protein paxillin, which, in turn, increases AR-mediated transcription, by retaining AR 
in the nuclear compartment (Sen et al., 2014). Another example of non-genomic action of 
testosterone in the ovary is the rapid activation of PI3-K/Akt pathway documented in neonatal 
mouse ovaries, an effect blocked by the AR-antagonist flutamide (Yang et al., 2010).  
 
1.2.3 Antiandrogens 
AR antagonists or androgens directly bind or block the AR, and prevent the biological 
effects of androgens to occur. Steroidal antiandrogens, such as cyproterone acetate or 
medroxyprogesterone acetate, share an analogue chemical structure with androgens and bind 
the AR (Helsen et al., 2014). Non-steroidal antiandrogens bind the AR, and impair the AR 
binding to DNA. First generation non-steroidal antiandrogens include flutamide and 
bicalutamide (Helsen et al., 2014). Enzalutamide, also known as MDV3100, was introduced in 
2009 as a second generation non-steroidal antiandrogens, with stronger AR affinity and has a 
dual action of AR blockade: it prevents AR translocation to the nucleus and inhibits AR binding 
to ARE on DNA (Tran et al., 2009). The working mechanism of Enzalutamide is depictured in 
Figure 1-7. 
  22 
 
 
Figure 1-7 Mechanism of action of Enzalutamide (MDV). DHT binds the AR and induces the 
formation of a co-activator binding platform (AF1), nuclear translocation and transcription of 
AR-responsive genes. Enzalutamide (Enz) inhibits the formation of AF1 and prevents nuclear 
translocation, making it a potent antiandrogen. Adapted from Helsen et al, with kind permission 
of BioScientifica Limited. Copyright 2014.  
 
1.3 Physiology of the ovary 
1.3.1 Function and structure of the ovary 
The ovary is the central female reproductive organ, a gonad and endocrine gland. It 
houses a fixed reserve of gametes and ensures the cyclic release of (a) mature fertilizable 
oocyte(s) (Figure 1-8). The single follicle is the fundamental unit of the ovary and is composed 
of an oocyte surrounded by specialized endocrine cells (granulosa and theca cells). It produces 
peptide hormones and sex steroids that modulate the maturation of the oocyte and regulate 
follicle cell growth and differentiation through local auto- and paracrine signaling pathways. 
Secreted into the blood stream, androgens and oestrogens exert endocrine effects and prepare 
the reproductive organs for fertilization. Following ovulation, the remaining follicle 
differentiates into a corpus luteum, responsible for progesterone production, required to allow 
for implantation and early embryo development (Lebbe and Woodruff, 2013). 
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The outer cortex of the ovary is a rigid, avascular environment, containing the immature 
primordial follicle reserve, and surrounded by the ovarian surface epithelium. It consists of 
tightly packed spindle-shaped fibroblasts, smooth muscle, endothelial and inflammatory cells, 
as well as precursor theca cells. Its role is to sustain the ovarian architecture by providing 
structural support to the growing follicles. The stroma secretes a variety of cytokines, 
chemokines and growth factors that steadily co-regulate—in an autocrine and paracrine 
manner—the early development of its enclosed follicles (Lebbe and Woodruff, 2013). The 
inner medulla has a more elastic composition and consists of loose connective tissue and 
harbors the ovarian vasculature. It is home to the developing pool of follicles, as well as the 
corpus luteum and albicans, remaining products of the follicle following ovulation (Figure 1-
8).  
 
Figure 1-8 Schematic overview of the ovary, showing the main cell types and follicle stages. 
The follicle consists of an oocyte or ovum surrounded by granulosa cells and theca cells. 
Preovulatory follicles contain a central fluid-fuild space called an antrum. After ovulation, the 
somatic cells differentate in a corpus luteum. The central area of the ovary is the medulla, the 
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outer layer the cortex, surrounded by the ovarian surface epithelium. Reprinted from Sexual 
bodies: anatomy and physiology, by Marcus Tye with kind permission of Flat World 
Knowledge.  
 
1.3.2 Folliculogenesis and oogenesis in vivo   
Follicles form during embryonic development, and establish the dormant primordial 
pool. Once the primordial follicle activated, it is called a primary follicle, that develops into a 
secondary pre-antral follicle in the gonadotrophin-independent stage. This developmental 
process takes approximately 6 months in women (Gougeon, 1996). While the majority of 
growing follicles are lost in atresia, a small cohort of antral follicles is recruited for further 
growth, dominance, and ovulation under the cyclic stimulation of gonadotrophins during the 
follicular phase of the menstrual cycle. The terminal follicular differentiation is called 
luteinization and occurs during the luteal phase. 
 
1.3.2.1 Bipotential gonad and formation of germ cell syncytia 
During the first stages of fetal life, the mammalian gonad, localized in the urogenital 
ridge, is ‘bipotential’, meaning that it develops similarly in both male and female embryos. 
Sexual differentiation of the gonad starts when primordial germ cells, that migrate from the 
yolk sac, colonize the gonad (Richards and Pangas, 2010). Research in the last decades has 
identified factors, mainly in the mouse, that regulate the active process of differentiation of the 
bipotential gonad to an ovary, with simultaneous suppression of testis-determining pathways. 
Following colonization, the primordial germ cells multiply through mitosis and differentiate to 
oogonia that form syncytia or germ cell nests (Pepling and Spradling, 1998). Oogonia will 
undergo the first stages of meiosis and get arrested in prophase I (Pangas and Rajkovic, 2006). 
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After meiotic recombination, each oocyte holds a unique genetic constitution (Gosden and Lee, 
2010).  
 
1.3.2.2 Primordial follicle formation  
As illustrated in Figure 1-9, syncytia will gradually break down, which happens by 
invasion of single layers of flattened epithelial cells, pre-granulosa cells, into the germ cell 
nests. Pre-granulosa cells envelop the individual oocytes to form the primordial follicle and 
surrounding stroma cells (Tingen et al., 2009). This happens prenatally in humans, and a few 
days after birth in mice (Peters et al., 1975). An important number of oocytes will get lost in 
this process, as their count drops from approximately 6 million to 1-2 million at birth in humans, 
and 10,000 in mice (Gosden, 1987, Pepling and Spradling, 2001). The primordial follicle pool 
represents the reserve of follicles available. Even though this follicle reserve seems to subsist 
in a resting state, it is continuously and tightly regulated by follicular fate decisions: most 
follicles will undergo programmed cell death, a large number stay quiescent, and only a few 
will be selected into the growing pool (Tingen et al., 2009, Kim, 2012, Sanchez and Smitz, 
2012). A central dogma in reproductive biology claims that the quantity and maintenance of 
the primordial follicle pool determines the individual woman’s reproductive lifespan. By 
puberty, approximately 400,000 primordial follicles remain, and menopause sets in when the 
follicle count is approximately 1,000 (te Velde et al., 1998). The concept of a fixed non-
renewable ovarian reserve has recently been challenged, by the hypothesis of neo-oogenesis 
derived from human germ cell stem cells (Johnson et al., 2004, Johnson et al., 2005, White et 
al., 2012). The current opinion regarding the existence of neo-oocyte in women is divided in 
the field, and their physiologic relevance remains unproven (Notarianni, 2011). 
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Figure 1-9 Prenatal and early postnatal ovarian follicle development in the mouse. Primordial 
germ cells increase in number and migrate to the bipotential gonad, where they differentiate to 
oocytes. Closely after birth, clusters or syncytia of germ cells break down to form primordial 
follicles. Adapted and reprinted from Richards et al, with kind permission of American Society 
for Clinical Investigation, Copyright 2010.  
 
1.3.2.3 Primordial follicle activation 
 Primordial follicles recruited to enter the growing pool exhibit a change in the epithelial 
cell shape, from squamous to cuboidal, with subsequent proliferation of granulosa cells.  On 
molecular level, the follicle activation process remains largely a mystery, although progress has 
been made in the discovery of genetic regulation of follicle activation, mainly through work in 
genetically modified mice. It is believed that follicle fate regulation in the primordial follicle 
pool is maintained by various forms of inhibitory signals (Adhikari and Liu, 2009). The 
phosphoinoside 3-kinase (PI3K) pathway has been identified as a key regulator for the status 
of primordial follicles (Reddy et al., 2008, Castrillon et al., 2003) (Figure 1-10). A basal degree 
of intra-oocyte PI3K activation is required for maintaining survival of the oocyte throughout 
the long dormancy of these follicles (Reddy et al., 2010). An elevated intra-oocyte PI3K balance 
results in oocyte growth and follicle activation (Zheng et al., 2012). Similarly, PTEN 
(phosphatase and tensin homolog) reverses PI3K action and ensures sustained dormancy of the 
primordial follicles. Condition Gdf-Cre PTEN knock-out mice exhibit premature ovarian 
  27 
failure due to rapid follicle depletion as a result of global primordial follicle activation (Reddy 
et al., 2008). Another negative regulator of the PI3K pathway is FOXO3 (forkhead box O3) 
(Castrillon et al., 2003, Liu et al., 2007, John et al., 2008). Inactivation of these PI3K repressors 
by KIT ligand and other growth factors plays a crucial role in the recruitment of the primordial 
follicle, at least in mice (Sanchez and Smitz, 2012).   
 
 
Figure 1-10 Presumed roles of intra-oocyte phosphoinoside 3-kinase (PI3K) signaling in 
controlling the fate of the primordial follicle pool. An optimal PI3K balance maintains follicle 
survival during dormancy, elevated PI3K signaling leads to follicle activation, while 
suppressed PI3K signaling leads to follicle loss. Adapted and reprinted from Zheng et al, with 
kind permission of Elsevier, Copyright 2012.  
 
1.3.2.4 Primary and secondary follicles 
Primary follicles initiate growth of both their oocyte and granulosa cells, which requires 
a considerable generation of metabolic energy. The oocyte will secrete glycoproteins, that will 
assemble in a circumferential way to form a tick porous shell or coat, the zona pellucida 
(Wassarman et al., 1996).  
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Homogenous follicle growth and differentiation will strongly depend on oocyte-somatic 
cell bidirectional communication. Metabolic cooperation between both compartments is 
essential for the survival of the oocyte. Oocytes are not able to carry out some essential 
metabolic processes, such as glycolysis, uptake of amino acids and synthesis of cholesterol. 
The oocyte manages these metabolic deficiencies by cooperating with the surrounding 
granulosa cells (Sugiura and Eppig, 2005)). It has been shown that, rather than being solely a 
passive recipient of nutritional support, the oocyte has a commanding role on the metabolic 
gene expression in these somatic cells, by the secretion of paracrine factors such as growth 
differentiation factor 9 (GDF9), and the closely related bone morphogenetic factor 15 (BMP15) 
and fibroblast growth factors (FGFs) (Sugiura et al., 2007, Su et al., 2008). On the other hand, 
GDF9 and BMP15 collaborate in enhancing somatic cell growth and differentiation (Gosden 
and Lee, 2010). Intercellular communication between oocyte and somatic cells happens through 
heterologous gap junctions (Kidder and Mhawi, 2002), diffusion, secreted factors and 
endocytosis. This intercellular communication of great importance for the follicle, which must 
stay a coordinated unit until ovulation. 
Anti-Müllerian hormone (AMH), a member of the tumor growth factor (TGF)-b 
superfamily, was first discovered as a testicular glycoprotein causing regression of the 
Müllerian ducts during male embryonic sexual differentiation (Müllerian inhibiting substance) 
(Cate et al., 1986). In females, AMH is produced exclusively by granulosa cells, and production 
starts in the primary follicle stage. Its role is less obvious than in male sexual development, but 
it has become clear that AMH exerts inhibitory actions on the activation of primordial follicles, 
in rodents (Durlinger et al., 2002) and humans (Carlsson et al., 2006).   
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By acquiring a second layer of granulosa cells, the follicle enters the secondary stage, 
and its growth will remain under control of intra-ovarian regulators until the pre-antral stage 
(Richards and Pangas, 2010). 
 
1.3.2.5 Pre-antral to antral follicle transition 
 As the granulosa cell layers increase around the growing oocyte, pre-theca cells are 
recruited from the surrounding stoma and differentiate to theca cells by acquisition of 
steroidogenic function (Young and McNeilly, 2010). Theca cell layers form along the basal 
membrane that surrounds the granulosa cell layers. The follicle builds its own capillary bed 
within the theca cell layer, enabling it to interact with systemic endocrine factors, essential for 
the switch to the gonadotrophin-dependent phase, and for delivering the required nutrient and 
growth factors for the granulosa cells and the oocyte.  
Theca cell maturation and androgen generation are initially solely under auto/paracrine 
control, by factors secreted by the oocyte and the granulosa cells, before becoming responsive 
to LH and insulin during later development (Lebbe and Woodruff, 2013). GDF-9, secreted by 
the oocyte, is essential for theca cell function, as GDF-9 knockout mice fail to develop a theca 
cell layer (Dong et al., 1996). More specifically, GDF-9 has shown to induce expression of the 
key enzyme of androgen biosynthesis, CYP17A1, in pre-antral follicles (Orisaka et al., 2009, 
Vitt et al., 2000b), while suppressing CYP19A1 activity (Vitt et al., 2000a). BMP-4, BMP-6 
and BMP-7, also members of the TGF-b superfamily, have opposite effects, and act via insulin-
like peptide 3 to decrease CYP17A1 expression; they are potent inhibitors of thecal androgen 
secretion (Glister et al., 2005, Glister et al., 2013). Gremlin, chordin, and follistatin, which are 
local binding factors, have the ability to reverse BMP protein’s function and exhibit stimulatory 
effects on theca cell function (Glister et al., 2005). During follicle maturation granulosa cells 
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produce activin that locally suppresses androgen production (Knight et al., 2012). Activins act 
by facilitating FSH secretion and action, thereby enhancing estradiol secretion. Inhibins are 
secreted by the antral follicles, their structure is closely related to activins, sharing common b-
subunits, but they are functional antagonists of activins and decrease FSH action (Figure 1-11). 
Insulin, working in synergy with LH, via receptors expressed on theca cells, induces CYP17 
expression and increases thecal androgen production (Franks et al., 1999). KIT ligand promotes 
thecal differentiation via Erk1/2 –mediated up-regulation of steroidogenic factor 1 (SF-1) (Jin 
et al., 2005).   
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Figure 1-11 Schematic overview of the different stages of folliculogenesis. AMH, Inhibin B and 
Estradiol secretion and interaction with hypothalamo-pituitary axis. Reprinted from Visser et 
al, with kind permission from Macmillan Publishers Ltd: Nature Reviews. Copyright 2012.  
 
AMH levels peak in follicles reaching the stage of FSH selection (preantral stage in 
mice, antral stage in women, Figure 1-11), and decline in mural granulosa cells (but not in 
cumulus cells) as the follicle enters the gonadotrophin-dependent phase (Durlinger et al., 2002, 
La Marca et al., 2009, Weenen et al., 2004, Andersen et al., 2010, Dumesic and Richards, 2013). 
When AMH levels are high, FSH sensitivity of the follicle remains low. In fact, AMH functions 
as a break for FSH-recruitment of antral follicles (Durlinger et al., 2001). Its level has to 
decrease to allow the follicle to be recruited by FSH. In vitro, AMH diminishes the FSH-
induced expression of aromatase (CYP19A1) (Grossman et al., 2008), thereby increasing the 
ration of androgen/oestrogen in the follicle. AMH levels reflect antral follicle count, and serum 
AMH level has become an surrogate marker for follicular reserve in clinical care (Pigny et al., 
2006, Visser et al., 2012, Kristensen et al., 2012).  
The development of a cavitation or fluid-filled central cavity, called antrum, is a 
conspicuous finding in most mammals, including rodents and humans. The graafian follicle is 
characterized by antrum formation that accompanies the exponential granulosa cell 
proliferation and aromatase (CYP19A1) expression, and happens in response to an intrinsic 
paracrine factor (Gore-Langton and Daniel, 1990). Antral follicular fluid is composed by 
transudates of plasma, and follicular secretions (Edwards, 1974). Physiologically, the antrum 
acts as a barrier, limiting passive diffusion of blood-derived gaseous, nutritive and hormonal 
substances across the follicular wall of the rapidly expanding avascular follicle harboring the 
maturing oocyte (Gore-Langton and Daniel, 1990). Structurally, the antrum divides the 
granulosa cell population into central cumulus oophorus cells, and mural granulosa cells 
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proliferating between the antral cavity lining and the basal membrane. Both granulosa cell 
subpopulations are morphologically and functionally distinct, in their steroidogenic capacities 
(Hillensjo et al., 1981), AMH production (Ueno et al., 1989), and LH-receptor distribution 
(Camp et al., 1991). The oocyte plays an important paracrine role in the trans-differentiation of 
granulosa cells to cumulus oophorus cells (Eppig et al., 1997). In mural granulosa cells, FSH 
has proliferative effects, and induces LH-receptor expression, while in in cumulus cells FSH 
does not induce LH-receptor but stimulates production and secretion of hyaluronic acid, 
resulting in mucification and cumulus cell expansion, a prerogative for ovulation (Eppig, 1979). 
 
1.3.2.6 Selection of the dominant follicle(s) 
 FSH restricts the growing follicle cohort in order to allow a dominant follicle to emerge 
in mono-ovulating species, or a larger amount of follicles in poly-ovulators. In women, the rise 
in FSH during the luteal-follicular transition triggers the selection of the follicle that will 
ovulate next, which happens when sufficient FSH is accumulated in the follicular fluid for a 
threshold level to be reached (Welt et al., 1997). The oestrogen and inhibin production by the 
dominant follicle will provide feedback to the hypothalamic-pituitary axis and down-regulate 
FSH secretion, leading to atresia of the remaining cohort of growing follicles (Welt et al., 1997) 
The oocyte of the dominant follicle will continue to develop and accumulate all key 
regulatory factors required for fertilization (Gosden and Lee, 2010). It is important to keep in 
mind that, while the spermatozoon essentially makes a genetic contribution for embryogenesis, 
the oocyte, far more voluminous, is the main cytoplasmic donor, having accumulated all RNA, 
proteins and key organelles required for post-fertilization embryo development (Figure 1-12), 
(Gosden and Lee, 2010).  
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Figure 1-12 Schematic overview of molecular and cellular development of human oocytes. 
Oocyte development is initiated by oocyte growth in small follicles. Competence to resume 
meiosis is reached shortly before ovulation. Transcription becomes silenced after resumption 
of meiosis. Protein synthesis increases to a plateau when the oocyte is fully grown. Adapted 
and reprinted from Gosden and Lee with kind permission from the American Society for 
Clinical Investigation. Copyright 2010.  
 
The somatic follicular compartments and the antral cavity rapidly expand in the pre-
ovulatory follicle, resulting in large estradiol secretion, essential for establishing endometrial 
proliferation and generating the gonadotrophin surge prior to ovulation. 
 
1.3.2.7 Ovulation 
 Ovulation is the unique phenomenon by which the mature pre-ovulatory follicle, 
triggered by the pituitary mid-cycle LH-surge, ruptures and releases a fertilizable oocyte, and 
transdifferentiates the somatic cells to form the corpus luteum (Richards et al., 1998) (Figure 
1-11).  
Ovulation is considered to be a triad of events: cumulus expansion, follicular rupture 
and luteinization. In response to the LH surge occurring prior to ovulation, cumulus cells start 
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to secrete hyaluronic acid, leading to mucidification and cumulus cell expansion (Eppig et al., 
1997). The oocyte will complete its first meiotic division as pictured in Figure 1-13. The oocyte, 
until that point arrested in the prophase of meiosis I, first starts dissolving the envelope of its 
nucleus, a process called germinal vesicle breakdown. A spindle, which is a microtubular 
structure allowing chromosomal movements during cell division, will assemble and align the 
diploid set of chromosomes in the center of the oocyte (called the metaphase). The spindle 
relocates to the pole of the cell, while homologous pairs of chromosomes exchange genetic 
information by forming cross-overs between them, before they segregate in 2 haploid sets 
(anaphase). Finally, an asymmetric cell division takes place with the formation and extrusion 
of the first polar body. The DNA content of the oocyte has been divided, to become an egg, still 
maintaining the majority of the cytoplasm, containing critical stores of maternal components 
essential for fertilization and pre-implantation embryo development. The egg is arrested in 
metaphase II, which it will complete upon fertilization (Clift and Schuh, 2013).  
 
 
Figure 1-13 Schematic image of oocyte maturation and chromosome configuration. Following 
germinal vesicle envelope breakdown, the spindle assembles and moves to the surface of the 
oocyte. Half of the homologous chromosomes segregates and is extruded in the polar body. 
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Around the remaining chromosomes a spindle assembles. The egg arrests in metaphase II until 
fertilization. Adapted from Clift and Schuh, with kind permission from Nature Publishing 
Group. Copyright 2013.  
 
Progesterone-receptor, a down-stream target of LH, is known to be an essential mediator 
of the follicular rupture (Lydon et al., 1996). Progesterone-receptor activation triggers a 
precisely localized inflammatory cascade, with vascular changes and appearance of matrix 
metalloproteinases breaking down the extracellular matrix and ovarian surface epithelium to 
permit extrusion of the oocyte into the oviduct or fallopian tube (Robker et al., 2000).  
Luteinization refers to the terminal differentiation of the granulosa and theca cells, with 
a steroidogenic shift toward progesterone secretion, development of vascularization and 
cessation of proliferation. The corpus luteum is essential for the uterine implantation and early 
survival of the embryo (Murphy, 2000). If the egg is not fertilized, the corpus luteum will 
involute to a corpus albicans or fibrous scar.  
 
1.3.3 Reproductive cycle 
1.3.3.1 Menstrual cycle 
The duration of the menstrual cycle is typically 28 ± 3 days and is divided into two phases: 
the follicular or proliferative phase, and the luteal or secretory phase (Figure 1-14).  
As shown in Figure 1-3 and Figure 1-11, pituitary gonadotrophin secretion is basically 
under negative feedback control by estradiol, progesterone and inhibin (Welt et al., 1997). 
Rising estradiol levels provide negative feedback at the level of the hypothalamus and inhibit 
GnRH and consequently FSH secretion. Rising estradiol levels also provide positive feedback 
with stimulation of LH secretion at the level of the pituitary gland. Decreasing estradiol levels 
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will suppress LH secretion (Welt et al., 1997). Inhibin is secreted in 2 forms, A and B, by the 
follicle and inhibit FSH secretion. Inhibin B is produced by the dominant follicle and peaks in 
the follicular phase. Inhibin A is produced by the corpus luteum and peaks in the luteal phase 
(Messinis, 2006). 
The follicular phase starts on the first days of the menstrual bleeding, and lasts until 
ovulation, occurring mid-cycle (typically day 14). Pituitary FSH, that begins to rise in the last 
days of the previous menstrual cycle, as a results of falling levels of ovarian steroids, will 
cyclically recruit a cohort of 2-5mm antral follicles for further growth and maturation 
(Baerwald et al., 2012). One follicle will emerge as dominant, and is thought to have the highest 
FSH-responsiveness and most abundant estradiol and inhibin-B secretion. As a result, FSH 
levels will decrease and the remaining cohort of antral follicles will die by apoptosis. The rising 
estradiol levels stimulate endometrial and myometrial growth in the uterus, and the cervix 
produces increased amounts of mucus, reducing the vaginal acidity, making it more accessible 
for the entry of sperm. Immediately before ovulation, estradiol levels will reach a peak and the 
enhanced LH secretion will regulate the peri-ovulatory events. The pre-ovulatory LH surge is 
accompanied by a smaller peak in FSH levels, which might be physiologically significant (Kol 
and Humaidan, 2010).  
 At the start of the luteal phase, following ovulation, progesterone secretion by the corpus 
luteum increases and provides negative feedback to the hypothalamic-pituitary unit, and plasma 
levels of LH and FSH decrease. Progesterone is known to raise the basal body temperature by 
0.3-0.50C, and this observation is used to track ovulation. Progesterone increases endometrial 
glandular secretions, and is required to render the endometrium receptive for blastocyst 
implantation. A rise in oestrogen, produced by the corpus luteum, causes further inhibition of 
gonadotrophin secretion, causing corpus luteum suppression with decreased oestrogen and 
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progesterone secretion, and FSH levels begin to rise to initiate the next cyclical recruitment of 
antral follicles. At the level of the endometrium, intense vasospasm occurs in the arterioles, 
leading to ischemia, desquamation and menstrual bleeding. 
 Alternatively, the wane of the corpus luteum is prevented by blastocyst implantation. 
The production of human chorionic gonadotrophin (HCG) by the embryo, which has a similar 
action as LH, maintains corpus luteum survival and progesterone production for 8-12 weeks, 
until the placenta takes over this function.  
 
 
 
Figure 1-14 The menstrual cycle, with circulating levels of gonadotrophins (LH and FSH), 
ovarian steroid hormones (estradiol, progesterone) and cyclical endometrial changes, during 
the follicular and luteal phase. Adapted and reprinted with kind permission from UpToDate.  
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1.3.3.2 Estrous cycle 
 In rodents, the reproductive cycle lasts 4-5 days, and is called the estrous cycle. To 
determine the different cycle phases (proestrous, estrous, metestrous and diestrus), investigators 
typically use vaginal smear cytology and assess the proportion of epithelial cells, cornified cells 
and leucocytes (Evans and Long, 1922) (Table 1-2). 
 
Table 1-2 Characteristics of the mouse estrous cycle, with regard to vaginal smear cytology 
and levels of pituitary and ovarian hormones (based on (Caligioni, 2009)) 
Estrous cycle phase Vaginal smear 
cytology 
LH and FSH levels  Ovarian hormones 
Proestrous Nucleated epithelial 
cells 
Surge during the 
night 
E2 level peak, 
followed by P4 
Estrous Anucleated cornified 
epithelial cells 
low E2 remain elevated 
in the morning, then 
fall back to basal 
levels 
Metestrous Mix of leucocytes, 
epithelial and 
cornified cells 
low Low 
Diestrous Leucocytes low E2 starts to rise 
Abbreviations: E2: estradiol, P4: progesterone  
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1.3.4 Folliculogenesis and oogenesis in vitro 
Alongside the development of assisted reproduction with its clinical implications, 
scientists have been working for more than 40 years on techniques to mature follicles and 
oocytes in vitro, with the aim to improve and widen the applications of reproductive biology. 
In 1977, John Eppig showed for the first time, that mouse oocytes were able to grow and mature 
in vitro, if cultured in the presence of granulosa cells, thereby proving the crucial interactions 
between both cells (Eppig, 1977). Since then, in vitro culture of ovarian follicles and oocytes 
has provided novel knowledge on follicle biology and the mechanisms involved in oocyte 
maturation. An important clinical application of in vitro follicle growth and maturation is under 
development for women desiring to spare their fertility before undergoing gonadotoxic 
oncology treatments. Oncofertility has emerged as a new discipline, linking reproductive 
medicine and oncology, and researches treatment alternative treatment options for ovarian 
tissue transplantation in female cancer patients of reproductive age (Jeruss and Woodruff, 2009, 
Woodruff, 2010). 
Follicle culture has been achieved in vitro, employing 2-dimensional (2D) or adhesive 
systems, or more recently, in spherical 3-dimensional (3D) systems.  
 
1.3.4.1 Pioneering methods of follicle culture  
In 2D culture systems, different types of substrates are used, such as culture dishes 
(Eppig, 1977, Cortvrindt et al., 1996) or collagen trans-wells (Eppig and Schroeder, 1989), to 
which the granulosa cells adhere, allowing the follicle to expand on a flat surface.  
The follicle structure is remodeled, and although gap-junctions and basal membrane continuity 
might be disrupted (Desai et al., 2010), this method have been proven successful in producing 
live offspring in rodents following in vitro follicle culture, oocyte maturation and IVF (Eppig 
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and Schroeder, 1989). Its application in larger mammals, including human (Abir et al., 1997), 
is hampered by the abnormal follicle expansion and aberrant paracrine signaling (Ksiazkiewicz, 
2006).  
 
1.3.4.2 Encapsulated in vitro follicle growth 
To overcome the challenges faced while culturing follicles in 2D, novel non-adherent 
techniques, allowing for 3D follicle proliferation, have recently been developed, including 
‘floating’ and ‘encapsulated’ models (Brito et al., 2014) (Figure 1-15). For the purpose of this 
thesis, the focus is on the alginate encapsulated 3D follicle culture technique, developed by Dr 
Teresa Woodruff, in collaboration with Dr Lonnie Shea at Northwestern University, a decade 
ago.  
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Figure 1-15 (a) Secondary mouse follicle encapsulated in an alginate bead (edge of bead 
indicated by arrows). (b) Follicles stained for viability 1 day after encapsulation are healthy. 
(c,d) Follicles cultured in alginate beads (c) maintain their morphology at day 4 of culture, 
while follicles cultured on 2D substrates (d) have a disrupted follicular architecture. Scale bar 
= 30 µm. Reprinted from Kreeger et al, with kind permission of Pergamon, Copyright 2006.  
 
Alginate is a polysaccharide of repeating b-D-mannuronic and a-L-guluronic units, 
isolated from cell walls of brown algae. It is liquid in its natural form, but cross-links in the 
presence of calcium, and forms a solid-like hydrogel used to surround the follicle (Figure 1-
16).  
 
Figure 1-16 Alginate is a polysaccharide, derived from seaweed, that crosslinkes in the 
presence of calcium to form a solid gel, used to encapsulate ovarian follicles. Courtesy to the 
Woodruff Lab. 
 
 Having achieved success with live birth of healthy offspring in mice (Xu et al., 2006a) 
(Figure 1-17), these 3D model equally support spherical expansion of follicles isolated from 
larger mammals, including murine, bovine, goat, canine, non-human primate, and human-
derived follicles (Xu et al., 2006a, Araujo et al., 2014, Silva et al., 2015, Songsasen et al., 2011, 
Min Xu, 2009, Xu et al., 2009). Studies across species have enabled comparative assessments 
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of biology unique to each species, for example, the physical rigidity of the biomaterial, while 
providing important new insights into the conserved mechanisms governing the follicle 
development (Woodruff and Shea, 2011). 
 
 
Figure 1-17 (A) After 8 days of culture, immature follicle reached the pre-ovulatory stage (B) 
an outer theca cell layer indicated by 3b-hydroxysteroid dehydrogenase staining. (C) 
Meiotically arrested cultured oocytes (D) Resumption of meiosis after exogenous HCG 
stimulation. (E) Metaphase II oocytes fertilized in vitro, and (F) resulting in live offspring after 
transfer into the oviduct of pseudopregnant mouse. Bar 1⁄4 100 mm (A, B), 50 mm (C–E). 
Reprinted from Xu et al, with kind permission of Mary Ann Liebert INC Publishers, Copyright 
2006. 
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Alginate is non-degradable and non-adhesive, and adaptable, making it a unique tissue-
engineered system to support in vitro follicle growth (Kreeger et al., 2005). Through chemical 
changes, extra-cellular matrix proteins, such as collagen, fibronectin or laminin, can be 
incorporated in the alginate scaffold, which has shown to improve the rate of meiotically 
competent oocytes (Kreeger et al., 2006). Additionally, alginate concentrations can be 
modified, which leads to changes in the rigidity of the alginate bead and consequently variation 
in the forces exerted on the enclosed follicle. Decreased alginate concentrations have been 
found to improve follicle growth and oocyte meiotic competence (Xu et al., 2006b, West et al., 
2007). 
 
1.3.4.3  Follicle culture medium and additives 
In vitro follicle culture is dependent on various additives within the culture medium, such 
as nutrients, gonadotrophins, energy substrates, antioxidants and vitamins, involved in in vivo 
endocrine and paracrine regulation of follicle growth and maturation (Brito et al., 2014). 
Follicle culture protocols may include serum, containing many different substrates and growth 
factors, or include purified proteins such as albumin and fetuin (Demeestere et al., 2005). The 
addition of FSH and insulin, transferrin and selenium in follicle culture medium has shown to 
improve follicle growth and morphology, oocyte maturation and steroidogenesis (Silva et al., 
2004, Demeestere et al., 2005). The optimized culture protocol for murine alginate-based 
follicle culture consists of a-minimal essential medium (MEM), substituted with insulin-
selenium-transferrin, FSH, bovine serum albumin (BSA) and fetuin (Xu et al., 2006a). 
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1.4 Effect of androgens on the on the different stages of follicular development 
1.4.1 Pharmacological studies 
1.4.1.1 Primordial to primary follicle transition 
 Testosterone enhances in a non-genomic way the intra-oocyte PI3K balance in mouse 
primordial follicles, thereby increasing by more than two-fold the ratio of primary to primordial 
follicles (Yang et al., 2010). A cortical autograft experimental model in female sheep treated 
with DHEA for 10 weeks resulted similarly in an increased activation of primordial follicles 
(Narkwichean et al., 2014). Rapid non-genomic activation of the PI3K/Akt pathway by 
androgens has been described in other target cells of androgen action (Baron et al., 2004, Kang 
et al., 2004, Cinar et al., 2007). In lamb ovaries, the increase of primary follicle numbers 
following a 5-day incubation with testosterone, was mainly attributed to a decreased rate of 
atresia (Qureshi et al., 2008). In rhesus monkeys, testosterone treatment equally appears to 
promote primordial follicle activation, through elevated intra-oocyte IGF1 (insulin growth 
factor 1) signaling (Vendola et al., 1999a, Vendola et al., 1999b). This androgen action is 
probably non-genomic, as AR is not detected, or is below limit of detection, in primordial 
follicles (Weil et al., 1998). Nevertheless, it is interesting that IGF1 receptor-mediated 
protection from apoptosis is similarly achieved through activation of PI3 kinase (Shelton et al., 
2004). 
 
1.4.1.2 Primary to secondary follicle transition 
 Intercellular communication is of paramount importance for follicle development and 
survival. Gap junctions are intracellular channels, allowing direct exchange of small molecules 
between cells. Connexins are building stones of gap junctions, and connexin 43 is the main 
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connexin found in gonads. In fetal bovine ovaries, exposure to the anti-androgen flutamide at 
mid-gestation decreases the expression of connexin 43 and the amount of granulosa cell-oocyte 
gap junctions (Knapczyk-Stwora et al., 2013). On the contrary, in the mouse ovary (Yang et 
al., 2015b), and in a luteinized granulosa cell line (Wu et al., 2010a), a down-regulation of 
connexin 43 expression is observed in androgen-excess conditions. A non-identical granulosa 
cell differentiation status between both studies could possibly explain the observed dual effect. 
 Testosterone, but not estradiol, stimulates, in a dose-dependent way, the acquisition of 
a second layer of granulosa cells in fetal bovine follicles, and this effect is blocked by the AR 
antagonist flutamide (Yang and Fortune, 2006). The proliferative properties of testosterone 
could be partly mediated through increasing the availability of metabolic energy to the cell, 
such as enhanced glucose-metabolism via Glut4 pathways (Sato et al., 2008). In rhesus 
monkeys, AR expression positively correlates with granulosa cell growth and androgen 
treatment up-regulates the expression of AR in the granulosa cells of healthy pre-antral and 
antral follicles (Weil et al., 1998). Similar findings have been observed in mouse ovarian stroma 
cells (Yang et al., 2015b) and ovaries from testosterone-treated transsexual women (Chadha et 
al., 1994).  
 
1.4.1.3  Pre-antral to antral follicle transition 
 Immunohistochemistry and steroid measurements performed in in vitro-cultured murine 
follicles, elegantly showed that the AR protein translocate from the cytoplasm to the nucleus in 
granulosa and theca cells at the moment the follicle starts to produce androgens (Lenie and 
Smitz, 2009). Indeed, the timeframe surrounding antrum formation is a critical stage of 
androgen action, where AR expression is at its highest (Weil et al., 1998, Lenie and Smitz, 
2009, Yang et al., 2015b). Murine follicles cultured in the presence of anti-androgen serum or 
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with the AR-antagonist Casodex, grew smaller and showed impaired antrum formation, and 
these features were rescued when adding androstenedione or DHT (Murray et al., 1998). 
Treatment of pre-antral follicles with androgen precursors such as DHEA, DHEAS and 
androstenedione, employed at doses ranging from 10-11 to 10-7 M, have equally shown to 
provoke a dose-dependent increase in murine follicle size during culture (Wang et al., 2001). 
In a steroid-depleted environment, obtained by trilostane treatment, a steroid synthesis 
inhibitor, pre-antral macaque follicles in 3D alginate-encapsulated culture exhibited decreased 
survival, grew smaller and developed less frequently an antrum compared with control follicles 
(Rodrigues et al., 2015). High dose (50 ng/ml) testosterone and DHT treatment (Rodrigues et 
al., 2015), as well as estradiol treatment (100 pg/ml and 1ng/ml) (Ting et al., 2015) were able 
to rescue follicle survival and antrum formation to control levels. In this primate model, both 
androgens and oestrogens are survival and growth factors in pre-antral and antral follicles (Ting 
et al., 2015).   
Moreover, a clear synergistic effect between androgens and FSH on pre-antral and antral 
follicle growth has been demonstrated. Vendola and Weil treated female adult rhesus monkeys 
with short term implants of testosterone or DHT, and demonstrated a robust stimulation of 
antral follicle growth, with upregulation of granulosa cell AR and FSH-R expression (Weil et 
al., 1999, Vendola et al., 1998). In individual follicles, the AR and FSH-R expression was 
positively correlated (Weil et al., 1999). Similarly, in small human antral follicles of naturally 
cycling women, a positive correlation between androgen levels in follicular fluid  and FSH-R 
expression in granulosa cells has been observed (Nielsen et al., 2011). It is important to note 
that, in humans, the AR expression precedes the FSH-R expression during follicle development 
(Rice et al., 2007). The concept is that locally produced androgens act via granulosa cell AR to 
promote FSH-induced granulosa cell differentiation. On a molecular level, ligand-activated AR 
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enhances FSH action by stimulating cAMP-mediated post-receptor signaling (Hillier and 
Tetsuka, 1997). A recent study started to unravel the underlying mechanisms of androgen action 
in the antral follicle, and showed that androgen increase FSH-R protein expression, but not 
mRNA, and enhance the mRNA expression of miR125, which protects the follicle from atresia 
(Sen et al., 2014). 
 
1.4.1.4 Pre-ovulatory follicle, ovulation and oocyte maturation 
 Administration of 1 mg testosterone (but not the higher doses) during the follicular 
phase in gilts, increased FSH-R expression in pre-ovulatory follicles, augmented estradiol 
levels and resulted in a higher number of corpus lutea (Cardenas and Pope, 1994, Cardenas et 
al., 2002). Immature mice, superovulated with pregnant mare serum gonadotrophin (PMSG), 
had an improved response when treated with low dose DHT (50mg/kg), but not with higher 
doses, and cyproterone acetate, an AR antagonist, abolished the androgen effect (Ware, 1982). 
A subsequent study in rats, stimulated with PMSG, showed that at lower DHT doses (4 
injections of 1mg/kg DHT), ovulation rates were decreased as a result of decreased follicle 
development and decreased estradiol secretion (Conway et al., 1990). A recent experiment 
confirmed again increased ovulatory rates when gonadotrophin-stimulated mice are exposed to 
low dose androgen treatment (0.25 mg DHT), while in high dose (25 mg DHT) androgen 
conditions this effect was lost (Sen et al., 2014). From these different studies it is clear that 
optimal intra-follicular androgen levels are required to allow the ovary to achieve full-potential 
oocyte yield. 
 Androgen levels are also of importance for oocyte meiotic maturation. Gill et al. showed 
that testosterone (250 nM) was capable of triggering meiotic resumption in mouse oocytes kept 
arrested in vitro in prophase I by phosphodiesterase inhibitor 3-isobutyl-1-methylxan- thine 
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(IBMX) (Gill et al., 2004). A study published more than 20 years ago, showed that short-term 
exposure of murine oocytes to supraphysiological doses of testosterone (µM range) clearly 
inhibited their capacity to resume meiosis, as well as post-fertilization embryo development 
(Anderiesz and Trounson, 1995). Romero et al cultured mouse follicle with FSH and 
aromatisable androgens and observed that meiotic maturation was compromised in follicles 
exposed to androgen concentrations above 200 nM (Romero and Smitz, 2010). 
 
1.4.2 Genetic studies  
 Another approach to delineate AR actions in the ovary is provided by studying the 
phenotype of the female global androgen receptor knockout (ARKO) mouse. With the help of 
recent conditional gene-targeting approach three different mice have been generated, 
containing a targeted deletion of an exon of the AR. Their specific features were the subject of 
a detailed review by Walters, KA (Walters, 2015). ARKOEx1 (Shiina et al., 2006), ARKOEx2 
(Hu et al., 2004) and ARKOEx3 (Walters et al., 2007, Cheng et al., 2013) mice carry a 
heterozygous deletion of AR exon 1, 2 and 3 respectively. All global ARKO mice were 
subfertile (had fewer pups per litter), showed compromised oocyte and follicle development, 
altered gonadotrophin regulation and decreased ovulation rates (Walters, 2015).  
 Further, 2 granulosa cell specific ARKO mice were generated: GC-ARKOEx2 (Sen and 
Hammes, 2010) and GC-ARKOEx3 (Walters et al., 2012b), resulting in subfertility, longer 
oestrus cycles, increased atretic follicles, reduced ovulation rates and premature follicle 
depletion for the GC-ARKO Ex2 mice. The oocyte specific ARKO mouse generated by Sen and 
Hammes (Sen and Hammes, 2010) exhibited maintained fertility. This means that nearly all 
reproductive defects observed in the female global ARKO mouse could be explained by the 
lack of AR in granulosa cells (Sen and Hammes, 2010).  
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1.5 Androgen excess and polycystic ovary syndrome (PCOS) 
1.5.1 Introduction to PCOS  
PCOS is the most frequent endocrine disorder in women and the major cause of 
oligoanovulation. PCOS is a heterogeneous condition, with a range of reproductive and long-
term metabolic complications, that are further aggravated if obesity is present. It affects 5%-
20% of women of reproductive age, depending on the diagnostic criteria employed, and 
manifests clinically predominantly with menstrual dysfunction and hirsutism (March et al., 
2010, Sirmans and Pate, 2013).  
 
1.5.2  Etiology and pathophysiology of PCOS 
 The etiology of PCOS is still unclear, but likely results from a genetic-environmental 
interaction.  
Published case-control genetic studies have yielded multiple candidate genes, but due 
to the lack of large cohort studies, their individual importance remains elusive (Kosova and 
Urbanek, 2013). Genome-wide association studies have mapped genetic susceptibly loci in 
Chinese (Chen et al., 2011, Shi et al., 2012, Lee et al., 2015)  and European ancestry women 
(Hayes et al., 2015) with PCOS phenotypes; several identified genes are involved in the 
regulation of gonadotropin secretion and action, underlying the crucial role of FSH and LH in 
the pathogenesis of PCOS.  
The presence of obesity, sedentary lifestyle and unhealthy diet are the main 
environmental factors, aggravating the PCOS phenotype (Diamanti-Kandarakis et al., 2006a).  
Hyperandrogenism and insulin resistance are cardinal features of PCOS (Figure 1-18).  
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1.5.2.1 Hyperandrogenism  
Hyperandrogenemia is the most consistent feature in PCOS, and originates from the 
ovaries, adrenal gland, as well as peripheral tissue generation from DHEA and increased 
peripheral conversion of testosterone to DHT (Ehrmann et al., 1995, Stewart et al., 1990) . 
Ovarian excess androgen production is related to an intrinsic abnormality of theca cell 
function, possibly resulting from enhanced steroidogenic enzyme activity (Nelson et al., 2001, 
Franks and Hardy, 2010). The gonadotrophin secretion is altered in PCOS, with a plasma ratio 
of LH to FSH levels that is characteristically increased. It is believed that oestrogens, derived 
from peripheral aromatization of androgens, exert positive feedback with pituitary 
hypersecretion of LH and negative feedback with hyposecretion of FSH (Rebar et al., 1976). 
The increased LH further drives thecal androgen production. The inappropriately low FSH 
levels are responsible for deficient dominant follicle selection, follicular arrest and anovulation 
(Hillier, 1994, Franks, 1995).  
An adrenal contribution to androgen excess might exist in some patients, manifesting 
by increased circulating DHEA and DHEAS levels (Kumar et al., 2005). The adrenal androgen 
excess may result from qualitative changes in the androgen secreting enzyme CYP17A1, with 
increased 17,20 lyase activity, promoting androgen production, although this hypothesis could 
not be proofed in vitro (Azziz et al., 1998, Martens et al., 2000).  
In simple obesity, almost one quarter of circulating testosterone originates from 
peripheral conversion of androstenedione, a reaction mediated by 17b-hydroxysteroid 
dehydrogenase (also called aldoketoreductase type 3, AKR1C3), mainly occurring in adipose 
tissue (Quinkler et al., 2004). New evidence points towards increased AKR1C3 activity in 
subcutaneous adipose tissue in women with PCOS, driving adipose androgen generation 
(O'Reilly et al., 2015). In women with PCOS, significantly increased 5a-reductase activity in 
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peripheral target tissues, such as in the liver, is a recognized contributor to the excess androgen 
production (Fassnacht et al., 2003). Increased 5a-reductase activity was found in both obese 
and nonobese PCOS women, and correlated with BMI, insulin levels and homeostasis model 
assessment (Stewart et al., 1990, Vassiliadi et al., 2009). Increased 5a-reductase activity was 
also observed in daughters of women with PCOS (Torchen et al., 2016), thereby amplifying 
androgen action in target tissues.  
 
1.5.2.2 Insulin resistance  
Insulin resistance is the diminished ability of insulin to mediate its metabolic actions for 
the production and uptake of glucose and the breakdown of lipids, resulting in a compensatory 
increased insulin secretion, called hyperinsulinemia (Kahn, 1985). Insulin resistance is present 
in up to 70% of the PCOS patients, in obese as well as lean patients (Brennan et al., 2009). In 
PCOS, the peripheral metabolic insulin resistance has a selective pattern, affecting muscle and 
adipose tissue but not the ovary (Diamanti-Kandarakis and Dunaif, 2012). Even in the presence 
of insulin resistance, insulin interacts with insulin-like growth factor to increase CYP17A1 
activity and androgen production in the theca cells (Bergh et al., 1993)  
Obesity is a known causative factor for insulin resistance, but seems to have an 
exacerbated effect in obese PCOS women compared to BMI-matched control women 
(Manneras-Holm et al., 2011). Abdominal, or central, obesity has an enhanced metabolic 
activity and is more detrimental for the development of insulin resistance, compared with 
subcutaneous obesity (Barber and Franks, 2013).  
Androgen excess and insulin resistance are closely associated in PCOS.  A mechanistic 
or causative link between both conditions has not been established yet. Abnormal kinase 
hyperphosphorylation of both the insulin receptor and CYP17A1, causing insulin resistance 
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and androgen excess respectively, has been investigated in fibroblasts of PCOS women, but 
this study failed to proof this hypothesis (Martens et al., 2000). 
 
 
Figure 1-18 Current understanding of PCOS pathophysiology. Androgen excess and insulin 
resistance perpetuate the vicious cycle of increased ovarian and extra-ovarian androgen 
production and adipose tissue oestrogen generation. The latter results in deficient 
gonadotropin secretion, contributing to the ovarian hyperandrogenenism and the deficient 
dominant follicle selection, leading to chronic anovulation. Obesity reinforces the vicious cycle. 
 
1.5.3 Diagnostic criteria 
The Rotterdam criteria for the diagnosis of PCOS (Rotterdam, Eshre Asrm-Sponsored 
PCOS consensus workshop group), established in 2003 and revised in 2004 (Rotterdam, 2004), 
resulted from a general agreement on 3 characteristic features of PCOS. Because the condition 
is heterogeneous, not all patients are equally affected, and 2 out of the 3 following criteria are 
  53 
required for diagnosis: clinical and/or biochemical signs of hyperandrogenism, menstrual 
disturbancies (oligo-or anovulation) and the presence of polycystic ovaries on ultrasound.  
The Rotterdam criteria have extended the previously published National Institute of Health 
(NIH) criteria, focusing on hyperandrogenemia and menstrual irregularities, by adding a 
subgroup of patients with polycystic ovaries (PCO) on ultrasound, coupled with either signs of 
androgen excess or chronic anovulation. Recent guidelines for PCO diagnosis recommend the 
presence of ³25 follicles on ultrasound, and an ovarian volume > 10ml (Dewailly et al., 2014b).  
In 2006, the Androgen Excess Society has reinforced the notion that hyperandrogenism is the 
cardinal feature of PCOS, and should be present at diagnosis, together with menstrual disorders 
and/or PCO (Azziz et al., 2006).  
The diagnostic criteria for PCOS, summarized in Table 1-3, all have to be preceded by 
the exclusion of other causes of androgen-excess or related disorders, such as congenital adrenal 
hyperplasia (CAH) and its non-classical form, Cushing’s disease, androgen-producing adrenal 
or ovarian tumours, idiopathic or racial hirsutism, hyperprolactinaemia and thyroid disorders  
(Sirmans and Pate, 2013, Pasquali et al., 2016a). 
 
Table 1-3 Diagnostic criteria for PCOS, to be employed after exclusion of other causes of 
androgen excess or related disorders 
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Using the diagnostic criteria, four different combinations and PCOS phenotypes are 
determined: i) hyperandrogenism and oligoamenorrhea, ii) hyperandrogenism, polycystic 
ovarian morphology without oligoamenorrhea, iii) oligoamenorrhea and polycystic ovarian 
morphology without hyperandrogenism and iv) hyperandrogenism, oligoamenorrhea and 
polycystic ovarian morphology.  
 
1.5.4 Genetics of PCOS 
PCOS is a common and heritable disease, as observed in families and twin studies 
(Legro et al., 1998). Hyperandrogenemia is found in daughters of women with PCOS during 
puberty, which may result from genetic factors or epigenetic modifications of androgens in 
utero during specific developmental time-frames (Sir-Petermann et al., 2009) A large genome-
wide association study in women with National Institute of Health PCOS diagnosis 
(hyperandrogenism and anovulation), of European ancestry has determined 3 loci of genetic 
susceptibility, associated with the highest risk for metabolic morbidities (insulin resistance and 
dysglycemia), and reproductive hormone levels (Hayes et al., 2015). The different loci 
discovered in this study are discussed below, and add to another list of PCOS susceptibility loci 
in Chinese patients diagnosed according to the Rotterdam criteria (Shi et al., 2012). It is 
considered that these variants only account for the minority of the PCOS-heritability (Hayes et 
al., 2015)  
 
1.5.4.1 Chromosome 11p14. FSHB/ARL14EP locus 
FSHB encodes the FSH b polypeptide, and was strongly associated with LH levels as 
well as PCOS diagnosis in European (Hayes et al., 2015) and Asian (Tian et al., 2016) women 
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. These findings strongly suggest that gonadotrophin dysregulation is involved in the etiology 
of PCOS. FSH levels are relatively deficient in PCOS and LH-secretion is increased, 
contributing to anovulation and androgen excess.  
 
1.5.4.2 Chromosome 8p32.1 GATA4/NEIL2 locus 
The GATA4 proteins are zinc-finger transcription factors that have promotors in many 
genes, and are involved in gonadal development (Gustin et al., 2016) and steroidogenesis 
(George et al., 2015). NEIL 2 encodes a protein involved in DNA repair. 
 
1.5.4.3 Chromosome 9q22.32 c9orf/FANCC locus 
This locus has also been found to be associated with PCOS (Rotterdam criteria) in Han-
Chinese (Shi et al., 2012) and encodes for proteins involved in proteolysis and activation of 
peptides (aminopeptidase O), and DNA-repair (FANCC) (Hayes et al., 2015) 
 
1.5.5 Clinical signs and symptoms of PCOS 
The Stein-Leventhal syndrome was first described in 1935 in 7 women with 
amenorrhea, hirsutism and bilateral polycystic ovaries (Stein, 1955). The long-standing debate 
and difficulties surrounding a consensus regarding diagnostic criteria for PCOS result from the 
heterogeneous clinical manifestations of this syndrome. In most cases, PCOS comes to clinical 
attention because of menstrual irregularities, leading to subfertility, or skin manifestations of 
hyperandrogenism, such as hirsutism or acne. In later life, the metabolic challenges come at the 
forefront of medical attention in PCOS women: insulin resistance and increased risk of type 2 
diabetes, hepatic steatosis (Kelley et al., 2014) and an enhanced cardiovascular risk profile, 
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especially in the presence of obesity. Lifestyle measurements, such as weight reduction and 
exercise, are considered to be the most effective means to normalize the menstrual cycle and 
prevent metabolic complications (Jayasena and Franks, 2014).  
 
1.5.5.1 Biochemical hyperandrogenism 
Total serum testosterone concentration is the first-line laboratory test for diagnosing 
PCOS. Immunoassays, in particular direct platform assays, are largely inaccurate for measuring 
testosterone levels in the female range (Rosner et al., 2007), and mass-spectrometry based 
assays are now considered to be the most appropriate technique, but require age- and ethnicity-
based reference ranges (Conway et al., 2014) Two recent studies have demonstrated the 
superior sensitivity and specificity of LC-MS/MS-measured androstenedione in diagnosing 
hyperandrogenism in women with PCOS, compared with testosterone (O'Reilly et al., 2014, 
Pasquali et al., 2016b). Free androgen index (FAI), calculated by the ratio between total 
testosterone and SHBG (Vermeulen et al., 1999) is the most sensitive measure of 
hyperandrogenism in PCOS (Conway et al., 2014). Circulating DHEA and DHEAS levels are 
heterogeneously affected among PCOS women, and are not conferred diagnostic value, but are 
related to varying degrees of adrenal contribution to androgen excess.  
 
1.5.5.2 Clinical hyperandrogenism  
Clinical signs of androgen excess are hirsutism, excess hair growth, in a male-type 
pattern, acne and androgenic alopecia (Legro et al., 2013). Hirsutism is a common feature, and 
present in up to three quarter of women with PCOS (DeUgarte et al., 2006). The severity of 
hirsutism is recorded clinically using the modified Ferriman-Gallwey index (Yildiz et al., 2010) 
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whereby terminal hair growth and distribution is examined in 9 areas of the body and a score 
of > 8/36 is considered pathological (Figure 1-19). This score has been criticized, because of 
the large variability of the scoring system with poor agreement between patient and medical 
staff observations (Wild et al., 2005). Younger age, larger waist circumference and higher 
serum testosterone levels were independent predictors of hirsutism in an observational study of 
1297 PCOS patients (Panidis et al., 2013).  
 
 
Figure 1-19 Modified Ferriman-Gallwey score. Terminal hair growth is scored from 1 
(minimally present) to 4 (equivalent to hairy male), in 9 body areas: upper lip, chin, chest, arm, 
upper and lower abdomen, lower back and tights. If no terminal hair is present in a specific 
area, the score is 0. A sum of scores > 8, is considered as clinically relevant hirsutism. 
Reprinted from Yildiz, with kind permission of Oxford University Press, Copyright 2010.  
 
A recent study observed that the modified Ferriman-Gallwey score did not correlate 
with blood total testosterone levels, which indicate that local androgen metabolism at the 
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pilosebaceous unit, dependent on local steroidogenic enzyme expression, circulating androgen 
levels and local androgen receptor expression, determine the severity of hirsutism (Pasquali et 
al., 2016b). 
Mild hirsutism requires local cosmetic treatment (waxing or shaving), and topical facial 
Eflornithine cream inhibiting hair growth, which may reduce the frequency of hair removal. An 
alternative consists of permanent photo-epilation therapy by laser (Legro et al., 2013).  
The addition of systemic treatments, aiming to reduce androgen production or decrease 
the sensitivity of the hair follicle to androgens, are recommended for severe hirsutism (Jayasena 
and Franks, 2014). Both the ESHRE/ASRM (Fauser et al., 2012) and the Endocrine Society 
(Legro et al., 2013) guidelines suggest oral contraceptive pills as first line systemic treatment 
to improve hirsutism, acne and menstrual irregularities for those PCOS patients not seeking 
fertility. The first generations of progestin were related to testosterone and had varying degrees 
of androgenic effects, while the recent progestins are designed to have progesterone-receptor 
activity and have no or even anti-androgenic effects (such as drosperidone or cyproterone 
acetate) (Yildiz, 2015).  
 
1.5.5.3  Oligo/Amenorrhea  
 Women with PCOS experience uterine bleedings that are unpredictable, with regard to 
the onset and the duration of the periods (Burgers et al., 2010). This reflects the disturbed 
menstrual pattern, with dysfunctional follicle maturation and failure of the emergence of a 
dominant follicle, resulting in chronic anovulation (Franks, 1995). Circulating oestrogen levels 
in PCOS women are normal or even increased, resulting in normal endometrial proliferation, 
and the vaginal bleedings are frequently oestrogen-breakthrough bleedings. Secondary 
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amenorrhea refers to the absence of menstruation for ³ 6 months in a women with previous 
periodic bleedings, while oligomenorrhea is used to design < 9 menstruations per year.  
Lifestyle measurements and weight loss (5-10% of total body weight) are the primary 
treatment in overweight and obese PCOS patients, and have the ability to restore menstrual 
regularity and ovulation (Moran et al., 2009). If weight reduction is unsuccessful, and fertility 
is not warranted, low dose combined oral contraceptive pills have the benefit of providing 
regular withdrawal bleedings (Fauser et al., 2012, Legro et al., 2013). Oral contraceptives (OC) 
contain a combination of low dose of oestrogens, generally ethinyl estradiol in a dose of 20-35 
µg and a progestin (0.1-0.3 mg). Oestrogens and progestins in OC exert negative feedback on 
the hypothalamus, with suppression of FSH and LH secretion, and subsequently absence of 
dominant follicle secretion, ovulation, endometrial priming and fertile cervical mucus secretion 
(Christin-Maitre, 2013). The hormonal preparations might have adverse cardiovascular and 
metabolic outcomes in some PCOS patients, such as the occurrence of venous thrombosis or 
the increased risk of diabetes (Yildiz, 2015). To prevent these complications, a thorough patient 
and family history and clinic examination is required, before prescribing OC. The World Health 
Organisation (WHO) has published Medical eligibility criteria for contraceptive use (Yildiz, 
2015). 
Metformin, an insulin sensitizer, in combination with weight loss, can ameliorate 
ovulation rates in women with PCOS (Moghetti et al., 2000). 
 
1.5.5.4 Anovulation and infertility 
 Oligomenorrheic women with PCOS have a reduced fecundability, meaning that they 
may take a longer time to conceive, but their final family size is comparable to that of the 
population as a whole (Fauser et al., 2012). Chronical anovulation and amenorrhea however, 
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leads to infertility in approximately 40% of women with PCOS (Sirmans and Pate, 2013). In 
most instances, ovulation can be induced pharmacologically, if lifestyle measures have proven 
to be ineffective. Clomiphene citrate is the first line treatment (Legro et al., 2013). It is an orally 
administrated oestrogen receptor antagonist, that is given in the first days of the menstrual cycle 
to decrease the negative feedback of oestrogen on gonadotropin secretion. At the adequate dose, 
it has the ability to raise plasma FSH levels to adequate follicular phase levels, and stimulate 
ovarian follicle maturation (Thessaloniki, 2008). Metformin is sometimes used in combination 
with Clomiphene citrate, but its benefit in ovulation induction is not proven (Jayasena and 
Franks, 2014). In a double blind randomized controlled trial, grouping 288 PCOS patients 
treated in multiple centers, ovulation rates following clomiphene treatment were 72%, and 
following clomiphene plus metformine 64% (Moll et al., 2006). Alternative ovulation induction 
techniques are low dose gonadotrophin stimulation, laparoscopic ovarian drilling (Hendriks et 
al., 2014), or IVF.  
 
1.5.5.5 Metabolic risks 
Obesity is a common, but not necessary, feature of PCOS, and when present, it 
aggravates the adverse metabolic profile of the patient, because of its independent association 
with type 2 diabetes mellitus and cardiovascular morbidity (Galani and Schneider, 2007). 
Insulin resistance and subsequent hyperinsulinemia drive androgen excess and lay the basis for 
the increased risk for developing glucose intolerance and type 2 diabetes later in life (Moran et 
al., 2010). However, overt deterioration of glucose metabolism is almost uniquely observed in 
obese women with PCOS, with BMI levels > 30 kg/m2, while lean PCOS women display 
intrinsic insulin resistance, but to a less extent compared with their obese peers (Pasquali and 
Gambineri, 2013)   
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Women with combined hyperandrogenemia, anovulation and polycystic ovarian 
morphology, the most severe form of PCOS, are clearly at increased risk developing 
cardiovascular events (Wild et al., 2010). These patients generally have increased body weight, 
but still have a higher degree of central adiposity, dyslipidaemia and insulin resistance 
compared with age- and BMI-aged controls (Fauser et al., 2012). However, PCOS is a highly 
heterogeneous condition, and affected women can move between phenotypes depending on 
alterations in body weight, diet and exercise, with subsequent modifications of their metabolic 
risk profile (Welt and Carmina, 2013).  
It has become recently clear that androgen excess is an independent driver of metabolic 
risk, and that increasing severity of androgen excess is associated with higher prevalence of 
insulin resistance and adverse metabolic risk profile (O'Reilly et al., 2014, Pasquali et al., 
2016b). 
 
1.5.6 Ovarian manifestations of PCOS  
1.5.6.1 Intrinsic deregulation of early follicular development 
The characteristic histological feature of PCOS ovaries is an increased number of 
growing follicles, with the presence of atretic cystic follicles, in an enlarged collagenous stroma 
(Hughesdon, 1982). A similar ovarian phenotype is found in patients with adrenal androgen 
excess, such as congenital adrenal hyperplasia (White and Bachega, 2012, London, 1987), 
indicating that androgens are essential contributors to the exaggerated follicle development. 
Morphological studies indicate that the dysfunctional follicular development in PCOS starts at 
the early gonadotrophin independent stages. Ovarian cortical biopsies from anovulatory PCOS 
women showed a 6 times increase in density of pre-antral follicle numbers compared to normal 
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ovaries, including primordial and primary follicles (Webber et al., 2003). The balance between 
resting and growing follicles in PCOS is clearly disturbed, but the underlying mechanisms 
remain poorly understood (Franks and Hardy, 2010). AMH, known to play a role in suppressing 
primordial follicle recruitment, has been implicated in this process. Immunostaining for AMH 
in cross-sections of normal and PCOS ovaries have shown that primary and transitional follicles 
from ovaries of anovulatory PCOS women express less AMH protein (Stubbs et al., 2005). The 
relative AMH-deficiency in the early stage PCOS follicles could possibly contribute to the 
increased follicle activation. On the other hand, studies have shown, that, when sustained in in 
vitro culture, PCOS follicles exhibit decreased atresia rates, and survived longer than normal 
follicles (Webber et al., 2007). Decreased atresia and prolonged longevity would be another 
explanation for the increased pool of growing follicles observed in PCOS. However, in vivo, 
atresia rates in PCOS ovaries were comparable with normal follicles (Maciel et al., 2004).  
The endocrine cells of PCOS follicles show signs of intrinsic deregulations. Human 
granulosa and theca cells from normal cycling women and PCOS patients exhibit different 
behavior in culture, especially with regard to their gonadotrophin sensitivity and the response 
to insulin. Granulosa cells from anovatory PCOS women were steroidogenically more active 
and produced 6-10 times more estradiol in response to FSH than normal granulosa cells (Mason 
et al., 1994). This is probably explained by the increased expression of FSHR on PCOS 
granulosa cells, induced by the local androgen excess (Mason et al., 1994). PCOS theca cells 
showed a more than 10-fold increase in basal and LH-induced androstenedione production (the 
main ovarian androgen secreted in vivo) during primary culture, compared with normal theca 
cells (Gilling-Smith et al., 1994). Production of progesterone, 17-OH progesterone, DHEA and 
testosterone were also increased, in basal condition, and this was more pronounced following 
forskolin-stimulation, mimicking LH-induction (Nelson et al., 1999). Moreover, mRNA 
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expression studies in PCOS-derived theca cells demonstrated increased expression of 
steroidogenic enzymes CYP11A1, CYP17A1 and 17b-HSD in human theca cells, and the 
activity of CYP17A1, 3b-HSD and 17b-HSD was increased compared with theca cells obtained 
from normally cycling women (Nelson et al., 1999). Normal small pre-antral follicles were 
found to become responsive to LH-stimulation when they reached 9.5-10 mm diameter, while 
the PCOS follicles showed premature LH-responsiveness, that became obvious at diameters of 
only 4 mm (Willis et al., 1998). The androgen excess and the inadequate response to LH 
override the FSH-induced aromatase expression and prematurely switched the granulosa cell 
steroid outcome from oestrogen to progesterone (Willis et al., 1998). 
Furthermore, 5a-reductase activity significantly increased in PCOS follicles compared 
with control follicles (Jakimiuk et al., 1999), and the accumulation of 5a-reduced androgen 
further suppressed aromatase activity (Agarwal et al., 1996).  
Insulin, at physiological doses, interacts with insulin-like growth factor to increase 
CYP17A1 activity and androgen production in ovarian theca cells (Bergh et al., 1993). Insulin 
resistance, frequently associated with PCOS, results in compensatory hyperinsulinaemia, which 
in turn fuels the androgen hypersecretion (Diamanti-Kandarakis and Dunaif, 2012). As 
mentioned earlier, insulin resistance in PCOS appears to be selective. Studies in human 
granulosa-lutein cells, obtained at egg retrieval following gonadotrophin-stimulation in the 
setting of IVF, have shown that ovarian steroidogenesis in PCOS remained responsive to the 
stimulatory effects of insulin (Rice et al., 2005). However, the metabolic effects of insulin, i.e. 
glucose uptake and utilization, were decreased in granulosa-lutein cells obtained from 
anovulatory PCOS women (Rice et al., 2005) or even absent in PCOS women with diagnosed 
insulin resistance (Fedorcsak et al., 2000).   
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1.5.6.2 Stromal hyperplasia, rigidity, hypervascularity, and inflammation 
Histological examination of polycystic ovaries revealed a highly increased thickness of 
the cortical, but mostly the subcortical medullar stroma, associated with hypervascularity 
(Hughesdon, 1982). The enlarged ovarian stromal volume can be measured by ultrasound and 
correlates with the degree of hyperandrogenism (Fulghesu et al., 2007, Kyei-Mensah et al., 
1998). Microarray data from PCOS ovarian tissue showed differential expression of genes 
known to be involved in extracellular matrix organization (Jansen et al., 2004). On the protein 
level, several molecules involved in fibrogenesis were upregulated in PCOS stroma (Ma et al., 
2007). Increased levels of basic fibroblast growth factor (bFGF) were measured in serum and 
follicular fluid of PCOS women (Artini et al., 2006). The enhanced fibroblast proliferation and 
extracellular matrix deposition results in increased rigidity of the ovarian cortex (Lebbe and 
Woodruff, 2013). An important research question is whether the stromal hyperrigidity 
contributes to the intrinsically altered steroidogenic behavior of the antral follicles in PCOS 
(Woodruff and Shea, 2011). Although ‘rigid’ or non-permissive culture conditions in murine 
in vitro follicular culture were associated with decreased steroid production in multi-layered 
follicle (Xu et al., 2006b), the effect of rigidity on smaller follicles has not been studied yet. 
The blood flow velocity, examined by color Doppler ultrasound, was greatly increased 
in polycystic ovaries (Zaidi et al., 1995), mainly in the cortex (Delgado-Rosas et al., 2009). 
Circulating vascular endothelial growth factor (VEGF) levels were typically increased in PCOS 
women, and were correlated with the Doppler measurements of ovarian stromal blood flow 
(Agrawal et al., 1998). Laparoscopic ovarian drilling, a surgical technique aiming to reduce the 
ovarian volume, reduced Doppler measurements of ovarian stromal blood flow (Parsanezhad 
et al., 2003), with concomitant decrease of plasma levels of VEGF (El Behery et al., 2011) and 
androgens (Kaaijk et al., 2000). The increased cortical blood flow in PCOS maintains the 
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exaggerated connective tissue proliferation and, importantly, supplies the enclosed early-staged 
follicles with inadequate amounts of oxygen, metabolic and endocrine factors (Lebbe and 
Woodruff, 2013). The profoundly altered follicular microenvironment in PCOS is an important 
disruptor of the normal follicle dynamics (Figure 1-20). 
PCOS is also characterized by a chronic low-grade inflammatory process, which is more 
prominent in the presence of obesity, and manifests with elevated plasma levels of C-reactive 
protein (CRP), inflammatory cytokines (IL-6 and others), and leucocytes (Diamanti-
Kandarakis et al., 2006b). The contribution of these inflammatory parameters in the 
pathogenesis of PCOS remains unclear. It has been postulated that, as follicle become activated 
to grow, it chemically attracts stromal macrophages, which stay associated with this follicle 
throughout its maturation (Tingen et al., 2011). In benign prostate hypertrophy, stromal 
hyperplasia is partly mediated through the infiltration of macrophages, and their recruitment is 
described as an androgen-dependent mechanism (Izumi et al., 2013). Similar epithelial-stromal 
interactions might possibly play a role in the pronounced stromal hyperplasia occurring in 
PCOS (Lebbe and Woodruff, 2013).  
The communication between the ovarian follicular and stromal compartment is a crucial 
notion that contributes to the complex pathogenesis of PCOS (Lebbe and Woodruff, 2013), 
(Figure 1-20). 
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Figure 1-20 Working model for follicular-stromal interactions in the pathogenesis of PCOS. 
Follicular arrest results from the imbalance between androgens, FSH and AMH. Circulating 
FSH-levels are inappropriately low and dominant follicle selection fails. The PCOS cortex 
shows signs of remodeling, partly mediated by increased local androgen concentrations, and 
maintained by increased cortical blood flow. Reprinted and adapted from Lebbe et al, with kind 
permission of Oxford University Press. Copyright 2013. 
 
1.5.6.3 Oocyte quality in PCOS  
The oocyte quality in PCOS has mainly been studied in the context of assisted 
reproduction, in infertile PCOS women not responding to ovulation-induction by clomiphene. 
As mentioned earlier, PCOS is characterized by an increased FSH sensitivity. During controlled 
ovarian stimulation, the requirement for exogenous gonadotrophins is reduced (Sahu et al., 
2008, Mulders et al., 2003). To diminish the risk of ovarian hyperstimulation syndrome (OHSS) 
low-dose gonadotropin protocols have been developed for PCOS, facilitating the development 
of an appropriate amount of follicles (Kumar et al., 2011). Nevertheless, at the time of egg 
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retrieval, the yield is typically increased in PCOS, compared with non-PCOS controls (Heijnen 
et al., 2006, Weghofer et al., 2007). The fertilization potential of PCOS oocytes is decreased 
and indicative of compromised oocyte quality (Urman et al., 2004). The chromosomal 
organization and euploidy rates appear to be normal in PCOS (Sengoku et al., 1997, Weghofer 
et al., 2007). But the microenvironment of the oocyte, the follicular fluid, contains hallmarks 
of metabolic dysregulation contributing to the impaired oocyte quality, and more pronounced 
in obese PCOS patients, with elevated free androgen index and free fatty acids (Niu et al., 
2014). The cytoplasmic oocyte development is clearly altered in PCOS, and reflected by a 
distinctly abnormal gene expression profile (Wood et al., 2007).  
The increased oocyte yield counter-balances the reduced oocyte quality and the final 
result is similar clinical pregnancy and live birth rates between PCOS patients and controls 
following assisted reproduction (Bailey et al., 2014, Weghofer et al., 2007, Heijnen et al., 2006, 
Urman et al., 2004). A recent retrospective study reported decreased pregnancy and live birth 
rates in obese PCOS patients compared with lean PCOS patients (Bailey et al., 2014). 
In vitro maturation (IVM) has recently become an alternative for standard assisted 
reproductive techniques, IVF and intracytoplasmatic sperm injection (ICSI) (Lindenberg, 
2013). The main aim of this technique is to avoid the risk of ovarian hyperstimulation syndrome 
in PCOS, as the oocytes are retrieved from unstimulated cycles, but the success rates in terms 
of live birth are inferior to IVF (Das et al., 2014, Walls et al., 2015). Another concern regarding 
in vitro maturation, is the presence of high rates of meiotic abnormality in the immature oocytes, 
but no difference is observed in chromosomal and spindle configuration between PCOS and 
control oocytes (Zhu et al., 2015). 
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1.5.7 Animal models of female androgen excess 
1.5.7.1 Rodent models 
 Patient material for research is scarce in PCOS, and in vivo research faces ethical 
limitations. Hence, the use of animal models reproducing some of the reproductive and 
metabolic features of PCOS is of invaluable aid in the study of the pathogenesis and 
management of PCOS. Currently, rodent, sheep and non-human primate models of PCOS have 
been extensively studied (Caldwell et al., 2014). Rodent models have the advantage to be 
affordable, require easy logistical care, have a short reproductive cycle, brief gestational 
periods, and can be genetically manipulated (Caldwell et al., 2014).  
 Numerous rodent models have been generated over the last 50 years, to mimic one or 
more of the PCOS traits in women, employing a variety of treatments and manipulations, and 
are reviewed in (Walters et al., 2012a). Hyperandrogenism is the most consistent PCOS feature, 
and Table 1-4 summarizes the phenotypes of the recent rodent models employing prenatally or 
postnatally administered testosterone or DHT. 
 
Table 1-4 Ovarian and extra-ovarian phenotype in rodent PCOS models, generated by 
administration of pre-natal or postnatal testosterone (T) or dihydrotestosterone (DHT). 
Abreviations: estradiol (E2), progesterone (P4), luteinizing hormone (LH). 
Reference Type of rodent and 
treatment 
Intra-ovarian effects Extra-ovarian effects  
(Sullivan and 
Moenter, 2004) 
Mouse, prenatal 
DHT  
Irregular oestrous 
cycles 
­T and ­LH 
(Beloosesky et al., 
2004) 
Rat, postnatal T Cysts, ­­pre-antral 
follicles 
Delayed puberty, 
¯P4,­oocyte 
  69 
degeneration, insulin 
resistance 
(Wu et al., 2010b) Rat, prenatal T and 
DHT 
Irregular oestrous 
cycles, ­pre-antral 
and antral, ¯pre-
ovulatory follicles, 
¯corpus luteum 
­T, ­P4, ­E2, ­LH 
(Roland et al., 2010) Mouse, prenatal 
DHT 
Irregular oestrous 
cycles 
­T ­LH ­fasting 
glucose, impaired 
glucose tolerance, 
­size of visceral 
adipocytes 
(van Houten et al., 
2012) 
Mouse, postnatal 
DHT 
Anoestrous, ­atretic 
follicles, cysts 
­body weight, ­size 
of adipocytes, 
­leptin, 
¯adiponectin, 
glucose intolerance 
(Moore et al., 2013) Mouse, prenatal 
DHT 
Irregular oestrous 
cycles, ­antral 
follicles,¯ovulation 
­T, ­LH 
(Caldwell et al., 
2014) 
Mouse, prenatal 
DHT 
 
Irregular 
cycles,¯ovulation, 
Adipose hypertrophy 
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Mouse, postnatal 
long-term DHT 
¯preantral follicle 
health 
Plus ¯antral follicle 
health and acyclicity 
 
 
Plus ­body fat, 
dyslipidemia 
  
It is important to keep in mind that no single model entirely replicates the full-blown 
spectrum of PCOS in women. The phenotype heterogeneity of the rodent models is dependent 
on the time, duration and dose of androgen exposure and the use of aromatisable testosterone 
likely to induce oestrogen-dependent events. The use of long-term (>3 weeks) DHT in the 
postnatal pre-pubertal mouse induces most of the PCOS traits found in women (van Houten et 
al., 2012, Caldwell et al., 2014). 
 
1.5.7.2  Non-human primate models 
In utero exposure of non-human primates to androgens has generated model animals 
that exhibit striking similarities to PCOS women, with regard to anovulation, polycystic ovarian 
morphology, hyperandrogenism, LH hypersecretion and insulin resistance. These primate 
studies are highly informative, but come with an elevated cost, and require long developmental 
periods, and are, in contrast to rodents, not amendable to genetic engineering (Caldwell et al., 
2014).  
Table 1-5 highlights the ovarian and systemic characteristics of the reported primate 
PCOS models, generated by gestational or postnatal androgen exposure.  
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Table 1-5 Ovarian and systemic characteristics on primate models of PCOS, generated by 
prenatal or postnatal administration of testosterone (T) or dihydrotestosterone (DHT). 
Abbreviations: progesterone (P4), luteinizing hormone (LH) and Western Style Diet (WSD).  
Reference Treatment Intra-ovarian features Extra-ovarian features 
(Dumesic 
et al., 1997) 
Prenatal T none ­LH and ­LH/FSH 
(Vendola et 
al., 1998) 
Postnatal T and 
DHT 
­number of antral follicles, 
enlarged ovaries 
N/A 
(Abbott 
and Bacha, 
2013) 
Prenatal T in 
early gestation 
Oligomenorrhea, enlarged 
polyfollicular ovaries 
­LH, insulin resistance, 
abdominal obesity, 
hyperlipidaemia 
(McGee et 
al., 2012) 
Postnatal pre-
pubertal T 
No effect on ovarian 
morphology, menstrual 
cyclicity or ovulation rates  
­ LH pulse frequency, 
no clear metabolic 
features 
(McGee et 
al., 2014) 
Postnatal pre-
pubertal T, and 
Western Style 
Diet (WSD) to 
induce obesity 
WSD ± T result in ­ number of 
small antral follicles and 
¯ maximum follicle size.  
T + WSD: ­number of small 
antral follicles in the luteal 
phase and ¯P4 
WSD increased body fat 
from <2 to 15-19% 
LH pulse frequency ­ in 
control to similar levels 
as T-treated animals, LH 
pulse amplitude ¯ 
WSD ± T ¯insulin 
sensitivity after 1 year 
(Bishop et 
al., 2015) 
Western-Style 
Diet (WSD), 
WSD ± T result in ­numbers of 
small antral follicles, ­number 
differential gene 
expression for steroid, 
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with and without 
pre-pubertal T 
treatment 
of atretic follicles, ­CYP17A1 
staining, differential gene 
expression for ovarian 
pathways 
carbohydrate, lipid 
metabolism pathways 
 
Adult primates, exposed during gestation with testosterone, exhibit a variety of ovarian, 
hormonal and neuro-endocrine PCOS traits (Dumesic et al., 1997, Abbott et al., 2013). These 
studies raise the question of a fetal origin in PCOS, and to whether in utero exposure to 
androgen excess, coupled with hyperinsulinaemia and/or hyperglycemia, might predispose or 
aggravate PCOS in the offspring (Abbott and Bacha, 2013). This interesting hypothesis is 
challenged by a large prospective human cohort study, failing to observe a relationship between 
maternal or umbilical cord androgen concentrations and incidence of adolescence PCOS in the 
child (Hickey et al., 2009). However, the animal studies teach us that the time of androgen 
exposure during gestation is critical for the outcome of the offspring. Early-mid gestational 
androgen exposure resulted in LH hypersecretion and adverse metabolic outcomes (such as 
increased abdominal adiposity and insulin resistance), while androgen excess during late 
gestation provoked no LH-hypersecretion and induced a milder metabolic risk profile (Walters, 
2015). 
Feeding Rhesus monkeys with Western-style diet, rich in lipids and carbohydrates, 
generated obesity, which in turn, independent of androgen levels, provoked some PCOS 
features, such as LH hypersecretion and exaggerated small antral follicle development. 
However, obesity combined with androgen excess, clearly exacerbated the PCOS phenotype, 
inducing increased ovarian androgen secretion, luteal insufficiency, insulin-resistance, and 
altering the metabolic gene expression (Xu et al., 2015, Bishop et al., 2015, McGee et al., 2014). 
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In vitro alginate-encapsulated culture revealed that pre-antral follicles from Western-diet fed 
androgen-excess monkeys had impaired survival, decreased oestrogen and AMH production 
and produced meiotically-incompetent oocytes (Xu et al., 2015).  
 
1.6 Reproductive dysfunction in androgen deficiency syndromes  
1.6.1 Adrenal androgen deficiency 
1.6.1.1 Manifestations and diagnosis of adrenal deficiency 
There are two forms of adrenal insufficiency: primary and secondary failure. Primary 
adrenal failure (PAI) or Addison’s disease is a rare disorder, affecting predominantly women 
between 30 and 40 years of age, and resulting from auto-immune destruction of the 
steroidogenic cells in the adrenal cortex (Lebbe and Arlt, 2012). Secondary adrenal 
insufficiency results from deficient adrenocorticotropic hormone (ACTH) production, due to 
hypopituitarism related to a hypothalamic-pituitary disease or to negative feedback suppression 
of ACTH by pharmacological glucocorticoid treatment (for asthma or rheumatic disease for 
example) (Arlt and Allolio, 2003).  
Adrenal insufficiency manifests with signs and symptoms related to a decreased levels of 
glucocorticoid, mineralocorticoid (in PAI only) and adrenal androgen hormones, and their 
intensity depends on the onset and the extent of adrenal hypofunction. Classical symptoms 
include asthenia and excessive fatigability, gastro-intestinal complaints, weight loss, arterial 
hypotension and hyperpigmentation (in PAI only) (Table 1-6). Occasionally PAI presents with 
a life-threatening adrenal crisis, a fulminating shock with severe hypotension, acute abdominal 
pain, vomiting and increased body temperature (Arlt and Allolio, 2003).  
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Table 1-6 Clinical presentation of primary and secondary adrenal insufficiency, with symptoms 
related to deficient production of glucocorticoid, mineralocorticoid and adrenal androgen 
synthesis.  
Signs or Symptoms in Adrenal Insufficiency 
a. Related to Glucocorticoid Deficiency 
• Weakness 
• Asthenia, fatigue 
• Weight loss 
• Hypoglycemia 
b. Related to Mineralocorticoid Deficiency (occurs in PAI only) 
• Anorexia, nausea, vomiting, abdominal pain 
• Orthostatic hypotension, syncope 
• Salt craving 
• Hyponatremia, low bicarbonate levels 
• Hyperkalemia 
c. Related to Adrenal Androgen Deficiency 
• Low energy levels, decreased well-being 
• Reduced libido 
• Decrease in axillary and public hair 
d. Cutaneous and mucosal hyperpigmentation (in PAI only), related to an increase in 
proopiomelanocortin (POMC) 
 
The diagnosis of adrenal insufficiency relies on the demonstration of a decreased adrenal 
glucocorticoid reserve following exogenous ACTH stimulation in the presence of a suggestive 
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clinical context. In routine clinical practice, the short synacten test (SST) is considered a safe 
and reliable tool with established predictive diagnostic value. The cut-off for adrenal 
insufficiency is usually defined as plasma cortisol levels of < 500 nmol/L (18 µg/dL) 30 or 60 
minutes after 250 µg ACTH administration (Bornstein et al., 2016). Plasma ACTH levels 
further distinguish between primary (high ACTH) and secondary (low ACTH) forms of adrenal 
insufficiency.  
 
1.6.1.2 Management of adrenal insufficiency 
All patients with adrenal insufficiency require long-life hormonal treatment and 
surveillance, to ensure replacement of the physiological daily cortisol and aldosterone 
production (Arlt, 2009). In case of adrenal crisis, emergency hydrocortisone injection and fluid 
administration are life-saving (Arlt, 2009). A trial of adrenal androgen replacement, that can be 
achieved by 25-50 mg oral DHEA daily, can be tried in women with PAI suffering from low 
libido, decreased energy levels, or depressive symptoms, despite optimal glucocorticoid and 
mineralocorticoid hormone replacement (Bornstein et al., 2016), although the Endocrine 
Society guideline do not recommend this option, because of the paucity of data supporting 
efficacy and long-term safety (Wierman et al., 2014a). Patients diagnosed with adrenal 
insufficiency should remain under specialized care and benefit from adequate education 
regarding their disease and treatment needs. 
 
1.6.1.3 Fertility issues in primary adrenal insufficiency 
Subfertility is commonly referred to as the inability for a couple to achieve pregnancy 
after at least 12 months of regular unprotected sexual intercourse (Zegers-Hochschild et al., 
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2009). Subfertility is caused by a variety of male and female factors. The diagnosis of PAI in a 
women of reproductive age has repercussion on female fertility (Lebbe and Arlt, 2012). In a 
national Norwegian survey reporting on 269 female patients with PAI, a significant decline in 
fertility was observed; the standardized incidence ratio (SIR) of live birth was 0.97 before the 
diagnosis of PAI, and dropped to 0.69 after establishment of the diagnosis. Eight % of females 
experienced premature ovarian insufficiency following PAI, but even when excluding this 
subgroup, fertility in PAI women remained reduced at 0.72 (Erichsen et al., 2010). An Italian 
cohort study of 258 female PAI patients, from which 52 (20.2%) developed premature ovarian 
insufficiency, confirmed the strong association between both conditions; and observed 
increased prevalence in patients harboring an autoimmune polyendocrine syndrome (APS) 
(Reato et al., 2011).  
Premature ovarian failure is defined as hypergonadotrophic amenorrhea, with 
hypogonadism and infertility, occurring in a woman before the age of 40 (Goswami and 
Conway, 2007). Autoimmune premature ovarian failure is characterized by the presence of 
autoimmune antibodies directed against steroidogenic enzymes, such as 21-hydroxylase, 17-
hydroxylase or side-chain cleaving enzyme; leading to progressive exhausting of the follicular 
pool (Falorni et al., 2012). This type of premature ovarian failure is found almost exclusively 
in association with auto-immune PAI (Hoek et al., 1997), but might not be the sole factor 
responsible for decreased fertility rates found in these patients. It is firmly established that 
Addison’s patients suffer from impaired subjective health, and increased mortality (Bancos et 
al., 2015) which are likely to impact on reproductive function.  
The relative contribution of decreased adrenal DHEA production on ovarian function and 
the implications for subfertility in PAI remain unknown. Controlled clinical trials studying the 
effects of DHEA replacement on reproductive outcomes in women with PAI are currently 
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lacking. A recently published clinical case relates a spontaneous pregnancy following DHEA 
replacement in a previously infertile Addison’s patient with severe hypoandrogenism (Gleicher 
et al., 2016).   
 
1.6.2 Physiological androgen deficiency 
1.6.2.1 Age-related decline in circulating androgen levels and in ovarian reserve  
As illustrated in Figure 1-4, circulating DHEAS levels peak in the second decade, 
followed by a progressive decline with age.  This age-dependent decline in DHEAS level is 
parallel, but more pronounced, compared with the decrease in serum testosterone (Orentreich 
et al., 1984), and also shows important inter-individual variability (Spencer et al., 2007), 
suggestive of a genetic influence. 
The ovarian reserve consists of the resting pool of primordial follicles, which is the most 
abundant pool of follicles, that diminishes over time by atresia and entry into the growing 
follicle pool. In routine clinical practice, the growing pool of follicles is assessed by measuring 
early follicular phase FSH levels, circulating AMH levels or by antral follicle count using 
ultrasound measurement (Dewailly et al., 2014a). It is important to realize that these surrogate 
markers only target the pool of growing follicles, as the primordial follicle pool cannot be 
clinically assessed. A woman’s ovarian reserve is compared to age-related reference values and 
classified as normal for age, or low (low ovarian reserve, LOR).  
The DHEAS curve over time mimics closely the natural decline in fecundability observed 
over a woman’s reproductive lifespan; with a significant decrease beginning around the age of 
32 years and a steep decline observed after age 37 (Faddy et al., 1992). Indeed, age-related 
reduction in androgen levels parallels decrease in antral follicle count and circulating levels of 
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AMH (Nardo et al., 2009). The decrease in AMH and Inhibin B concentrations with advancing 
age is associated with a progressive increase in circulating levels of FSH (American College of 
et al., 2014). Advancing maternal age is characterized by decreased oocyte quality, as 
manifested by increasing aneuploidy and miscarriage rates (Balasch and Gratacos, 2012).  
 
1.6.2.2 Low ovarian reserve and poor ovarian response 
The diminished fertility potential with advancing age as most important determinant is 
termed low ovarian reserve (LOR), sometimes also referred to as premature ovarian ageing. If 
the abnormal ovarian reserve is accompanied by a raise of FSH into the menopausal range (> 
40 IU/l) in a women younger than 40 years of age, the diagnosis of premature ovarian failure 
(POF) or primary ovarian insufficiency is made (Goswami and Conway, 2007).  
Patients with low ovarian reserve do almost invariably have low success chances to 
achieve pregnancy spontaneously, and their subfertility is mostly addressed through in vitro 
manipulation of gametes and embryos, in a variety of treatments commonly called assisted 
reproductive techniques (ART); IVF is one of them (International Committee for Monitoring 
Assisted Reproductive et al., 2009). Although the overall success rates in achieving live birth 
with IVF are around 20% to 50% (Zegers-Hochschild et al., 2009), women with low ovarian 
reserve respond poorly to IVF; their outcomes are characterized by poor follicular development 
following gonadotropin stimulation, low oocyte yield, decreased oocyte quality and low 
pregnancy and live-birth rates (Reproductive et al., 2011). Poor ovarian response is the term 
used to indicate a reduced follicular response to ovarian stimulation, yielding a decreased 
numbers of oocytes for assisted reproduction (American College of et al., 2014). Poor ovarian 
response is defined by the presence of 2 out of 3 of the following criteria: advanced maternal 
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age, a previous episode of poor ovarian response, or an abnormal ovarian reserve test (AMH or 
antral follicle count) (Ferraretti et al., 2011). 
 
1.6.2.3 Androgen treatment in low ovarian reserve 
In the last decade androgen treatment has been used in reproductive medicine to ‘boost’ 
early follicle growth and development in the context of low ovarian reserve, and subsequently 
improve the success rates for live birth following ART. The aim of androgen treatment is to 
benefit from the described evidence of AR-mediated stimulatory effect on preantral follicle 
growth and survival, and the priming role on FSH-action, leading to increased follicle 
development and improved oocyte yield following ovarian stimulation (Prizant et al., 2014), 
although specific underlying mechanisms remain poorly understood.   
DHEA, which has been studied since more than 20 years for its anti-ageing properties 
(Morales et al., 1994, Arlt, 2004), has first shown to improve ovarian response to gonadotrophin 
stimulation in a small series published in 2000 (Casson et al., 2000). A few years later, DHEA 
as pre-treatment in IVF procedures in women with low ovarian reserve, was reported to improve 
oocyte yield and fertilization rates (Barad and Gleicher, 2006). Since then, DHEA has been 
widely used as adjuvant therapy for women with low ovarian reserve or ovarian ageing 
undergoing ART, and case reports indicate improved pregnancy rates (Barad et al., 2007, 
Gleicher and Barad, 2011), and reduced incidence of miscarriage (Gleicher et al., 2009). 
Testosterone has also, but to a lesser extent, been used as adjuvant therapy in IVF cycles for 
low responders, and beneficial effects on pregnancy rates have been reported (Kim et al., 2011).  
However, the clinical benefits of androgen supplementation in low ovarian reserve patients as 
an adjunct to ovarian stimulation remain highly debated (Sunkara et al., 2011) and even 
controversial (Urman and Yakin, 2012). A recent meta-analysis of a very limited number of 
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controlled randomized trials (Wiser et al., 2010) and case-control studies (Barad and Gleicher, 
2005, Gleicher et al., 2010) regarding the use of adjuvant DHEA demonstrated no effect on 
pregnancy and miscarriage rates in the treatment group (Narkwichean et al., 2013). The 
interpretation of the results of the studies is hampered by the different androgens used (DHEA 
and testosterone), different doses and durations of treatment, and by the fact that most reports 
fail to indicate baseline measurements of androgens in the patients (Fanchin et al., 2011). A 
recent Cochrane Database Review on 8 randomized controlled trials (n=878 participants) 
employing DHEA as adjunct therapy in poor responders, compared with placebo or no 
treatment, showed an association with increased live birth rates (OR 1.88, 95% CI 1.30 to 2.71) 
(Nagels et al., 2015). These numbers suggest that women who have 12% of chance of ongoing 
pregnancy or live birth if they do not receive treatment, increase their chances to 15-26% if 
treated with DHEA (Nagels et al., 2015). Although this increased success rate might seem 
convincing, the authors conclude that the quality of evidence was moderate, because of major 
limitations in the methodology of the included studies (Nagels et al., 2015).  
However, in the subgroup of women diagnosed with low ovarian reserve and concomitant 
hypoandrogenism, the rationale for androgen replacement is more obvious, and effectively 
improved IVF outcomes have been reported (Gleicher et al., 2013a, Gleicher et al., 2013b). 
Oral DHEA or transdermal testosterone are currently the most utilized androgen 
treatment options (Arlt, 2006). DHEA has the advantage of being a precursor hormone, that is 
converted to downstream sex steroids in target tissues that possess the appropriate steroidogenic 
enzyme machinery (Labrie, 2010). Therefore, DHEA supplementation rarely leads to 
supraphysiological circulating androgen level and systemic adverse virilizing effects 
Despite the weak clinical evidence, DHEA and testosterone supplementation are widely 
used in fertility clinics, illustrating the need for appropriately powered prospective randomized 
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trials to optimally guide evidence-based clinical practice (Sunkara et al., 2012). Women with 
low ovarian reserve clearly benefit from adequate measurements of adrenal and ovarian 
androgens, although the physician faces the sensitivity limitations of the current assays in 
precise measurements of female androgens in the lower quartile range (Wierman et al., 2006). 
Of note, the latest guidelines released by the Endocrine Society recommend against the 
generalized use of DHEA or testosterone for infertility because of insufficient evidence, and 
absence of clear indications (Wierman et al., 2014a). 
 
1.7 Research hypothesis and aims of the study 
This thesis aims to investigate the synthesis and metabolism of androgens in the different 
stages of folliculogenesis, and the effects of exogenous androgen exposure on follicle 
development and steroidogenesis, using a murine in vitro encapsulated three-dimensional 
follicle culture system and steroid metabolic profiling by liquid chromatography tandem mass 
spectrometry (LC-MS/MS).  
My hypothesis is that individual follicles progressively acquire the capacity to produce 
androgens in vitro, and that androgens are converted to oestrogens in the final stages of follicle 
development. I further hypothesize that addition of exogenous androgens or androgen 
precursors promotes follicle growth and steroid production in the early stages but impedes on 
antral follicle development.  
 
1.7.1 The endogenous sex steroid production by follicles in physiological conditions 
The steroidogenic function of the developing ovarian follicle has not been studied in 
detail yet, because of the difficulty to mimic in vivo conditions in the laboratory, and because 
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of the low concentrations of endogenous steroids synthetized, which render adequate 
measurements difficult. Previously published steroid hormone data were performed employing 
immunoassays, which are known to be less accurate compared to mass-spectrometry because 
they achieve lower sensitivity and specificity, and are prone to cross-reactivity (Stanczyk, 
2006).  
• I will measure the endogenous sex steroid production in murine follicles as they 
acquire steroidogenic capacity and develop to pre-ovulatory follicles, in basal 
conditions, with minimal FSH-stimulation, employing LC-MS/MS.  
• I will study the gene expression profiles of steroidogenic enzymes during follicle 
maturation and examine the association between sex steroid concentrations and 
steroidogenic gene expression results. 
 
1.7.2 The effect of exogenous androgens on endogenous follicular steroid production 
Androgen treatment is widely used in reproductive medicine, with the aim to increase 
fertility is women with low ovarian reserve, but indications and benefits of such treatment 
remain largely debated (Sunkara et al., 2012, Urman and Yakin, 2012, Gleicher et al., 2011, 
Narkwichean et al., 2013). I will examine if and to which extent the endogenous steroid 
production of the growing follicle is influenced by exposure to exogenous androgens.  
• I will examine the LC-MS/MS steroid metabolome in follicles exposed to the 
potent androgen DHT  
• I will study the metabolism of the androgen-precursor DHEA, employed as a 
steroid substrate, by developing ovarian follicles.  
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1.7.3 The androgen receptor-mediated effects of androgens on follicle development  
A few studies have looked at the direct effects of androgens at the single follicle level, 
in mice (Murray et al., 1998, Wang et al., 2001, Romero and Smitz, 2010, Tarumi et al., 2012, 
Tarumi et al., 2014, Sen et al., 2014) and non-human primates (Rodrigues et al., 2015). 
Although further knowledge on follicular androgen action has been gained through these 
studies, interpretation of androgen-mediated actions remained hampered by the use of 
aromatisable androgens or the lack of AR-blockade.   
• I will expose developing follicles to the non-aromatisable androgen DHT and 
examine the effects on follicle morphology and survival, steroid production, 
mRNA expression of target genes of follicle development and oocyte quality. 
• I will antagonize the androgen effects on the follicle, employing the highly 
selective anti-androgen enzalutamide (MDV), and explore the differential 
biological actions in comparison to DHT. 
 
1.7.4 The effects of increasing androgen provision to the growing follicle 
Most studies examining androgen-excess effects on ovarian physiology are using a whole 
animal or whole organ approach. The direct consequences of supra-physiological doses of 
androgens on individual maturing follicles and oocytes need further attention.  
• I will expose the maturing follicles to increasing doses of the androgen precursor 
DHEA, and examine the effects on follicle morphology, target gene expression, 
steroid and peptide hormone production and oocyte quality. 
• To delineate the androgen and oestrogen-dependent effects, I will compare these 
findings with those observed in follicles treated with an increased dose of DHT 
or estradiol (E2).   
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• I will use a whole organ approach, employing in vitro culture of neonatal CD1 
mice ovaries, to test the effects of increasing concentrations of DHT on ovarian 
follicle dynamics, evaluated by follicle counting.  
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2.1 Murine Encapsulated In Vitro Follicle Culture  
2.1.1 Animals 
CD1 mice were housed and bred in  
 in a temperature and light-controlled (12 h light, 12 h dark cycle) 
environment, and were provided with unrestricted access to water and chow (Mouse Diet 20 
Mouse Diet 20 (PicoLab 5058)). Non-weaned pups (day 15-17) were culled at , in a 
laminar flow hood, by cervical dislocation and the female reproductive tract was excised. The 
procedure was carried out in accordance with the UK Animal Act 1986.  
2.1.2 Follicle isolation procedure 
Following excision, the female reproductive tissue was transported in L15 Glutamax 
medium (Thermo Fisher Scientific, Loughborough, UK) supplemented with 1% Fetal Bovine 
Serum (FBS, Sigma-Aldrich, Gillingham, Dorset, UK) and 0.5 % Penicillin-Streptomycin 
(Thermo Fisher Scientific) in a carrier-incubator at 37°C. Upon arrival in the laboratory, ovaries 
were removed from their bursa (Figure 2-1) with the aid of forceps and using a dissection scope, 
on a 37°C heated, temperature controlled stage, in a laminar flow hood.  
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Figure 2-1Mouse ovarian dissection; excision of the female reproductive tract, followed by 
removal of the ovary from its bursa under the dissection scope. Courtesy of the laboratory of 
Dr.T.K. Woodruff, Northwestern University Chicago (Follicle handbook_2014).  
 
The released ovaries were transferred to a dish containing L15 medium supplemented 
with 0.1% DNase I (Lorne Laboratories Limited, Reading, UK) and 0.1% Liberase TM (Roche, 
Life Science, West Sussex, UK), and placed on a shaker in a 37°C 5% carbon dioxide (CO2) 
incubator for 35-40 minutes. After addition of 10% FBS, to terminate the enzymatic reaction, 
secondary multilayered follicles (diameter 150-180 µm) were mechanically isolated employing 
insulin-gauge needles under a dissection scope. Follicles were placed in maintenance medium 
containing minimal essential medium (α-MEM Glutamax, Life Technologies Ltd, Paisley, UK) 
with 1% FBS and 0.5% Penicillin-Streptomycin for 2-3 hours in a 37°C 5% CO2 incubator.  
 
2.1.3 Follicle encapsulation 
2.1.3.1 Preparation 
          Alginate (NovaMatrix, Sandvika, Norway) was lyophilized in the laboratory of Dr. 
T.K. Woodruff, at Northwestern University Chicago, and shipped to the University of 
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Birmingham as part of the collaboration in this project. The day prior to follicle culture, 
lyophilized alginate was reconstituted with sterile solution PBS without Ca2+ (Dulbecco’s 
Phosphate Buffered Saline without Calcium Chloride & Magnesium Chloride, 1X, Gibco, 
Life Technologies) to a concentration of 0.5%. After brief vortexing, the reconstituted 
alginate vial was left on orbital shaker overnight, or until completely dissolved. Before use, 
the tube was vortexed and centrifuged briefly to remove any air bubbles.   
Calcium solution was prepared by mixing 50 mM CaCl2 and 140 mM NaCl in 500 mL 
MilliQ water until dissolvation, and followed by sterile filtering with a 0.22 µm Millipore 
Stericup filter (Millipore, Watford, UK), in the laminar flow hood. 
To construct a mouth pipette, used to collect the follicles, YGON tubing (Thermo Fisher 
Scientific) was employed to insert a mouth piece into one end (Sigma-Aldrich), and a 0.22 µm 
MILLEX GP Filter (Millipore) at the other end. The filter was connected to an aspirator tube 
(Sigma-Aldrich), which has on the other side a 0.2 µm Syringe Filter (Nalgene, Thermo Fisher 
Scientific) placed. The tip part of a Pasteur pipette (VWR, Lutterworth, UK) was broken, and 
the sharp edges were melted under a flame, to obtain the glass pipette, which was placed into 
the cut end of a rubber bulb (Thermo Fisher Scientific). The glass pipette was closed using the 
rubber stopper from the aspirator tube (Sigma-Aldrich). A hole was performed in the stopper 
to allow the stripper tip (200 µm, Origio Ltd, Fareham, UK) to be placed (Figure 2-2).  
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Figure 2-2Schematic of a mouthpipette. Courtesy of the laboratory of Dr. T.K.Woodruff 
(follicle handbook_2014).  
 
2.1.3.2 Technique 
Following isolation, follicles were transferred, with the use of a mouthpipette, to 
maintenance medium containing minimal essential medium (α-MEM Glutamax, Life 
Technologies) with 1% FBS and 0.5% Penicillin-Streptomycin, and left to recover for 2-3 hours 
in a 37°C 5% CO2 incubator.  
Five mL of calcium solution was prepared in the outer ring of an IVF dish, and 0.5 mL 
of alginate was placed in the center ring. Under the dissection scoop in the laminar flow hood, 
follicles were transferred to dissection media for encapsulation. The mouth pipette was used to 
pick up 3 follicles, which were washed in alginate, and individually sucked up by a 10 µL 
pipette, set to 5 µL, while gently filling up the tip with alginate. The alginate/follicle content 
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was slowly expelled from the tip, perpendicular over the calcium solution, with the droplet 
gently touching the calcium solution and allowing the bead to crosslink for 2 minutes, with 
slight modifications to the previously described protocol (Xu et al., 2006a). The beads are 
transferred with a forceps to a new dish of maintenance medium in in a 37°C 5% CO2 incubator 
for a recovery period of 2-3 hours.  
 
2.1.4 Follicle culture and imaging 
2.1.4.1 Follicle culture medium 
Alginate beads were transferred to a 96-well plate, with each well containing 100 µl 
culture medium, consisting of α-MEM Glutamax supplemented with 3 mg/ml bovine serum 
albumine (BSA, MP Biomedicals, Leicester, UK), 10 mIU/ml recombinant follicle-stimulating 
hormone (rFSH, Gonal-f, Merck Sereno, Feltham, UK), 1 mg/ml bovine fetuin (see below) and 
5 µg/ml insulin, 5 µg/ml transferrin and 5 µg/ml selenium (ITS, Sigma-Aldrich). Fetuin, a 
glycoprotein added to follicle culture medium to prevent hardening of the zona pellucida 
(Schroeder et al., 1990), was dialyzed and lyophilized at the laboratory of Dr. T.K. Woodruff, 
at Northwestern University Chicago, and provided to the University of Birmingham as part of 
the collaboration in this project. Follicles were cultured for 6 days in 37°C 5% CO2 incubator. 
Media change (50 µl) was performed on alternate days; i.e. day 2 and 4 of culture. 
 
2.1.4.2 Follicle treatments 
For the treatment conditions, culture medium was supplemented with 25 or 50 nM DHT 
(Sigma-Aldrich); 100, 200 or 500 nM DHEA (Sigma-Aldrich); and 10 or 25 nM E2 (Sigma-
Aldrich). The steroid concentrations employed were based on published dose-response 
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experiments (Wang et al., 2001, Sen et al., 2014). For androgen receptor-blockade, 
Enzalutamide (MDV) (Axon Medchem, Groningen, T) was used at the dose of 1 µM, based on 
its IC50 value (Tran et al., 2009). 
 
2.1.4.3 Follicle imaging 
Following plating, encapsulated follicles were imaged using Nikon Eclipse Te300 light 
microscope (Leica, Nikon) with 10 X objective, on a 37°C, temperature-controlled heating 
plate. Those follicles with intact alginate beads, and with preserved integrity of the oocyte and 
somatic cell compartment were selected for culture. Imaging was repeated on day 2, 4 and 6 of 
culture. Images were analyzed using Image J Software (National Institutes of Health, Bethesda, 
MD, USA) (Figure 2-3). Follicles sizes were obtained by averaging two perpendicular 
measurements of follicle diameters. The movement of the oocyte to an eccentric position with 
appearance of a fluid-filled space determined the presence of an antrum. Follicles were 
classified as dead if the oocyte or somatic compartment appeared shrunken or dark, if their 
interphase was compromised or the alginate bead disrupted. Only surviving follicles were 
included in the data analysis.  
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Figure 2-3 Follicle growth and development during the 6-days of alginate-encapsulated 
culture. Antrum formation start around day 4 in basal conditions. Scale-bar 100 µm 
 
2.2 In vitro follicle maturation 
2.2.1 Removal of follicles from alginate beads 
Alginate lyase (Sigma-Aldrich) was added to maintenance medium (10 IU lyase/mL of 
media) and equilibrated in the 37°C 5% CO2 incubator for 30 minutes. All culture medium was 
removed from the wells containing alginate beads and 100 µl alginate lyase-maintenance 
medium mix was added to each well. The 96-well plate was transferred to the incubator for 25-
30 minutes. A mouthpipette with a bend 600 µm stripper tip was used to remove the follicles 
from the beads.  
2.2.2 Follicle maturation medium 
Follicles isolated from their alginate bead were transferred in a dish containing 
Follicle	growth	and	development	during	encapsulated	culture
Day	0 Day	2 Day	4 Day	6
Preantral follicle Antrum	Formation
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maturation medium composed of α-MEM Glutamax, 10 % FBS, 1.5 IU/mL human chorionic 
gonadotropin (HCG, Sigma-Aldrich), and 5 ng/mL epidermal growth factor (EGF) (BD 
Biosciences, Oxford, UK) for a washing step. Next, the follicles were placed in the center of an 
IVF dish containing maturation media and incubated for 16 hours at 37°C, 5 % CO2.  
 
2.2.3 Oocyte quality and maturation status 
After 16 hours in maturation medium, follicles released their oocyte-cumulus 
complexes. Oocytes were denuded from the surrounding cumulus cells by treatment with 0.3 
% hyaluronidase (Sigma-Aldrich) for 2-3 minutes in the 37°C, 5 % CO2 incubator, followed 
by and gentle aspiration, using a 100 µl pipette tip. The oocytes were transferred to L15 medium 
and covered by ultra-pure oil, followed by imaging. The oocyte quality was assessed and 
follicles were classified as healthy, or degenerated based on the cytoplasmic appearance (Figure 
2-4). Healthy oocytes were further divided as mature, or meiosis II, if a polar body was visible 
in the perivitelline space. Healthy oocytes that hadn’t resumed meiosis were classified as 
immature, and contained meiosis I and germinal vesical staged oocytes (Figure 2-4). 
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Figure 2-4 Oocyte quality and nuclear maturation following in vitro maturation at the end of 
culture. Completion of the first meiotic division is visualised by the presence of the first polar 
body in the perivitilline space (white arrow).Scale bar 100 µm.  
 
2.3 Neonatal mouse ovarian culture 
CD1 mice were housed and bred in  
. A temperature, humidity, and light (12hL/12hD) controlled barrier facility was used 
to house and breed the mice. Mice were provided with food and water ad libitum. The mice 
were fed Teklad Global (Madison, WI) irradiated chow (2919 or 2916) that does not contain 
soybean or alfalfa meal but does contain minimal phytoestrogens. Five-day old CD1 mice were 
culled by cervical dislocation and female reproductive tracts were excised.  Ovaries were 
removed from the ovarian bursa and washed twice with culture medium, consisting of a-
minimal essential medium (αMEM Glutamax) supplemented with recombinant FSH (10 
mIU/mL; A. F. Parlow, National Hormone and Peptide Program, National Institute of Diabetes 
and Digestive and Kidney Diseases), bovine serum albumin (3 mg/mL), bovine fetuin (1 
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mg/mL; Sigma-Aldrich, St. Louis, MO), insulin (5 ng/mL), transferrin (5 ng/mL), and selenium 
(5 ng/mL), as previously described (Jin et al., 2010). Ovaries were transferred into 6-well plates 
with tissue culture well inserts (nontissue culture treated; Millicell- CM, 0.4-um pore size; 
Millipore Corp., Billerica, MA). Into the compartment below the membrane insert, 1500 uL of 
culture medium was added, such that ovaries on the membrane were covered with a thin film 
of medium. Up to six ovaries were placed in each well. Ovaries were cultured in basal 
conditions or in medium supplemented with DHT (Sigma-Aldrich) at concentrations of 1x10-7 
M and 1x10-8 M with stock solutions prepared in ethanol, and diluted in growth medium. 
Control medium contained the equivalent amount of ethanol as treatment medium. The ovaries 
were incubated at 37C, 5% CO2, for 4 days (96 hours).  
2.4 Ovarian histology and follicle counting 
At the end of the culture period, ovaries were fixed overnight in modified Davidson 
solution at 4°C, transferred to 70% ethanol, and then dehydrated in an ethanol series and 
embedded in paraffin wax. Sections (5 µn) were stained with hematoxylin and eosin (H&E). 
20 X images were taken from each 5th section, using a color camera and microscope. The 
number of follicles at each developmental stage was counted and averaged in three serial 
sections from the largest cross-sections through the center of the ovary. Only follicles that 
contained an oocyte nucleus were counted, and follicles were classified according to 
morphological criteria, as described by Bristol-Gould et al (Bristol-Gould et al., 2006). 
Primordial follicles have a small oocyte that is partially or completely surrounded by squamous 
or cuboidal granulosa cells, and are generally found in clumps near the borders of the ovary. 
Primary follicles contain larger oocytes that are completely surrounded by cuboidal granulosa 
cells, and are found either in isolation or in small groups throughout the ovary. Those follicles, 
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with a larger oocyte then the primary follicles, and surrounded by more than one layer of 
granulosa cells, were counted as secondary follicles, only on the section where the nucleolus of 
the oocyte was present. 
 
2.5 Steroid analysis by Liquid Chromatography Mass Spectrometry  
As previously described (O'Reilly et al., 2014), follicle culture supernatant (approximately 1 
ml, pooled from 30-100 follicle incubations) was placed in sylinised glass TLC tubes, and 20 
µl of internal standard was added. Linear calibration series were prepared prior to each steroid 
extraction (Table 2-1).  
 
Table 2-1Sample calibration series for follicle culture media steroid measurement 
Calibration number Added volume of 
steroid stock 
preparation   (µl) 
Added volume of cell 
media (µl) 
Concentration (ng/ml) 
C0 0 1000 0 
C1 0.5 999.5 0.5 
C2 1 999 1 
C3 2.5 997.5 2.5 
C4 5 995 5 
C5 10 990 10 
C6 25 975 25 
C7 50 950 50 
C8 100 900 100 
C9 250 750 250 
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Steroids were extracted via liquid-liquid extraction, by adding 3 ml of tert-butyl-methyl-
ether (MTBE) to each sample, followed by vortexing and freezing for 1 hour. The upper liquid 
phase of the samples was then gradually transferred (approximately 800 µl per cycle) to a 96 
well plate employing glass Pasteur pipettes, with alternating cycles of evaporation at 55°C 
under nitrogen. Samples were reconstituted with 125 µl of methanol: water mixture (50:50) and 
frozen at -20°C until ready for analysis. Steroids were quantified by liquid chromatography 
tandem mass spectrometry (LC-MS/MS) using a Waters Xevo Mass Spectrometer with Acquity 
uPLC systems with following settings: electrospray ionization source with capillary voltage at 
4.0 kV, temperature source at 150°C, desolvation temperature of 500°C. Steroid identification 
was based on an identical retention time and 2 identical mass transitions when compared to an 
authentic reference compound. Quantification was performed relative to a calibration series 
(0.5-250 ng/ml of each steroid) with an appropriate internal standard. All measurements were 
performed in triplicate, except treatment condition DHT+MDV and DHEA100nM were 
assessed in duplicate because of shortage of biological material.   
 
2.6  Gene expression studies 
2.6.1 RNA extraction  
 At the end of cultures, we pooled 18-30 follicles for each experimental condition, which 
were immediately flash frozen in liquid nitrogen, and stored at -80°C until RNA extraction.  
 Total RNA was extracted from the follicles using the Qiagen RNeasy Micro Kit 
(Qiagen, Manchester, UK). All steps were performed on ice to prevent RNA degradation. 
Typically, 350 µl of buffer RTL Plus was added to the follicles, followed by disrupting and 
homogenizing the tissue using a Tissue Ruptor (Bio-Vortexer Laboratory Tube Mixer, 
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Research Products International, IL, USA). The lysate was centrifuged for 3 minutes at full 
speed. The supernatant, containing the RNA, was transferred to a genomic DNA Eliminator 
Spin column. Following centrifuge for 30 seconds at >8000 x g, the flow-through was 
discarded. In a next step, RNA extraction was performed using 350 µl of 70% ethanol to be 
added to the flow-through, and mixed by pipetting. The sample was transferred to an RNeasy 
MinElute spin column placed in a 2 ml collection tube, and centrifuged for 15 seconds at full 
speed, and the flow-through was discarded. In the following cleaning step, 700 µl of Buffer 
RW1 and 500 µl Buffer RPE were respectively added to the RNeasy MinElute spin column, 
followed by 15 seconds of maximum speed centrifugation and discard of the flow-through. The 
next washing step consisted of addition of 500 µl of 80% ethanol to the RNeasy MinElute spin 
column, with a 2 minutes’ centrifugation step. The RNeasy MinElute spin column was placed 
in a new 2 ml collection tube and centrifuged, with open lid, at full speed for 5 minutes to dry 
the membrane. The RNeasy MinElute spin column was finally placed in a new 1.5 ml collection 
tube and 14 µl RNase-free water used to suspend the RNA, followed by centrifuging for 1 
minute at full speed. 
 
2.6.2  RNA quality examination 
 The concentration and purity of the extracted follicular RNA was determined using 
NanoDrop technology (ND1000, Thermo Fisher Scientific).  
 The quality of total RNA was examined employing Agilent R6K Screen Tape System 
(Agilent Technologies, Cheshire, UK), which performs RNA quality control, following sample 
loading, analysis and imaging. Samples were prepared using the R6K Screen Tape assay kit 
following the manufacturer’s instructions, and performed at room temperature in RNA-free 
conditions. Briefly, 1 µl of RNA sample or high sensitivity RNA ladder were mixed with 4 µl 
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of R6K Sample Buffer. The samples and ladders were denaturated, by heating to 72°C for 3 
minutes, and then placed on ice for 2 minutes, and briefly centrifuged to remove material 
attached to the lid or cover. The samples and the ladder were loaded into the 2200 TapeStation 
with appropriate loading tips, the software was updated with sample name and the remaining 
of the analysis was automated.  
2.6.3 Complementary DNA (cDNA) generation and reverse transcription  
 RNA obtained from the follicle cultures was diluted to a final concentration of 50-100 
ng/µl and converted to cDNA using a AccuScript High Fidelity 1st Strand cDNA Synthesis Kit 
(Agilent Technologies), according to the instructions of the manufacturer. In this protocol, RNA 
was reverse transcribed into cDNA, in a microcentrifuge tube, by adding the following reagents, 
in order: 
- RNAse free water to a total volume of 16.5 µl 
- 2 µl AccuScript Reverse Transcription Buffer (10x) 
- 3 µl Random Primers 
- 0.8 µl dNTP mix (25nM each dNTP) 
- the amount of RNA required to obtain 100 ng 
The generated mixture was heated to 65°C for 5 minutes to denature RNA, followed by cooling 
at room temperature, which allowed primers to anneal to RNA. After this step, the following 
components were added to the reaction, in order, to a final reaction volume of 20 µl: 
- 2 µl of 100 mM DTT 
- 1 µl of AccuScript RT 
- 0.5 µl of RNase to inhibit ribonuclease 
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The reaction mix was incubated at room temperature for 10 minutes, to allow for extension of 
the primers. Then, the microcentrifuge tube was placed in a temperature-controlled block, at 
42°C for 60 minutes, to permit cDNA synthesis. The reaction was stopped by incubating the 
reaction mix at 70°C for 15 minutes. Samples were kept on ice for PCR amplification, or stored 
at -20°C until further use.  
2.6.4 Real-time Polymerase Chain Reaction (RT-PCR) 
2.6.4.1 Principle 
PCR is a highly sensitive and specific method to determine the presence of a target gene 
in a sample of cDNA, reverse transcribed from RNA. The double stranded DNA is exposed to 
high temperature which allows for denaturation to single strands. The temperature is then 
lowered to permit specific primers to anneal to their complementary single DNA strand. 
TaqMan probes are designed to bind the primers that are bound to their specific complementary 
DNA. The probes are conceived with a fluorescent reporter and a quencher. The latter 
suppresses the fluorescent signal of the reporter if the probe is unbound to the primer. At a 
specific extension temperature, DNA polymerase amplifies targeted DNA by elongating the 
primer. By binding the primer on the cDNA, the quencher of the TaqMan probe is removed by 
the DNA polymerase, which results in emission of a fluorescent signal. This process is 
amplified, by repeating the described cycle for a dedicated amount of times. The real-time PCR 
machine measures the increasing fluorescent signal each cycle. The higher the amount of target 
gene presence, the lower the cycle number at which the fluorescent signal is first detected, a 
number referred to as CT value.  
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2.6.4.2 Method 
 The target gene expression levels were assessed using an ABI sequence detection 
system (Perkin-Elmer Applied Biosystems, Warrington, UK). All analyses were assessed in 10 
µl final volume, containing 2 X TaqMan Universal PCR Master mix (5.0µl, Thermo Fisher 
Scientific), TaqMan Gene Expression Assay (20 X) of interest (0.5 µl) (Table2-2), nuclease 
free water (4.0 µl) and 0.5 µl cDNA template. All reactions were normalized against the 
housekeeping genes 18S rRNA and Ribosomal Protein L-18 (Rpl-18) rRNA. Data were 
expressed as ΔCT values, referring to CT of target gene minus CT of housekeeping gene.   
 
Table 2-2TaqMan Gene Expression Assays used (purchased from Life Technologies, Thermo 
Fisher Scientific) 
Gene Protein encoded Assay ID 
star steroidogenic acute regulatory protein Mm00441558_m1 
cyp11a1 cholesterol side-chain cleavage cytochrome P450 Mm00490735_m1 
cyp17a1 17-hydroxylase Mm00484040_m1 
cyp19a1 aromatase Mm00484049_m1 
hsd3b1 3b-hydroxysteroid dehydrogenase Mm01261921_mH 
hsd17b1     17b-hydroxysteroid dehydrogenase Mm00501692_g1 
AR androgen receptor Mm00442688_m1 
FSH-R follicle stimulating hormone receptor Mm00442819_m1 
LH-R luteinizing hormone receptor Mm00442931_m1 
AMH-RII anti-Müllerian hormone receptor 2 Mm00513847_m1 
GDF9 growth and differentiation factor 9 Mm00433565_m1 
BMP15 bone morphogenic protein 15 Mm00437797_m1 
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AMH anti-Müllerian hormone Mm00431795_g1 
RPL18 ribosomal protein 18 Mm02745785_g1 
 
2.7 Statistical Analysis  
Both graphical expression of experimental data and statistical analysis were performed 
with Prism 6 (Graph Pad) Software. P-values, reflecting the probability of an observed results 
arising by chance, was used to express statistical significance. A P-value <0.05 was set, as per 
convention, to reject the null hypothesis.  P-values were calculated using the following 
statistical tests:  
• Independent t-tests were employed to compare continuous variables (steroid 
hormone and dCT values) between 2 treatment conditions. Matched or repeated 
measurements were analyzed using paired t-tests, while unpaired t-tests were 
used for independent measurements.  
• One-Way ANOVA with post-hoc Tukey test was employed to analyze means of 
continuous variables (follicle and oocyte size, inhibin-B measurements) 
between 3 or more treatment groups.  
• Contingency analysis with Fisher’s exact test was used to compare categorical 
variables (survival, presence of an antrum, oocyte maturity). 
All studies were performed at least in three independent experiments, unless otherwise 
specified. 
 
 
  
 
3 In vitro folliculogenesis, oogenesis and 
steroidogenesis under physiological 
conditions   
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3.1 Introduction 
The final stages of follicular development and the process of ovulation result from a 
tightly regulated communication between the hypothalamic-pituitary axis and the ovary. The 
follicle becomes able to produce steroids in the secondary stage, just prior to antrum formation, 
when the theca cells are recruited to form a layer around the basal membrane surrounding the 
granulosa cell-oocyte unit (Young and McNeilly, 2010) (Figure 3-1). Theca cells differentiate, 
acquire steroidogenic function, and start producing small amounts of androgens, under the 
influence of granulosa cell-produced factors, such as activin and BMPs, and oocyte-derived 
signals such as GDF-9, and growth-factors such as insulin and IGF-1 (Logan et al., 2002). In 
the gonadotrophin-dependent antral stage, thecal androgen production is largely under pituitary 
control, by LH, transported by the bloodstream, and androgens acts as substrate for aromatase, 
with FSH regulating estradiol secretion in granulosa cells (Edson et al., 2009). Estradiol 
production from the dominant follicle triggers the pre-ovulatory LH surge, which in turn, 
prompts the follicle to release its mature oocyte, that is now able to get fertilized and give rise 
to the next generation.   
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Figure 3-1 Androgen and oestrogen synthesis throughout the different stages of follicle 
development. Androgens production occurs in the theca cells, from the secondary stage 
onward, and conversion to oestrogens occurs in the granulosa cells via aromatase (CYP19A1) 
activity in the antral follicle. Reprinted and adapted from Lebbe and Woodruff, with kind 
permission of Oxford University Press, copyright 2013. 
 
The alginate encapsulated in vitro follicular culture technique has proven to recapitulate 
all key events of folliculogenesis and oogenesis, known to occur during in vivo development 
(Xu et al., 2006a). Coordinated follicle growth, in 3- dimensions, with preserved follicle 
architecture, and, importantly, maintained paracrine signaling between the oocyte and the 
somatic compartment, is a major advantage of this technique (Kreeger et al., 2006). The follicle 
encapsulation provides a superior value to the follicle culture technique, compared with 
historical, 2-dimentional culture models, which have inherent adhesive properties, leading to a 
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partial dissociation in communication between the oocyte and its surrounding cells (Brito et al., 
2014). Follicle function, including steroid and peptide hormone production, has been 
documented in mouse follicles grown in alginate beads, using immunoassays (Skory et al., 
2015, Tingen et al., 2011, Jin et al., 2010, West-Farrell et al., 2009), steroid measurements 
include androstenedione, estradiol and progesterone (Figure 3-2). The important knowledge 
that has been gained through these results is the fact that the follicle is capable of sex steroid 
production in vitro (West et al., 2007), in a culture system employing a constant dose of rFSH, 
without addition of LH or FSH, in serum-free medium. 
 Here I repeat the study of folliculogenesis and oogenesis in basal conditions, employing 
the murine encapsulated in vitro follicle growth (eIVFG) system. I have trained in this technique 
at the laboratory of Dr. Teresa Woodruff at Northwestern University Chicago, and transferred 
the method to the University of Birmingham, and intended to validate my performance with 
this technique against published data. Following validation, I add new knowledge to this culture 
system, by examining endogenous steroid production by mass spectrometry-based steroid 
metabolome profiling, which has not been done before. 
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Figure 3-2 Estradiol, androstenedione and progesterone production by two-layered (A-C) and 
multilayered (D-F) secondary follicles during in vitro alginate encapsulated culture, for 
alginate concentrations at 3%, 1.5%, 0.7% and for oxidized (ox) and irradiated (irr) alginate. 
Steroids are measured by immunoassays in culture medium. Reprinted from (West et al., 2007) 
with kind permission from Pergamon, copyright 2007.  
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3.2  Methods  
3.2.1  Research strategy 
In this chapter, I will first examine the morphological characteristics of murine follicles, 
cultured in the alginate encapsulated system, in basal physiological conditions, with regard to 
follicle survival, growth, and oocyte quality. These characteristics will be compared with those 
previously published with the same method, in order to validate the quality of the method 
transfer. I will then explore the ability of LC-MS/MS methods to detect and quantify 
endogenous sex steroid production in developing murine follicles during in vitro culture. This 
is challenging, as follicular steroids are likely to be barely identifiable in view of the small 
amounts secreted by individual follicles. To overcome this challenge, conditioned media from 
follicles cultured in similar conditions will be pooled prior to steroid extraction.  
 
3.2.2 Murine encapsulated in vitro follicle growth (eIVFG) 
Immature multilayered secondary follicles, with a diameter of 150-180 µm, were 
mechanically isolated from pre-pubertal 15-17 day old CD1 female mice pups, after enzymatic 
digestion employing L15 medium supplemented with 0.1% DNase I and 0.1% Liberase TM, 
for 35-40 minutes on a shaker in a 37°C 5% CO2 incubator. Following a recovery period during 
which the follicles stayed in maintenance medium (α-MEM Glutamax medium with 1% FBS 
and 0.5% Penicillin-Streptomycin) in the CO2 incubator, individual follicles were examined 
under the dissection microscope and encapsulated in 0.5 % alginate, with slight modifications 
to the protocol described by Xu et al. Alginate-encapsulated follicles were placed in separate 
wells of a 96-well plate, each containing 100 µl culture medium, consisting of α-MEM 
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Glutamax supplemented with 3 mg/ml BSA, 10 mIU/ml rFSH, 1 mg/ml fetuin and 5 µg/ml ITS. 
Following plating, encapsulated follicles were imaged using Nikon Eclipse Te300 light 
microscope and healthy follicles with intact alginate beads were selected for culture. Follicles 
were maintained for 6 days in 37°C 5% CO2 incubator and media change (50 µl) and imaging 
was performed on alternate days. Images were analyzed using Image J Software. 
 
3.2.3 In vitro follicle maturation 
As previously described (Xu et al., 2006a), fully-grown follicles were, at the end of day 
6 of culture, retrieved from the alginate bead and transferred to maturation medium composed 
of α-MEM Glutamax, containing 10 % FBS, 1.5 IU/mL HCG, and 5 ng/mL EGF for 16 h at 
37°C, 5 % CO2. Oocytes were denuded from the surrounding cumulus cells by treatment with 
0.3 % hyaluronidase and gentle aspiration. The oocytes were classified as mature, or metaphase 
II, if a polar body was visible in the perivitelline space. Healthy oocytes that hadn’t resumed 
meiosis were classified as immature. Unhealthy oocytes were considered as degenerated. 
 
3.2.4 RNA extraction, reverse transcription and real-time PCR 
 At day 6 of culture, 18-30 follicles grown in similar conditions were pooled and flash 
frozen in liquid nitrogen. RNA was purified from the follicles using the Qiagen RNeasy Micro 
Kit according to the instructions of the manufacturer. RNA quantity and quality were assessed 
employing NanoDrop technology and Agilent High Sensitivity R6K Screen Tape System. RNA 
was diluted to a concentration of 50-100 ng/µl using RNA free water, and reverse transcribed 
to complementary DNA (cDNA) using a AccuScript High Fidelity 1st Strand cDNA Synthesis 
Kit. mRNA expression levels were assessed using real-time PCR technology, employing 
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reactions containing Taqman Universal PCR Master mix, probe-primer mix for the target gene, 
and 4.5 µl cDNA (100 ng), as published previously (Gathercole et al., 2007). All reactions were 
normalized against the housekeeping genes 18S and Rpl-18. Data were expressed as DCT 
values. We examined the expression of key steroidogenic enzymes, i.e. star, cyp11a1, cyp17a1, 
cyp19, hsd3b1 and hsd17b1, after confirmation of their presence and isotope-specificity in 
mouse ovarian tissue, based on published data (Payne and Hales, 2004).  
 
3.2.5 Follicle culture steroid extraction and LC-MS/MS analysis 
Because endogenous steroid production from individual follicles was expected to occur 
in very low concentrations that were below the detection limit of LC-MS/MS, conditioned 
media of 72-105 follicles, cultured in similar conditions, were pooled at day 2, 4 and 6 of 
culture. Media was stored at minus 80°C until analysis. Pooled follicle culture supernatant 
(approximately 1 ml) was placed in sylinised glass TLC tubes, and 20 µl of internal standard 
was added. Linear calibration series were prepared prior to each steroid extraction (Table 2-1). 
Three ml of tert-butyl-methyl-ether (MTBE) was added to each sample, followed by vortexing 
and freezing for 1 hour. The upper liquid phase of the samples was then gradually transferred 
to a 96 well plate employing glass Pasteur pipettes, with alternating cycles of evaporation at 
55°C under nitrogen. Samples were reconstituted with 125 µl of methanol: water mixture 
(50:50) and frozen at -20°C until ready for analysis. The LC-MS/MS measurements for control 
conditions were performed in triplicate. Data were expressed as mean ± SD, and were 
normalised to 100 follicles. 
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3.2.6 Statistical analysis 
Statistical analysis was performed with Prism 6 (Graph Pad) Software, using unpaired 
t-test to analyze steroid concentrations and paired t-test to examine ΔCT values from matched 
follicles at the beginning (Day 0) and end (Day 6) of culture. All experiments were 
independently performed at least in triplicate, unless otherwise specified. 
 
3.3 Results 
3.3.1 Physiological follicle development in the alginate encapsulated in vitro follicle 
growth system (eIVFG)  
3.3.1.1 Follicle growth, antrum formation and survival during culture 
The baseline characteristics, with biological and technical replicates, of follicles grown 
in basal standard conditions, i.e. in serum-free media, under a constant dose of 10 mIU/ml 
rFSH, are outlined in Table 3-1. Figure 3-3 is a representative image of a secondary 
multilayered follicle at the moment of encapsulation in the alginate bead, at day 0, the start of 
culture.   
 
Table 3-1 Baseline characteristics of follicles cultured in control conditions 
Condition Starting size (mean ± SD) Biological replicates Technical replicates 
Control follicles 163.6 ± 9.9 µm 156 10 
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Figure 3-3 Light-microscopic representative image of a multi-layered secondary follicle at the 
start of culture, containing an oocyte, several layers of granulosa cells, and some attached 
ovarian stroma cells; scale-bar:50 µm.  
  
Over the 6 days of culture, control follicles grew from 163.6±9.9 µm to a final follicle 
size of 296±45 µm. The increasing follicle size in basal conditions is outlined in Table 3-2 and 
Figure 3-4.   
 
Table 3-2 Growth characteristics of follicles cultured in control conditions 
Day of culture Follicle size (mean ± SD)  Follicle number 
0 163.6±9.9 µm 156 
2 185.9±23.5 µm 135 
4 232.6±34.5 µm 100 
6 296.0±45.0 µm 88 
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Figure 3-4 Follicle growth of follicles during eIVFG in basal conditions. Data are expressed 
as mean ± SD. Follicle numbers are outlined in Table 3-2.  
 
An important developmental step during in vivo follicle development is the acquisition 
of an antrum, a fluid-filled cavity formed in the centre of the follicle. The alginate eIVFG 
system allows for 3D expansion of follicle growth, maintaining the in vivo architecture, and 
therefore permits antrum generation in vitro (Brito et al., 2014). The development of the antrum 
is light-microscopically assessed by the outward movement of the oocyte, from a central to an 
eccentric position in the follicle. Figure 3-5 shows a light-macroscopic image of a small and 
large antral follicle during development. In basal conditions, a mean (SD) of 45±22 % of total 
follicles achieved antrum formation on day 4 of culture, and this percentage increased at 83±16 
% at the day 6 of culture.  
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Figure 3-5 Representative light-microscopic images of small (left) and large (right) antral 
follicles, grown in alginate beads allowing for 3-dimensional growth expansion and 
maintenance of in vivo follicle architecture. The antrum is the dark area that first displaces the 
ovary, and later fills the entire follicle centre, hiding the oocyte for the sight. Scale-bar: 50 µm 
 
Follicles were considered dead during culture if the oocyte or somatic cells looked 
unhealthy, if their integrity was disrupted, or in case of rupture of the alginate bead. Alginate 
gel-embedded follicles had a declining survival rate over time, as illustrated in Figure 3-6. Only 
survival follicles were included in data analysis.  
 
oocyte
antrum
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Figure 3-6 Follicle survival at day 0, 2, 4 and 6 of culture, in basal condition. Data are 
expressed as mean (SD). 
 
3.3.1.2 Oocyte development in physiological conditions 
At the end of culture, follicles were removed from their alginate beads and exposed to 
HCG and EGF to induce ovulation. Oocytes were recovered, denuded from the attached 
cumulus cells, imaged, and assessed for size and nuclear maturation status.  
In basal conditions, a mean (SD) of 69±11 % of the retrieved oocytes (n=26) completed 
the first meiotic division, and had a mean (SD) size of 68.1±4 µm; while 27±9 % stayed arrested 
in meiosis I, and measured 68.1±2 µm. The oocyte maturation status in control conditions is 
illustrated in Figure 3-7.  
 
0 2 4 60
50
100
day
su
rv
iv
al
 (%
) 
  116 
  
Figure 3-7 Oocyte meiotic maturation in standard conditions (n=26). Mature oocytes have 
extruded a polar body, while immature oocytes are healthy gametes arrested in Meiosis I. Dead 
or shrunken oocytes are considered degenerated. Data are expressed as mean ± SD. 
 
3.3.1.3 mRNA analysis of target genes of follicle development 
At the start and the end of culture, 30 follicles were pooled and flash frozen in liquid 
nitrogen, and RNA was extracted to allow for qRT-PCR analysis of target genes of 
folliculogenesis.  
With ongoing follicle maturation, we noticed a significant upregulation of LH-receptor 
expression (Table 3-3). The gene expression of AR was stable during follicle development. 
Oocyte-derived factor GDF9 and granulosa cell-derived BMP15, molecules involved in 
paracrine signalling, were significantly downregulated as the follicle entered the later stages of 
follicle development (Table 3-3). AMH, also involved in early follicle development, was 
significantly downregulated at the end of culture, however mRNA expression of its receptor, 
AMH-RII remained unchanged during follicle development (Table 3-3). 
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Table 3-3 Relative mRNA expression of target genes of follicle development, expressed as DCT 
values (normalized against 18S ribosomal RNA) ± SD (for each triplicate experiment from 30 
follicles from each group pooled prior to RNA extraction), in follicles at day 0 and 6 of follicle 
culture in basal conditions.  
Gene Protein encoded Day 0 Day 6 p 
AR androgen receptor 13.8±1.5 14.7±0.09 0.3 
FSH-R follicle stimulating hormone receptor 16.2±1.2 12.8±1.0 0.2 
LH-R luteinizing hormone receptor 16.1±0.6 11.7±0.2 0.005 
AMH-RII anti-Müllerian hormone receptor 2 14.8±1.1 14.8±1.1 0.9 
GDF9 growth and differentiation factor 9 12.6±0.5 18.3±0.4 <0.001 
BMP15 bone morphogenic protein 15 14.2±0.9 17.9±0.5 0.02 
AMH anti-Müllerian hormone 8.9±0.8 20.1±0.1 0.001 
 
 
3.3.2 Endogenous steroid synthesis under physiological culture conditions 
3.3.2.1 LC-MS/MS steroid synthesis profiling in the developing follicle  
Steroid concentrations were measured by LC-MS/MS in media collected on days 2, 4 
and 6 of folliculogenesis, pooling media from 72-105 follicle incubations from each timepoint; 
data were normalized to 100 follicles. Raw data of steroid measurements are mentioned in Table 
3-4.  
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Table 3-4 Steroid hormone production by the cultured follicles, measured by LC-MS/MS, in 
pooled follicle culture medium (72-105 follicles) at day 2, 4 and 6 of culture, and normalised 
to 100 follicles. Data are expressed as mean ± SD (n=3 measurements). 
Steroid Concentration at day 
2 (nmol/l) 
Concentration at day 
4 (nmol/l) 
Concentration at day 
6 (nmol/l) 
Progesterone (Prog) 0.6±0.5 0.8±0.7 11.0±1.2 
DHEA 1.4±1.4 1.9±1.4 9.6±3.4 
Androstenedione 
(Adione) 
0.1±0.1 2.3±0.2 47.5±1.3 
Testosterone  0 5.1±2.4 148.2±16.7 
DHT 0 0.7±1.2 2.6±3.7 
Estrone (E1) 0.5±1.0 0.9±0.9 14.4±1.4 
Estradiol (E2) 0 0.7±1.3 138.1±8.3 
 
 At day 2 of culture, steroid concentrations were close to the lower limit of 
detection (0.5-2.0 nmol/L) (Figure 3-8). At day 4, the androgen precursors DHEA and 
androstenedione and biologically active testosterone increased to quantifiable levels and 
oestrogens became detectable (Figure 3-8). By day 6 we observed a significant increase in 
androgen precursors and active androgens, with the most potent androgen, DHT, emerging in 
quantifiable levels for the first time. At that time point, progesterone was present in quantifiable 
amounts, and significant oestrogen generation was observed, in the majority biologically active 
E2. At day 6 of culture, testosterone was the main androgen secreted in culture (with a mean 
(SD) of 71±4% of total androgens), followed by androstenedione (22±0.5%), DHEA (5±1%) 
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and low but quantifiable amounts of DHT. E2 was the principal oestrogen secreted (90±0.3% 
of total oestrogens) (Table 3-4 and Figure 3-8).  
 
 
Figure 3-8 Steroid hormone production by the cultured follicles in physiological conditions, 
measured by LC-MS/MS, in pooled follicle culture medium (72-105 follicles) at day 2, 4 and 6 
of culture, and normalised to 100 follicles. Data are expressed as mean ± SD (A) Schematic 
showing the steroidogenic pathway, with colour coding of the different steroids assessed in 
culture medium: Progesterone (Prog), Dehydroepiandrosterone (DHEA), Androstenedione 
(A’dione), Testosterone, Dehydrotestosterone (DHT), Estrone (E1) and Estradiol (E2). (B) 
Endogenous steroid production in basal conditions. 
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3.3.2.2 Steroidogenic enzyme expression in the developing follicle 
Corresponding to the increasing generation of active sex steroids across follicle 
development, steroid enzyme mRNA was also accumulating with time. A significant increase 
in mRNA expression of 17b-hydroxysteroid dehydrogenase (hsd17b1; p<0.001, Table 3-5) was 
measured by day 6.  This enzyme catalyzes the conversions of androstenedione to testosterone 
and estrone to estradiol and is FSH responsive (Peltoketo et al., 1999). Concurrently, mRNA 
levels of the FSH regulated aromatase (cyp19a1) gene, responsible for activation of androgens 
to oestrogens, significantly increased with follicle maturation (p<0.01, Table 3-5). In line with 
the increasing levels of progesterone, side-chain cleavage enzyme, cyp11a1 also increased 
(p<0.01, Table 3-5). These experiments showed that the murine follicle is equipped with the 
necessary steroidogenic machinery to produce sex steroids in a developmental stage -dependent 
fashion (Figure 3-9).   
 
Table 3-5 Relative mRNA expression of target genes of steroidogenesis, expressed as DCT 
values (normalized against 18S ribosomal RNA) ± SD (for each triplicate experiment from 30 
follicles from each pooled prior to RNA extraction), in follicles at day 0 and 6 of follicle culture 
in basal conditions.  
Gene  Enzyme encoded Day 0 Day 6 P 
value 
star steroidogenic acute regulatory protein 15.4±0.4 15.3±0.7 0.8 
cyp11a1 cholesterol side-chain cleavage cytochrome 
P450 
13.9±0.4 12.5±0.1 0.006 
cyp17a1 17-hydroxylase 13.3±0.05 12.8±0.07 0.4 
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cyp19 Aromatase 15.5±0.09 12.3±1.3 0.04 
hsd3b1 3b-hydroxysteroid dehydrogenase 10.9±1.4 9.6±0.3 0.2 
hsd17b1 17b-hydroxysteroid dehydrogenase 15.2±0.1 11.1±0.2 0.002 
 
 
Figure 3-9 Schematic representation of steroidogenic pathway in the follicle with indication of 
enzymes which gene-expression was upregulated during in vitro follicle development (indicated 
by an asterix), ensuring increasing active sex steroid and progesterone synthesis with ongoing 
follicle maturation.  
 
3.4 Discussion 
Folliculogenesis and oogenesis in murine eIVFG systems have been described in detail 
previously (Xu et al., 2006a). I have repeated these experiments, in order to validate the quality 
of the eIVFG culture methods, that I have transferred to the University of Birmingham 
following training in the laboratory of Dr Teresa Woodruff, who has developed the technique 
  122 
in collaboration with Dr Lonnie Shea. Slight modifications in the culture protocol have been 
introduced, such as the use of 0.5% alginate instead of 1.5%, a different encapsulation 
technique, and a culture period that has been shortened from 8 to 6 days. Of note, a different 
recombinant FSH preparation was used in my study. Follicle growth characteristics (mean 
follicular size at day 6 in my study 296 ± 45 versus 300 µm) , as well as oocyte size (68 ± 4 
versus 68 ± 2 µm) and percentage mature oocytes (69 ± 11% versus 70 ± 9%) were similar in 
my hands compared with those published in the reference study. The capacity of the oocyte 
grown in vitro to develop to a stage where it is able to transition to meiosis II, is considered to 
be the ultimate arbiter of follicle culture quality (Hartshorne, 1997). This means that my 
produced outcomes can be considered valid. However, the survival rates at the end of culture 
were significantly lower compared to those obtained in the pilot study (57 ± 20% versus 
93±2%). This could be related to inferior follicle quality at the start of culture, fewer experience 
with the technique, or to animal- or laboratory-related factors. Only surviving follicles have 
been included in the data analysis, which means that the generated results were not adversely 
impacted by the lower survival rates.  
My study extends the application of the eIVFG technique by coupling it to modern LC-
MS/MS steroid profiling. I report, for the first time, a quantitative multi-steroid metabolome of 
the developing follicle, indicative of FSH-stimulated endogenous production of androgens, 
oestrogens and progestins in vitro, in a folliculogenesis-stage dependant manner. The steroid 
hormone pattern reported was in accordance with the current knowledge of follicular steroid 
production, and consistent with in vivo hormone dynamics (Hillier, 1994). Androgen secretion 
was quantifiable around day 4, which corresponds to the developmental stage of antrum 
formation and gonadotrophin responsiveness. Oestrogen biosynthesis increased sharply 
between day 4 and 6 of culture, corresponding to aromatase expression as the follicle reached 
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ovulatory maturity. At day 6, progesterone secretion started to increase slightly, prior to 
luteinisation. Gene expression profiles showed upregulated gonadotrophin expression with 
follicle maturation. Parallel to increasing FSH-R expression, FSH-dependant steroidogenic 
enzymes, Hsd17b1 and Cyp19, were significantly increased, as well as LH-R. Upregulation of 
LH-R prepares the follicle for ovulation, i.e. cumulus cell expansion, oocyte meiotic maturation 
and luteinisation. According to the 2-cell, 2-gonadotrophin hypothesis, LH stimulates 
androstenedione production by theca cells, which provides substrate for oestrogen biosynthesis 
by granulosa cells (McNatty et al., 1979). In the employed culture system however, maturing 
follicles produce significant amounts of estradiol in a LH-free and serum-free medium. This 
means that follicular cells are able to constitutively produce androgens in the absence of 
provision of cholesterol and LH. Paracrine theca cell LH-independent androgen production is 
known to occur under the influence of insulin (Barbieri, 1994, Erickson et al., 1990), present in 
physiological amounts in the employed culture medium. Expression of Star, a theca cell marker 
(Kiriakidou et al., 1996), remained stable during follicle culture, which suggests that de novo 
theca cell formation was limited, and granulosa-theca cell trans-differentiation possibly 
accounts for the observed androgen production.  
During the development from immature to pre-ovulatory follicle, testosterone was the 
predominant steroid, closely followed by estradiol in the terminal follicle, in a 1/1 ratio. 
Interestingly, the steroid distribution of the day 4 murine follicle resembled the pattern observed 
in follicular fluid of the androgen-dominant follicle in regularly menstruating women (Kushnir 
et al., 2009). In human however, androstenedione was the main androgen secreted, and 
progesterone production was more prominent compared with mice.  
In my study, LC-MS/MS measured similar (West-Farrell et al., 2009) or lower (Xu et 
al., 2006a, Jin et al., 2010) concentrations for androstenedione and estradiol, compared to those 
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obtained in similar culture conditions but measured with immunoassays. These differences 
could be explained by fact that immunoassays are prone to cross-reactivity, which may lead to 
falsely increased concentrations (Stanczyk, 2006). Interestingly, androstenedione and estradiol 
immunoassays showed significantly increased concentrations in follicles grown in adherent 2D-
culture systems, compared with non-adherent alginate systems, despite similar follicle growth 
and oocyte quality parameters, a finding attributed to differences in theca cell development 
(Sanchez et al., 2012). A major advantage of mass-spectrometry is the ability to simultaneously 
measure multiple steroid concentrations, while immunoassays are limited to one molecule. The 
method used in this study has been validated (O'Reilly et al., 2014), and we believe that the 
concentrations of steroids presented here are a true representation of the dynamic endogenous 
steroid production in murine follicles. The ultimate goal would be to apply this method to study 
human sex steroid production in vitro.  
  
  
 
4 Effects of exogenous androgen exposure 
and antagonism on the developing follicle 
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4.1 Introduction 
Encapsulated in vitro ovarian follicle culture (eIVFC) is a powerful tool that has enabled 
the study of autonomous follicle growth, oocyte maturation, ovulatory mechanics and signaling 
pathways (Kreeger et al., 2006, West-Farrell et al., 2009, Hornick et al., 2013, Skory et al., 
2015). This 3D culture system takes advantage of biomaterials that maintain germ and somatic 
cell coupling and has been applied to a wide variety of species including murine, bovine, goat, 
canine, non-human primate, and human-derived follicles (Xu et al., 2006a, Araujo et al., 2014, 
Silva et al., 2015, Songsasen et al., 2011, Min Xu, 2009, Xu et al., 2009).  Studies across species 
have enabled comparative assessments of biology unique to each species, for example, the 
physical rigidity of the biomaterial, while providing important new insights into the conserved 
mechanisms governing the follicle development  
A particularly challenging question is the direct role of androgens on ovarian follicle 
development and oocyte maturation; eIVFC is ideally suited to evaluate the direct effect of 
these steroid hormones in an isolated, individual follicle. Although androgens are vital for 
female fertility, recent studies only begin to unravel the underlying mechanisms of action. 
Androgens exert their effect through the androgen receptor, a member of the nuclear receptor 
superfamily (Gelmann, 2002). In rodents, primates and human, androgen receptor is detected 
in granulosa cells from the primary stage onward, and its concentration peaks in the antral 
follicle stage (Sen and Hammes, 2010, Weil et al., 1998, Rice et al., 2007). Using the eIVFC 
conditions, testosterone was shown to directly increase macaque secondary follicle survival and 
growth supporting the notion that androgens regulate follicle dynamics (Rodrigues et al., 2015). 
Further support of this notion is derived from the murine androgen receptor global knockout 
models, in which females are subfertile and have reduced follicle development, poor oocyte 
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quality, altered gonadotrophin regulation and decreased ovulation rates (Hu et al., 2004, Shiina 
et al., 2006, Walters et al., 2007, Cheng et al., 2013). Elegant studies utilizing a granulosa cell-
specific murine androgen receptor deletion model have produced a mirror image of these 
findings, thereby proving that androgen receptor-mediated androgen action is crucial for the 
development and function of the ovarian follicle (Sen and Hammes, 2010, Walters et al., 
2012b).  Increasing attention focuses on non-genomic androgen signaling pathways, including 
the activation of the protein paxillin, which, in turn, increased androgen receptor-mediated 
transcription, crucial mechanisms shown to be involved in the androgen-mediated promotion 
of follicle growth and survival (Sen et al., 2014). Several 2D murine follicle culture studies 
employed exogenous administration of androstenedione (Romero and Smitz, 2010, Murray et 
al., 1998, Wang et al., 2001, Tarumi et al., 2012) or testosterone (Wang et al., 2001, Romero 
and Smitz, 2010), and have shown intrafollicular convertion to estradiol, as measured by 
immunoassay. These powerful studies provide the impetus to assess the role of androgens more 
closely in the eIVFC setting and to couple this analysis with the steroid metabolome at each 
stage of follicle development. 
Here we examined the impact of exogenous administration of DHT and the selective 
androgen receptor antagonist enzalutamide (MDV) on follicular steroid production and 
development. 
 
4.2 Methods  
4.2.1 Research strategy 
In this chapter, I will study the direct effects of AR-mediated androgen action on 
follicular development. My outcomes will include follicle survival, follicle growth, target gene 
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analysis, steroid and peptide hormone production, oocyte growth and nuclear maturation status. 
To allow me to delineate if the observed androgen effects are mediated through the androgen 
receptor, I will use the potent AR agonist DHT, and the selective AR-antagonist enzalutamide 
(MDV).  
 
4.2.2 Follicle treatments 
Exogenous androgen exposure to the follicles was examined by the addition of 25 nM 
of DHT to the basal growth medium. The concentration employed was based on published 
dose-response experiments (Sen et al., 2014). All steroid treatments were diluted as appropriate 
in serum-free α-MEM media. Androgen-receptor antagonism was obtained by treatment with 
enzalutamide (MDV), at the dose of 1 µM, based on its IC50 value (Tran et al., 2009). Fresh 
treatments, at the initial dose, were provided during the media change at day 2 and 4.  
 
4.2.3 In vitro follicle culture and oocyte maturation 
Immature multilayered secondary follicles, with a diameter of 150-180 µm, were 
mechanically isolated from pre-pubertal 15-17 day old CD1 female mice pups, after enzymatic 
digestion using L15 medium supplemented with 0.1% DNase I and 0.1% Liberase TM, for 35-
40 minutes on a shaker in a 37°C 5% CO2 incubator. Following a recovery period during which 
the follicles stayed in maintenance medium (α-MEM Glutamax medium with 1% FBS and 0.5% 
Penicillin-Streptomycin) in the CO2 incubator, individual follicles were examined under the 
dissection microscope and encapsulated in 0.5 % alginate, with slight modifications to the 
protocol described by Xu et al. (Xu et al., 2006a). Alginate-encapsulated follicles were placed 
in separate wells of a 96-well plate, each containing 100 µl culture medium, consisting of α-
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MEM Glutamax supplemented with 3 mg/ml BSA, 10 mIU/ml rFSH, 1 mg/ml fetuin and 5 
µg/ml ITS. Following plating, encapsulated follicles were imaged using Nikon Eclipse Te300 
light microscope and healthy follicles with intact alginate beads were selected for culture. 
Follicles were maintained for 6 days in 37°C 5% CO2 incubator and media change (50 µl) and 
imaging was performed on alternate days. Images were analyzed using Image J Software. As 
previously described (Xu et al., 2006a), fully-grown follicles were, at the end of day 6 of 
culture, retrieved from the alginate bead and transferred to maturation medium composed of α-
MEM Glutamax, containing 10 % FBS, 1.5 IU/mL HCG, and 5 ng/mL EGF for 16 h at 37°C, 
5 % CO2. Oocytes were denuded from the surrounding cumulus cells by treatment with 0.3 % 
hyaluronidase and gentle aspiration. The oocytes were classified as mature, or metaphase II, if 
a polar body was visible in the perivitelline space. Healthy oocytes that hadn’t resumed meiosis 
were classified as immature. Unhealthy oocytes were considered as degenerated. 
 
4.2.4 Real-time qPCR analysis of target genes 
Target genes of steroidogenesis and follicle development were analysed by real-time 
qPCR as described in Section 2.4 and according to a previously published protocol (Gathercole 
et al., 2007). To resume, at the end of culture, 21-28 pooled follicles cultured in similar 
treatment conditions (control, DHT or MDV) were flash frozen in liquid nitrogen, followed by 
RNA extraction with quality control, cDNA generation and qRT-PCR analysis using specific 
primers and probes and normalised cDNA concentrations. All reactions were normalized 
against the housekeeping genes 18S and Rpl-18. Data were expressed as dCT values. 
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4.2.5 LC-MS/MS analysis of steroid hormones 
Conditioned media of 32-97 follicles, cultured in similar conditions, were pooled at day 
2, 4 and 6 of culture. Media was stored at minus 80°C until analysis. Pooled follicle culture 
supernatant (approximately 1 ml) was placed in sylinised glass TLC tubes, and 20 µl of internal 
standard was added. Linear calibration series were prepared prior to each steroid extraction 
(Table 2-1). Three ml of tert-butyl-methyl-ether (MTBE) was added to each sample, followed 
by vortexing and freezing for 1 hour. The upper liquid phase of the samples was then gradually 
transferred to a 96 well plate employing glass Pasteur pipettes, with alternating cycles of 
evaporation at 55°C under nitrogen. Samples were reconstituted with 125 µl of methanol: water 
mixture (50:50) and frozen at -20°C until ready for analysis. The LC-MS/MS measurements 
for DHT conditions were performed in triplicate, for DHT+MDV conditions in duplicate. Data 
were expressed as mean ± SD, and were normalised to 100 follicles. 
 
4.2.6 Peptide hormone measurement 
Inhibin B was measured by ELISA at Anhs Lab (Kit AL-107, Webster, Texas) as part 
of the collaboration established with Dr Teresa Woodruff. The assay was performed on 1/5 
diluted conditioned media. The dynamic range of the assay is 6, 12.7-1300 pg/ml, the limit of 
detection is 1.6 pg/ml. 
 
4.2.7 Statistical analysis  
Statistical analysis was performed with Prism 6 (Graph Pad) Software, using one-way 
ANOVA with post-hoc Tukey test to analyze follicle growth at each time point, inhibin-B 
measurements at each time point, and oocyte size at day 6 between multiple treatment 
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conditions. Fisher’s exact test was used for survival, antrum formation and nuclear maturation 
status. Unpaired t-test was employed to analyze differences in steroid concentrations and dCT 
values between treatment versus control conditions, for independent experiments. All 
experiments were independently performed at least in triplicate, unless otherwise specified. 
 
4.3 Results 
4.3.1 Follicle growth, survival and oocyte maturation  
We examined the morphological characteristics of the developing follicle by imaging 
the individual follicles at days 0, 2, 4 and 6 of culture, under control conditions (n=156) and 
after incubation with DHT (n=150) and MDV (n=89), respectively. We studied follicle growth, 
by measuring follicle diameters, the appearance of the antrum, defined by the movement of the 
oocyte to an eccentric position with appearance of a fluid-filled space, as well as follicle 
survival.   
DHT-treated follicles exhibited increased growth at all examined stages of follicular 
development compared with control follicles (Figure 4-1), reaching a final average diameter of 
336±34 µm, compared to 296±45 µm in controls (p<0.0001 at day 2, 4 and 6) (Figure 4-2). 
Conversely, MDV-treated follicles showed significantly restricted growth compared to control 
follicles (Figure 4-1), reaching a final diameter of 255±51 µm (P<0.0001 at day 2, 4 and 6)  
(Figure 4-2).  
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Figure 4-1 Representative light-microscopic images of control follicles, DHT- and MDV-
treated follicles at day 0, 2, 4 and 6 of culture. DHT-treated follicles exhibited increased 
growth, and MDV-treated follicles decreased growth compared with control follicles.  
 
 
Figure 4-2 Follicle diameters at the start, and at day 2, 4 and 6 of culture for control follicles 
(dotted line), follicles treated with 25 nM DHT, and follicles exposed to enzalutamide (MDV). 
DHT-exposed follicles had an overall increased follicle growth, while MDV-treated follicles 
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exhibited overall growth restriction, to a similar extent. Data are expressed as mean ± SD for 
89-156 follicles. ****p< 0.0001 for the comparison of control to DHT and MDV respectively.  
 
 Inhibin B production, a marker of granulosa cell mass (Lenie and Smitz, 2009), was 
significantly decreased in MDV-challenged follicles at day 6 of culture (737±358 versus 
3563±992 in DHT-exposed follicles, p=0.01) (Figure 4-3). 
 
  
Figure 4-3 Inhibin-B concentrations, measured by ELISA, in DHT-, MDV- and untreated 
follicles, on day 2, 4, and 6 of culture. Data represent mean ± SD for 6 follicles for each 
treatment condition. Inhibin-B was significantly decreased in MDV conditions at day 6, 
compared with DHT conditions.  
  
 DHT supplementation resulted in significant acceleration of the pre-antral to antral 
follicle transition, with also a higher total number of follicles reaching the antral stage at day 6. 
At day 4 of culture, an antrum was present in 77±17% of the DHT-treated follicles, compared 
to 45±22% of control follicles (p<0.0001), and at day 6 this percentage increased at 99±2 in the 
DHT-group compared with 83±16% in the control group (p<0.001) (Figure 4-4). By contrast, 
MDV-treated follicles showed evidence of delayed antrum formation, with 35±17% rates at 
day 4 (p<0.05) and 69±42% at day 6 (p=0.1) (Figure 4-4). 
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Figure 4-4 Antrum formation in control follicles (dotted line), DHT 25 nM and MDV-follicles. 
DHT follicles achieve earlier and more complete antrum formation, compared with controls, 
and MDV-treated follicles have delayed antrum formation. Data are expressed as mean ± SD 
for 7-10 experiments. * <0.05, ***<0.001, ****< 0.0001 for the comparison of controls to 
DHT and MDV, respectively. 
 
We also observed a significantly increased survival rate of DHT-treated follicles, 
compared with control follicles (69±22 % versus 57±20 %, P=0.01), indicating that they were 
better protected from follicle atresia; survival of MDV-treated follicles did not differ from 
controls (54±28 versus 57±20 %, ns) (Figure 4-5).   
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Figure 4-5 Follicle survival at the end of culture, in control follicles, follicles treated with 25 
nM DHT, and follicles exposed to the AR-antagonist enzalutamide (MDV). DHT-exposed 
follicles have increased follicle survival (P<0.05). Data are expressed as mean ± SD for 7-10 
independent experiments.* ≤0.01 
 
Taken together, these results document a crucial role of androgens in the in follicle 
growth and antrum formation and protection from atresia.  
At day 6 of follicle culture, we performed in vitro maturation, employing HCG and EGF 
to induce ovulation. Oocytes were denuded from cumulus cells and examined for size and 
nuclear maturation status, expressed as percentage meiosis II. Neither DHT exposure nor MDV 
treatment significantly impacted on oocyte size or nuclear maturation, as compared to control 
follicles (Figure 4-5). 
 
 
Figure 4-6 Oocyte status in control follicles, follicles treated with 25 nM DHT and follicles 
treated with MDV, with regard to size (left) and nuclear maturation (right). No difference were 
observed in either conditions. Data are expressed as mean ± SD for nuclear maturation, oocyte 
size is presented in box and whisker plots with boxes representative of the interquartile range 
and whiskers of the 5th and 95th centile, respectively, for at least 3 experiments, 14-30 oocytes 
per group.  
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At the end of culture, 21-28 follicles cultured in the presence of DHT or MDV, were 
pooled and flash frozen in liquid nitrogen, and RNA was extracted to allow for qRT-PCR 
analysis of target genes of folliculogenesis (Table 4-1). The differential gene expression for 
GDF-9, BMP-15 and AMH, with upregulated levels in DHT-treated follicles and 
downregulated levels in MDV-exposed follicles (Table 4-1) were likely to reflect changes in 
growth and maturation status in the treated follicles.  
 
Table 4-1 Relative mRNA expression of target genes of steroidogenesis and follicle 
development, expressed as DCT values (normalized against 18S ribosomal RNA) ± SD (for each 
triplicate experiment from 21-28 follicles from each treatment group pooled prior to RNA 
extraction), in follicles treated with 25 nM DHT or MDV at day 6 of culture. P values reflect 
differential expression between DHT and MDV conditions. 
 
Gene  Protein encoded DHT MDV p 
AR androgen receptor 17.0±0.0 15.5±1.1 0.07 
FSH-R follicle stimulating hormone receptor 14.9±0.9 14.9±0.8 1 
LH-R luteinizing hormone receptor 13.1±1.3 13.7±1.0 0.5 
AMH-RII anti-Müllerian hormone receptor 2 16.0±0.9 16.7±1.1 0.2 
GDF9 growth and differentiation factor 9 19.7±0.8 17.6±0.9 0.03 
BMP15 bone morphogenic protein 15 20.5±0.8 16.7±1.6 0.02 
AMH anti-Müllerian hormone 20.2±0.9 18.2±0.8 0.04 
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4.3.2 Exogenous androgen exposure and antagonism reveals an androgen receptor-
mediated autocrine feedback loop in the follicle 
To determine the impact of androgens on follicular function, we explored the effects of 
exogenous androgen administration on follicular steroidogenesis. For this we used exposure to 
DHT, the most potent androgen, that, in contrast to testosterone, cannot be converted to 
oestrogens by aromatase activity. We compared the effects of DHT on follicular steroidogenesis 
to the effects of additional administration of the highly selective androgen receptor antagonist 
enzalutamide (MDV).  
No significant changes in steroid production between the different treatment conditions 
were observed at day 2 and day 4 (Figure 4-7; Table 4-2 and 4-3). However, endogenous 
synthesis of DHEA, androstenedione and testosterone was clearly altered in DHT and 
DHT+MDV conditions at day 6 (Figure 4-7; Table 4-2 and 4-3). In response to exposure to 25 
nM of DHT, day 6 follicles showed a significantly lower endogenous androgen production 
(androstenedione + testosterone, 80±15 nmol/L vs. 208±10nmol/L in controls, p<0.01); this 
decrease was most prominent for testosterone (p<0.01) and androstenedione (p<0.01). In the 
presence of androgen receptor antagonism, DHT+MDV, this effect was reversed and follicles 
showed increased endogenous androgen production (490±256 nmol/L, P<0.05 vs. DHT-treated 
follicles).  
 
Table 4-2 Steroid hormone production by the cultured follicles, exposed to 25 nM DHT 
throughout culture. Steroids are measured by LC-MS/MS, in pooled follicle culture medium 
from 63-97 follicle incubations at day 2, 4 and 6 of culture, and normalised to 100 follicles. 
Data are expressed as mean ± SD (n=3 measurements). 
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Steroid Concentration at day 
2 (nmol/l) 
Concentration at day 
4 (nmol/l) 
Concentration at day 
6 (nmol/l) 
Progesterone (Prog) 1.4±0.2 2.0±0.2 10.9±0.5 
DHEA 2.0±1.1 2.5±2.1 3.3±1.4 
Androstenedione 
(Adione) 
0.7±0.4 3.3±0.7 18.3±5.2 
Testosterone  0.8±0.0 5.8±0.7 59.1±10.9 
DHT 37.2±13.1 54.6±15.4 66.2±28.3 
Estrone (E1) 0.89±0.4 3.5±1.7 5.8±5.1 
Estradiol (E2) 0 1.1±2.0 77.2±10.8 
 
Table 4-3  Steroid hormone production by the cultured follicles, exposed to 25 nM DHT + MDV 
throughout culture. Steroids are measured by LC-MS/MS, in pooled follicle culture medium 
from 32-50 follicle incubations at day 2, 4 and 6 of culture, and normalised to 100 follicles. 
Data are expressed as mean ± SD (n=2 measurements). 
Steroid Concentration at day 
2 (nmol/l) 
Concentration at day 
4 (nmol/l) 
Concentration at day 
6 (nmol/l) 
Progesterone (Prog) 5.5±2.4 8.7±4.6 45.2±2.3 
DHEA N/A 1.4±2.0 41.9±42.4 
Androstenedione 
(Adione) 
0 0 76.0±52.5 
Testosterone  0 4.9±1.1 371.8±246.0 
DHT 65.1±36.3 34.4±6.4 131.0±103.9 
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Estrone (E1) 0 1.49±2.1 4.3±6.1 
Estradiol (E2) 0 0 169.6±75.9 
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Figure 4-7 Steroid profile in control follicles, and follicles treated DHT 25 nM ± androgen-
receptor antagonist MDV (enzalutamide) at day 2, day 4 and day 6 of culture, measured by LC-
MS/MS in pooled conditioned medium from 32-97 follicles. Data are normalized to 100 
follicles, and expressed as mean ± SD (n=3 measurements for control and DHT, 2 experiments 
for DHT+MDV condition). The color coding refers to Figure 3-9: Progesterone (yellow), 
DHEA (light green-blue), Androstenedione (dark green-blue), Testosterone (light blue), 
Dehydrotestosterone (dark blue), Estrone (light pink) and Estradiol (dark pink). 
 
Corresponding mRNA expression analysis showed no changes in steroidogenic 
enzymes between DHT- and MDV-treated follicles, except for 17-hydroxylase (cyp17), which 
expression was decreased in MDV-treated follicles (Table 4-4). Moreover, a significant 
downregulation of androgen receptor mRNA in DHT-treated follicles (DCT 17.0±0.9 vs. 
14.7±0.0 in untreated follicles, p<0.05) and a trend toward upregulation of androgen receptor 
expression in MDV-treated follicles (DCT 15.5±1.1, p=ns vs untreated follicles) was noticed. 
 
Table 4-4 Relative mRNA expression of target genes of steroidogenesis and follicle 
development, expressed as DCT values (normalized against 18S ribosomal RNA) ± SD (for each 
triplicate experiment from 21-28 follicles from each treatment group pooled prior to RNA 
extraction), in follicles treated with 25 nM DHT or MDV at day 6 of culture. P values reflect 
differential expression between DHT and MDV conditions. 
Gene  Protein encoded DHT MDV p 
star steroidogenic acute regulatory protein 16.8±0.5 17.8±0.6 0.09 
cyp11a1 cholesterol side-chain cleavage cytochrome P450 13.1±0.3 13.8±0.6 0.1 
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These findings point towards an androgen receptor-mediated feedback circuit, at the 
level of the follicle, involved in androgen exposure in the developing follicle. 
 
4.4 Discussion 
In this study, a detailed analysis of the AR-mediated androgen effects on the 
development of follicle and oocyte was performed. The current results support a crucial role of 
androgen action in follicle growth and survival. These observations were in line with the 
previously reported follicular growth-promoting effects of androgens (Murray et al., 1998, 
Wang et al., 2001, Sen et al., 2014, Vendola et al., 1998), their role in protecting from atresia 
(Sen et al., 2014) and enhancing follicle survival (Rodrigues et al., 2015). More specifically, 
we showed that the process of antrum formation occurred earlier and to a higher extent in DHT-
treated follicles, and was impaired in AR-blocked follicles. Follicles grown in anti-androgen 
serum (Murray et al., 1998), or in the absence of FSH (Sen et al., 2014) or steroid-depleted 
follicles (Rodrigues et al., 2015), all had decreased antrum formation. These observations are 
cyp17a1 17-hydroxylase 13.1±0.1 14.0±0.2 0.002 
cyp19 Aromatase 15.1±0.9 15.6±0.8 0.5 
hsd3b1 3b-hydroxysteroid dehydrogenase 10.1±0.7 10.0±0.8 0.8 
hsd17b1 17b-hydroxysteroid dehydrogenase 11.9±0.7 11.6±0.8 0.6 
AR androgen receptor 17.0±0.0 15.5±1.1 0.07 
FSH-R follicle stimulating hormone receptor 14.9±0.9 14.9±0.8 1 
LH-R luteinizing hormone receptor 13.1±1.3 13.7±1.0 0.5 
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suggestive of AR-mediated androgen action in facilitating and optimizing antrum formation, a 
key developmental step in FSH-dependent follicle maturation.  
It has been shown that during preantral follicle development, theca-cell derived 
androgens act via the AR and via non-genomic pathways to enhance FSH-induced proliferation 
and differentiation of granulosa cells (Sen et al., 2014). In basal conditions, although AR is 
expressed, immature follicles require approximately 4 days in culture to produce sufficient 
androgens to bind cytoplasmic AR and translocate it to the nucleus where AR becomes 
transcriptionally active (Lenie and Smitz, 2009). In case of exogenous androgen 
supplementation, this process occurs earlier and AR-signalling is enhanced (Lenie and Smitz, 
2009), which might explain the promotion of growth and antrum formation observed in DHT-
treated follicles. In the present study, differential gene-expression between DHT- and MDV-
challenged follicles was not able to determine AR-responsive genes. This seems 
understandable, as only a very limited number of AR-induced genes in the ovary are currently 
known: Kit-ligand, mi-RNA125b, cyclooxygenase-2, cyclin-dependant kinase inhibitor-1/p21 
and liver receptor-homolog 1 (Prizant et al., 2014). A more thorough analysis of gene 
expression by RNA sequencing of DHT-and MDV-treated follicles could possible provide new 
AR-targets.  
Oocyte growth and maturation was not affected by AR agonist (DHT) or antagonist 
(MDV) treatment. Tarumi et al treated mouse ovarian follicles in culture with a concentration 
rate of 10-10 to 10-6 M DHT and found no effect on the capacity of the oocyte to resume meiosis 
following an ovulatory stimulus (Tarumi et al., 2014). Lenie et al found no effect on oocyte 
quality when treating mouse follicles during in vitro culture with the AR-antagonist 
hydroxyflutamide or bicalutamide (in a concentration range of 5nM - 5µM) (Lenie and Smitz, 
2009). Only the highest dose (50µM) of AR-blockade resulted in decreased oocyte meiotic 
Chapter 4       Androgen agonism and antagonism in the developing follicle   
 
 143 
maturation (Lenie and Smitz, 2009). Possibly, AR-modulating treatments have no adverse 
effect on oocytes because the AR remains inactive in the oocyte during preantral follicule 
development. In fact, AR expression was mainly found in the oocyte cytoplasm and was almost 
absent in the oocyte nucleus of preantral follicles in culture (Gill et al., 2004, Lenie and Smitz, 
2009).  
When follicles were exposed to exogenous DHT, a potent androgen that cannot be 
further converted, a compensatory mechanism was observed, resulting in diminished 
endogenous androgen secretion. This adaptation of steroid production was AR-mediated, as it 
was abolished in the presence of enzalutamide, a potent AR-antagonist, which prompted 
increased endogenous androgen synthesis. Moreover, in the presence of saturating 
concentrations of ligand, AR mRNA was downregulated. Reversely, when AR was structurally 
antagonised, follicular AR mRNA expression tended to increase. Taken together, these findings 
are indicative of a feedback circuit, at the level of the follicle, aiming to maintain sufficient AR 
stimulation in the developing follicle. The observed major up-and downregulation of androgen 
synthesis occurred independent of pituitary stimulation, and illustrates the capacity of the 
follicle to adapt, in an autonomous paracrine or autocrine way, to an endocrine challenge. The 
effects of androgens and antiandrogens on follicular steroidogenesis have not been studied in 
detail yet. Simultaneous addition of testosterone and flutamide to porcine follicles in culture 
increased progesterone synthesis, while testosterone or flutamide alone resulted in decreased 
follicular progesterone production (Duda et al., 2012). Administration of testosterone-
enanthate, in vivo and in vitro, to adult male rats, decreased basal and HCG-induced testosterone 
production in testicular Leydig cells, while AR-blockade by cyproterone acetate increased 
testicular androgen levels (Bjelic et al., 2014). In the latter study, testosterone-enanthate 
administration induced significant decrease in mRNA expression levels of the steroidogenic 
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enzymes Star, Cyp11a1, Hsd3b1, Cyp17 and Hsd17b4, while enzyme levels in cyproterone 
acetate treated animals were similar to control conditions (Bjelic et al., 2014). Flutamide and 
casodex treatment in prepubertal male rates also resulted in elevated circulating and testicular 
androgen levels; the antiandrogens stimulated testicular steroidogenesis via increased 
gonadotrophin secretion (Rulli et al., 1995). In my study, DHT and MDV modulated follicular 
steroidogenesis, but how this was achieved needs further investigation. Steroid protein changes 
were not accompanied by alterations of gene expression levels of steroidogenic enzyme or 
gonadotrophin receptor, suggesting that the steroid enzyme bioactivity was directly or 
indirectly altered in treatment conditions.  
In summary, I found that AR-mediated androgen action plays a crucial role in follicle 
growth, antrum development and protection from atresia. Exogenous androgen exposure 
resulted in decreased AR mRNA expression and reduced endogenous androgen production, 
while androgen antagonism reverted these effects. These findings are suggestive of an autocrine 
feedback loop in the follicle, involved in maintaining androgen homeostasis in the developing 
follicle.  
The murine eIVFG system represents a multiparametric assay, suitable to study AR-
mediated actions in follicle and oocyte development. This system could be used to gain more 
inside into the reproductive repercussions of endocrine disruptors with known androgenic or 
antiandrogenic effects (Diamanti-Kandarakis et al., 2009).  
 
 
 
  
 
5 Effects of increasing concentrations of 
exogenous androgens and oestrogens on 
follicular development 
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5.1 Introduction 
In clinical conditions of androgen excess, as observed in women with PCOS, preantral 
and antral follicle numbers are increased and development is arrested in the mid-antral stage, 
leading to chronic anovulation and subfertility (Jonard and Dewailly, 2004, Jayasena and 
Franks, 2014, Franks et al., 2006). PCOS follicles exhibit theca cell hypertrophy and metabolic 
dysfunction leading to hyperandrogenism. The follicle arrest is attributed to a hormonal 
imbalance between androgens and follicle-stimulating hormone (FSH), disturbing the selection 
of the dominant follicle that will ultimately ovulate (Franks, 1995). However, the direct intra-
follicular effects of androgen excess remain poorly understood. Miscarriage risk is increased, 
and oocyte quality is reduced in PCOS, and assisted reproductive interventions might be 
necessary although still ineffective in some women (Fauser et al., 2012, Legro et al., 2013, 
Urman et al., 2004).  PCOS is associated with metabolic dysfunctions, such as obesity, 
metabolic syndrome, hyperinsulinism and insulin resistance, and patients are at increased risk 
of type 2 diabetes and cardiovascular events (Goodarzi et al., 2011). On the other hand, in 
women with low ovarian follicle reserve, androgen supplementation through the androgen 
precursor DHEA or testosterone, is widely used to improve follicular development and fertility 
in assisted reproduction, although precise indications, dose and treatment duration are currently 
unknown (Sunkara et al., 2012, Narkwichean et al., 2013, Nagels et al., 2015).  
In non-human primates, in vivo exposure to exogenous androgens in early gestation 
resulted in PCOS-like ovarian dysfunction in the adult offspring, with follicle excess, 
oligomenorrhea and hyperandrogenemia (Abbott et al., 1998, Eisner et al., 2002).  During 
puberty in female primates, hyperandrogenism associated with obesity also triggered ovarian 
disturbances evocative of PCOS (McGee et al., 2014).  
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In mice, prenatal administration of DHT, specifically at day 16-18 of gestation, caused 
irregular estrous cysles, reduced preantral follicle development, decreased oculation and 
changes in adipose biology in the mature offspring (Caldwell et al., 2014). Several models of 
postnatal administration of exogenous testosterone or DHT in rodents triggered disrupted 
ovarian cyclicity, anovulation, atretic follicles, ovarian cysts, as well as hyperandrogenism, LH 
hypersecretion and insulin resistance  (McDonald and Doughty, 1972, Ota et al., 1983, Arai et 
al., 1981, Manneras et al., 2007, van Houten et al., 2012, Caldwell et al., 2014). DHEA-induced 
rodent models of hyperandrogenism showed similar ovarian phenotypes but generally there 
were no associated increased neuro-endocrine drive (Roy et al., 1962, Familiari et al., 1985, 
Anderson et al., 1992, Lai et al., 2014). High fat diet induced metabolic alterations in DHEA-
treated mice, such as impaired glucose tolerance and insulin resistance (Lai et al., 2014). Of 
note, long-term DHEA administration in mature mice did not provoke reproductive alterations 
evocative of PCOS (Caldwell et al., 2014).  
Several 2D murine follicle culture studies employed exogenous administration of 
androstenedione (Romero and Smitz, 2010, Murray et al., 1998, Wang et al., 2001, Tarumi et 
al., 2012) or testosterone (Wang et al., 2001, Romero and Smitz, 2010), and have shown 
intrafollicular convertion to estradiol. The administration of high doses of androgens to growing 
follicles in culture was accompanied by decreased oocyte meiotic maturation (androstenedione 
and testosterone at ³200 nM) (Romero and Smitz, 2010) and aberrant oocyte morphology (10-
5 M androstenedione (Tarumi et al., 2012). Because aromatisable androgens were employed in 
this studies, it was unclear whether the observed effects were related to excess androgens or 
oestrogens.  
These powerful studies provide the impetus to assess the role of androgen precursors 
more closely in the eIVFC setting and to couple this analysis with the steroid metabolome at 
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each stage of follicle development. We employed increasing doses of the clinically used 
androgen precursor DHEA, to examine the effects on follicle development, steroid metabolism 
and oocyte quality. To delineate androgen and oestrogen-mediated effects, follicles were treated 
with increased concentrations of DHT and E2. We next examined the effect of increasing DHT 
concentrations on the overall ovarian follicle dynamics, by performing follicle counting on 
cultured neonatal mouse ovaries.  
 
5.2 Methods  
5.2.1 Research strategy 
In this chapter, I will first study the direct effects of the sex steroid precursor DHEA on 
follicular development. My outcomes will include follicle survival, follicle growth, target gene 
analysis, steroid hormone production, oocyte growth and nuclear maturation status. To allow 
me to delineate the observed effects with regard to androgen or oestrogen-mediated origin, I 
will compare the outcomes with those observed in follicles treated with increased doses of the 
non-aromatisable androgen DHT and the biologically active oestrogen E2. In a next set of 
experiments, DHT administration to neonatal whole ovaries in culture is studied to delineate 
the effects of exogenous androgens on follicle progression.   
 
5.2.2 Follicle treatments  
Growing follicles were exposed to DHEA at doses of 100, 200 and 500 nM, based on 
described statistically significant effects of DHEA at 10-9 M in preantral follicles grown in FSH-
supplemented in vitro culture (Wang et al., 2001). The doses of DHT were adopted from 
published dose-response experiments (Sen et al., 2014, Wang et al., 2001), and the doses of E2 
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used were based on follicle culture experiments in primates (Ting et al., 2015). All steroids 
were diluted as appropriate in serum-free a-MEM medium. Fresh treatments, at the initial dose, 
were provided during media change at day 2 and 4 of culture.  
 
5.2.3 In vitro follicle culture and oocyte maturation  
Immature multilayered secondary follicles, with a diameter of 150-180 µm, were 
mechanically isolated from pre-pubertal 15-17 day old CD1 female mice pups, after enzymatic 
digestion using L15 medium supplemented with 0.1% DNase I and 0.1% Liberase TM, for 35-
40 minutes on a shaker in a 37°C 5% CO2 incubator. Following a recovery period during which 
the follicles stayed in maintenance medium (α-MEM Glutamax medium with 1% FBS and 0.5% 
Penicillin-Streptomycin) in the CO2 incubator, individual follicles were examined under the 
dissection microscope and encapsulated in 0.5 % alginate. Alginate-encapsulated follicles were 
placed in separate wells of a 96-well plate, each containing 100 µl culture medium, consisting 
of α-MEM Glutamax supplemented with 3 mg/ml BSA, 10 mIU/ml rFSH, 1 mg/ml fetuin and 
5 µg/ml ITS. Following plating, encapsulated follicles were imaged using Nikon Eclipse Te300 
light microscope and healthy follicles with intact alginate beads were selected for culture. 
Follicles were maintained for 6 days in 37°C 5% CO2 incubator and media change (50 µl) and 
imaging was performed on alternate days. Images were analyzed using Image J Software. As 
previously described (Xu et al., 2006a), fully-grown follicles were, at the end of day 6 of 
culture, retrieved from the alginate bead and transferred to maturation medium composed of α-
MEM Glutamax, containing 10 % FBS, 1.5 IU/mL HCG, and 5 ng/mL EGF for 16 h at 37°C, 
5 % CO2. Oocytes were denuded from the surrounding cumulus cells by treatment with 0.3 % 
hyaluronidase and gentle aspiration, and their size and quality were assessed following imaging.  
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5.2.4 Neonatal mouse ovarian culture 
Ovaries from day 5 old pups were cultures in aMEM Glutamax medium, supplemented 
with 10mIU/ml recombinant FSH, 3 mg/ml bovine serum albumin, 1 mg/ml bovine fetuib and 
5 ng/ml insulin, transferrin and selenium, in 6-well plates with tissue culture well inserts, for 4 
days in a 37°C 5%CO2 incubator, as previously described (Jin et al., 2010). Ovaries were fixed, 
dehydrated in ethanol, embedded in paraffin and stained with hematoxylin and eosin (H&E). 
Imaging and follicle counting were performed as per previously reported protocol (Bristol-
Gould et al., 2006).   
 
5.2.5 Realtime qPCR analysis  
Target genes of steroidogenesis and follicle development were analysed by real-time 
qPCR as described in Section 2.4 and according to a previously published protocol (Gathercole 
et al., 2007). To resume, at the end of culture, 18-30 pooled follicles cultured in similar 
treatment conditions (control, DHT or MDV) were flash frozen in liquid nitrogen, followed by 
RNA extraction with quality control, cDNA generation and qRT-PCR analysis using specific 
primers and probes and normalised cDNA concentrations. All reactions were normalized 
against the housekeeping genes 18S and Rpl-18. Data were expressed as dCT values. 
 
5.2.6 LC-MS/MS steroid hormone analysis  
Conditioned media of 32-83 follicles, cultured in similar conditions, were pooled at day 
2, 4 and 6 of culture. Media was stored at minus 80°C until analysis. Pooled follicle culture 
supernatant (approximately 1 ml) was placed in sylinised glass TLC tubes, and 20 µl of internal 
standard was added. Linear calibration series were prepared prior to each steroid extraction 
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(Table 2-1). Three ml of tert-butyl-methyl-ether (MTBE) was added to each sample, followed 
by vortexing and freezing for 1 hour. The upper liquid phase of the samples was then gradually 
transferred to a 96 well plate employing glass Pasteur pipettes, with alternating cycles of 
evaporation at 55°C under nitrogen. Samples were reconstituted with 125 µl of methanol: water 
mixture (50:50) and frozen at -20°C until ready for analysis. The LC-MS/MS measurements 
for DHEA 200 nM conditions were performed in triplicate, for DHEA 100 and 500 nM 
conditions in duplicate. Data were expressed as mean ± SD, and were normalised to 100 
follicles. 
 
5.2.7 Inhibin B measurement 
Inhibin B was measured by ELISA at Anhs Lab (Kit AL-107, Webster, Texas) as part 
of the collaboration established with Dr Teresa Woodruff. The assay was performed on 1/5 
diluted conditioned media. The dynamic range of the assay is 6, 12.7-1300 pg/ml, the limit of 
detection is 1.6 pg/ml. 
 
5.2.8 Statistical analysis 
Statistical analysis was performed with Prism 6 (Graph Pad) Software, using one-way 
ANOVA with post-hoc Tukey test to analyze follicle growth at each time point, Inhibin-B 
measurements, and oocyte size at day 6 between multiple treatment groups. Fisher’s exact test 
was used for survival, antrum formation and nuclear maturation status. Unpaired t-test was 
employed to analyze steroid concentrations and dCT values, between treatment and control 
conditions, for independent experiments. All experiments were independently performed at 
least in triplicate, unless otherwise specified. 
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5.3 Results 
5.3.1 The androgen precursor DHEA is converted to active sex steroids in the developing 
follicle 
In this set of experiments, I tested whether the developing follicle is a target tissue for 
metabolism of the androgen precursor DHEA to downstream active sex steroids, and to which 
extent exogenous DHEA administration interfered with endogenous steroid synthesis in the 
follicle.  
Steroid profiling by LC-MS/MS revealed that DHEA was actively metabolized by the 
follicle at all time points, including the immature stage (day 2) when endogenous 
steroidogenesis was not quantifiable yet (Figure 5-1 and Table 5-1). Supplementation with 100 
nM DHEA revealed high capacity for androgen generation (androstenedione, testosterone and 
DHT) and high levels of aromatase activity at day 4, which appeared further enhanced by day 
6 (Figure 5-1 and Table 5-1). This steroidogenic profile was accompanied by significant 
downregulation of mRNA levels of steroidogenic enzymes, AR and gonadotrophin receptors 
(Table 5-2). 
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Figure 5-1 Steroid hormone profile of follicle cultured with supplementation of 100 nM DHEA, 
measured by LC-MS/MS, in pooled follicle culture medium (32-41 follicles) at day 2, 4 and 6 
of culture, and normalised to 100 follicles. Data are expressed as mean ± SD (2 measurements). 
Upper panel: Schematic showing the steroidogenic pathway, with colour coding of the different 
steroids assessed in culture medium: Progesterone (Prog), Dehydroepiandrosterone (DHEA) 
(exogenous addition), Androstenedione (A’dione), Testosterone, Dehydrotestosterone (DHT), 
Estrone (E1) and Estradiol (E2). 
 
When increasing DHEA concentrations to 200nM, we observed a further increase in 
androgen synthesis while oestrogen generation was decreased at day 4 (p<0.01, vs. DHEA 100 
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nM). A further increase of exogenous DHEA administration to 500 nM yielded a significant 
decrease in oestrogen generation at day 6 (p<0.05; vs. control, Figure 5-2 and Table 5-1).  
 
Table 5-1 Steroid hormone production by the follicles,cultured in the presence of 100, 200 or 
500 nM DHEA measured by LC-MS/MS, in pooled follicle culture medium (32-83 follicles) at 
day 2, 4 and 6 of culture, and normalised to 100 follicles. Data are expressed as mean ± SD 
(n=3 measurements for DHEA 200 nM , duplicates for DHEA 100 and 500 nM conditions). 
Steroid Prog  DHEA  A’dione Testo- 
sterone 
DHT E1 E2 
Day 2 
DHEA 100nM 
4.8± 
2.6 
139.3± 
0.3 
43.0± 
8.8 
32.4± 
3.0 
0.85± 
1.2 
0 0.5± 
0.7 
Day 2 
DHEA 200nM 
1.0± 
0.2 
120± 
6.6 
40.8± 
2.7 
31.5± 
0.6 
4.2± 
7.4 
0 0.7± 
1.2 
Day 3 
DHEA 500nM 
2.5± 
0 
332.1± 
93 
121.5± 
27.5 
90.7± 
20.5 
0 0 0 
Day 4 
DHEA 100nM 
6.7± 
2.7 
119.9± 
30.0 
38.2± 
0.8 
72.4± 
5.2 
12.6± 
7.0 
0.3± 
0.5 
36.3± 
1.8 
Day 4 
DHEA 200nM 
1.9± 
0.2 
109± 
47.9 
34.6± 
3.2 
80.3± 
10.0 
4.9± 
4.6 
3.0± 
0.8 
4.4± 
6.3 
Day 4 
DHEA 500nM 
4.0± 
0.4 
287.9± 
44 
137.1± 
33.9 
236.2± 
22.1 
0 0 7.9± 
11.2 
Day 6 
DHEA 100nM 
27.9± 
5.7 
69.0± 
0.0 
55.2± 
10.4 
226.1± 
56.0 
23.± 
22.2 
20.7± 
14.0 
352.8± 
239.0 
Day 6 7.1± 107.2± 55.5± 206.3± 0 4.05± 150.1± 
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DHEA 200nM 0.2 2.1 2.0 15.8 6.5 9.9 
Day 6 
DHEA 500nM 
8.3± 
0 
202.5± 
57.2 
89.0± 
41.2 
288.8± 
50.6 
0 8.2± 
4.1 
87.8± 
17.5 
 
 
Figure 5-2 Effect of increasing DHEA supplementation (100, 200 and 500nM) on follicular 
steroid hormone production, compared with control conditions. Steroids were measured LC-
MS/MS, in pooled follicle culture medium (32-83 follicles), and normalised to 100 follicles. 
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Data are expressed as mean ± SD (3 measurements for control and DHEA 200 nM and 2 
measurements for DHEA 100 and 500 nM conditions. The color coding refers to Figure 5-1. 
 
When calculating the androgen/oestrogen ratio ([androstenedione + testosterone] / 
[estrone + estradiol]), to assess aromatase (cyp19a1) activity (Lenie and Smitz, 2009, Kushnir 
et al., 2009), we found that DHEA 100 nM maintained the balance observed in control follicles 
(DHEA 100 nM vs. controls on day 6: 0.9±0.3 versus 1.3±0.01, p=0.3) whereas higher DHEA 
concentrations significantly increased the androgen/oestrogen ratio (DHEA 200 nM 1.7±0.09, 
p<0.01 vs. controls; DHEA 500 nM 4.3±1, p<0.05; day 6) (Figure 5-3).  
 
 
Figure 5-3 Androgen/oestrogen ratio on day 6, for follicles treated with 100, 200 and 500 nM 
DHEA compared with untreated follicle; data are expressed as mean ± SD, * p<0.05, ** 
p<0.01 for the comparison of untreated to treated follicles.  
 
Increased androgen/oestrogen ratios are indicative of decreased aromatase activity. At 
mRNA level we found a downregulation of cyp19a1 expression with DHEA as compared to 
control follicles (Table 5-2). 
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Table 5-2 Relative mRNA expression of steroidogenic enzymes, androgen receptor and 
gonadotrophin receptors, expressed as DCT values (normalized against 18S ribosomal RNA) ± 
SD (for each triplicate experiment from 18-30 follicles from each treatment group pooled prior 
to RNA extraction). *p<0.05, ** p<0.01 for comparison of untreated versus DHEA 100, DHEA 
200 and DHEA 500nM treated conditions respectively. 
 
Gene  Protein encoded DHEA 
0nM 
DHEA 
100nM  
DHEA 
200nM 
DHEA 
500nM 
star steroidogenic acute 
regulatory protein 
15.3±0.7 18.1±1.1 
(*) 
17.0±0.3 
(*) 
15.7±2.0 
 
cyp11a1 cholesterol side-chain 
cleavage cytochrome P450 
12.5±0.1 16.5±0.2 
(**) 
12.1±0.4 13.9±0.4 
(**) 
cyp17a1 17-hydroxylase 12.8±0.0 16.0±0.5 
(**) 
12.8±0.4 14.0±0.1 
(**) 
cyp19 Aromatase 12.3±0.3 15.9±0.8 
(*) 
14.1±0.4 14.9±0.2 
(*) 
hsd3b1 3b-hydroxysteroid 
dehydrogenase 
9.6±0.3 11.4±0.5 
(**) 
9.9±0.3 10.5±0.1 
(*) 
hsd17b1 17b-hydroxysteroid 
dehydrogenase 
11.1±0.2 12.5±0.3 
(*) 
11.3±0.3 12.2±0.3 
(*) 
AR androgen receptor 14.7±0.0 18.5±1.1 
(**) 
15.6±0.8 17.2±1.7 
FSH-R follicle stimulating hormone 
receptor 
12.8±1.0 16.6±0.9 
(**) 
13.7±0.2 15.6±0.6 
(*) 
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Taken together, the experiments utilizing exogenous DHEA administration as a probe, 
showed that earlier stages of the follicle development are also capable of active sex steroid 
generation. Moreover, increased exposure to DHEA results in inhibition of aromatase activity 
and consequently decreased oestrogen production. 
 
5.3.2 Effects of increasing concentrations of exogenous androgens and oestrogens on 
follicular growth and survival  
Next we looked at the impact of the androgen precursor DHEA on follicular 
development and oocyte maturation. DHEA can be converted to androgens and subsequently 
oestrogens; therefore, we compared this to the impact of increasing doses of non-aromatisable 
DHT, the most potent androgen, and the biologically active oestrogen, E2, to dissect effects 
that were potentially conveyed by androgens and oestrogens in a distinct fashion. 
Follicle size, reflective of follicular growth, was enhanced by DHEA 100 nM ( 
P<0.0001 at day 2, 4 and 6) and DHT 25 nM (P<0.0001 at all timepoints) (Figure 5-4); 
increasing androgen exposure to DHEA 200 nM neutralized this effect and a further increase 
to DHEA 500 nM and exposure to DHT 50 nM showed the opposite effect, with a significant 
reduction in follicle size (P<0.01 at day 6 for DHEA 500nM versus control, and P<0.05 at day 
6 for DHT 50nM versus control) for (Figure 5-4). The higher dose of E2 (25 nM) increased 
follicle size significantly (P<0.01 at day 2, 4 and 6 compared with control) while 10 nM E2 had 
no effect (Figure 5-4). 
 
LH-R luteinizing hormone 
receptor 
11.7±0.2 14.8±0.5 
(**) 
12.6±1.5 13.8±0.3 
(**) 
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Figure 5-4 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus control (dotted lines) on follicle size at day 0, 2, 4 and 
6 of culture. Data (n=31-156 follicles/condition) are expressed as mean ± SD for follicle 
diameter; Stars indicate significant changes between treatment and control conditions: ** 
p<0.01,*** p<0.001, **** p< 0.0001. 
 
The differences in follicle size are mirrored by changes in inhibin-B levels, a marker of 
granulosa cell proliferation, although the differences between treatment conditions did not quite 
reach statistical significance (Figure 5-5). Of note, Inhibin-B levels tended to be increased at 
day 4 in DHEA 100nM and E2 25n treated follicles (ns), compared with control and DHT-
exposed follicles (Figure 5-5).  
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Figure 5-5 Inhibin-B levels measured by ELISA in follicles treated with DHEA (100 and 
500nM), DHT (25 and 50 nM) and E2 (25nM) at day 2, 4 and 6. Data are represented by mean 
± SD for n=6 follicles per condition. No statistical significant changes were noted. 
 
Antrum formation was significantly enhanced by DHT 25 nM while increasing DHT to 
50 nM reverted this effect (Figure 5-6). DHEA 100 nM appeared to have a beneficial effect on 
antrum formation while higher concentrations had an adverse effect, though the differences 
failed to reach significance (Figure 5-6). E2 had no effect whatsoever on antrum formation 
(Figure 5-6).  
 
 
Figure 5-6 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus control (dotted lines) on antrum formation rates at day 
0, 2, 4 and 6 of culture. Data (n=31-156 follicles/condition) are expressed as mean ± SD; 
***p< 0.001, **** p< 0.0001. 
 
Follicle survival rates increased significantly with exposure to DHEA 100 and 200 nM 
and DHT 25 nM (Figure 5-7). This effect was lost when DHEA was increased to 500 nM and 
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DHT to 50 nM (Figure 5-7). By contrast, E2 at 10 nM yielded no discernible effect on follicle 
survival, while a significant increase was observed after increasing E2 to 25 nM (Figure 5-7). 
 
 
Figure 5-7 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus control (dotted lines) on follicle survival rates at day 
0, 2, 4 and 6 of culture. Data (n=31-156 follicles/condition) are expressed as mean ± SD, * 
p<0.05, ** p<0.01. 
 
5.3.3 Effects of increasing concentrations of exogenous androgens and oestrogens on 
oocyte development and quality  
Although DHEA 200 nM-treated follicles grew light-microscopically similar to control 
follicles (Figure 5-4), oocyte development was significantly impaired, with regard to 
cytoplasmic and nuclear development, as compared with control and DHEA 100 nM-exposed 
oocytes. Oocyte size was decreased to 62±4 µm in DHT 200 nM conditions, versus 67±3 µm 
in controls (p<0.0001) and 68.0±3 µm in DHEA 100 nM oocytes (p<0.0001) (Figure 5-8). 
Meiotic resumption for DHEA 200 nM-exposed oocytes occurred in 19±16%, versus 68±11% 
in control conditions (p<0.001) and 65±7% in DHEA 100 nM oocytes (p<0.001) (Figure 5-8). 
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Figure 5-8 Oocyte status in control follicles, follicles treated with 100 nM or 200 nM DHEA, 
with regard to (A) oocyte size and (B) oocyte nuclear maturation, for 24-48 oocytes per 
condition. Data are expressed as mean ± SD for nuclear maturation, oocyte size is presented 
in box and whisker plots with boxes representative of the interquartile range and whiskers of 
the 5th and 95th centile, respectively, for at least 3 experiments, 24-48 oocytes per group. *** p 
<0.001, **** p<0.0001 
 
Oocyte size was also significantly reduced by the highest concentrations of DHEA (500 
nM) and the higher DHT concentration (50 nM) (Figure 5-9). By contrast, E2 exposure had no 
effect on oocyte size (Figure 5-9). These findings were completely mirrored when assessing 
oocyte nuclear maturation, which was significantly decreased by higher androgen 
concentrations but not affected by oestrogen administration (Figure 5-10). 
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Figure 5-9 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus untreated follicles on oocyte size following in vitro 
maturation at day 6 of culture. Data are expressed as mean ± SD for nuclear maturation, oocyte 
size is presented in box and whisker plots with boxes representative of the interquartile range 
and whiskers of the 5th and 95th centile, respectively, for at least 3 experiment, 24-48 
oocytes/condition, * p<0.05, **** p<0.0001. 
 
Figure 5-10 Effect of increasing DHEA (100, 200 and 500 nM), DHT (25 and 50 nM), and E2 
(10 and 25 nM) supplementation versus untreated follicles on oocyte nuclear maturation 
following in vitro maturation at day 6 of culture. Data (n=24-48 oocytes/condition) are 
expressed as mean ± SD  for meiosis II rate , * p<0.05, *** p<0.001, **** p<0.0001. 
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5.3.4 The impact of increasing androgen administration on ovarian follicular dynamics 
in vitro 
After demonstrating that androgens promote the transition from the pre-antral to the antral 
stage, we tested whether androgen supplementation, at increasing concentrations, influenced 
follicle progression in the whole ovary, i.e. the transition from primordial to primary, and 
primary to secondary follicle stage. We employed neonatal CD1 mouse ovarian culture, in basal 
conditions and treatment with 10-8 and 10-7 M DHT for 4 days. At the end of the culture period, 
ovaries were fixed and stained with hematoxylin and eosin (H&E) (Figure 5-11). The number 
of follicles at each developmental stage was counted and were classified as primordial (a small 
oocyte partially surrounded by granulosa cells), primary (small oocytes completely surrounded 
by granulosa cells), and secondary (larger oocyte with more than one layer of granulosa cells) 
(Table 5-3).  
DHT supplementation did not change the percentage of follicles in the primordial pool, 
indicating that androgen exposure did not interfere with the rate of primordial follicle activation 
in our system (Figure 5-12  and Table 5-3). However, observations of the follicle dynamics 
within the growing pool revealed ovaries exposed to the lowest DHT concentration (10 -8 M 
DHT) have decreased follicle atresia compared with untreated follicles (Figure 5-13). This 
effect was lost in ovaries treated with a higher DHT concentration (10-7 M DHT), which  
exhibited a decreased amount of secondary follicles, indicative of a decrease in follicle 
progression from primary to secondary stage when  compared with control ovaries and ovaries 
treated with a lower DHT concentration (Table 5-2 and Figure 5-13).  
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Figure 5-11 Morphology of untreated and DHT-treated ovaries at the end of culture. (A) 
Brightfield microscope image of a control ovary at magnification 40 ,and  (B) of a 10-7M DHT-
treated ovary. (C) Haematoxylin-eosin (HE) stained section of a control ovary and (D) of a 10-
7M DHT-treated ovary at magnification 40. Scale bar = 100 µm. The number of primordial 
follicles and total number of growing follicles was similar between both groups. 
 
Table 5-3 Follicle classes in untreated ovaries, and ovaries cultured in presence of 10-8 or 10-
7 M DHT. The number of different follicle classes was counted per ovary, and expressed as % 
of total follicles. Data represent mean ± SD (n=3 ovaries per treatment group).** p<0.01 
compared with control. 
Follicle class Untreated ovaries 10-8 M DHT 10-7 M DHT 
Primordial  91.1 ± 0.8 %  87.5 ± 2.7 % 89.1 ± 4.1 %  
Primary 3.1 ± 0.6 % 6.2 ± 2.7 % 6.9 ± 4.4 % 
Secondary  4.2 ± 0.6 % 6.5 ± 0.3 % ** 2.0 ± 0.3 % ** 
Atretic 1.2 ± 0.4 % 0.8 ± 0.1 % 1.5 ± 0.3 % 
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Figure 5-12 Follicle counts in ovaries in untreated ovaries, and ovaries cultured in presence 
of  10-7 or 10-8M DHT. The number of different follicle classes was counted per ovary, and 
expressed as % of total follicles. Data represent mean ± SD (n=3 ovaries per treatment group). 
No significant differences were observed between groups for the different follicle classes, 
except for secondary follicles, which were decreased in 10-7 M DHT ovaries and increased in 
10-8M ovaries.   
 
 
Figure 5-13 Follicle dynamics in the growing follicle pool. Primary, secondary and atretic 
follicles, expressed as percentage of total growing follicles, for untreated ovaries and ovaries 
cultured in the presence of 10-8 and 10-7M DHT. Ovaries exposed to the lower concentrations 
of DHT, have a decreased amount of atretic follicles compared with controls, while exposure 
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to higher concentrations of DHT decreased the number of secondary follicles compared with 
controls and lower doses of DHT. 
 
Taken together, the ovarian experiments pointed toward a beneficial effect of lower dose 
androgen supplementation, with regard to follicle survival, and a detrimental effect of higher 
doses of androgens on follicle progression from the primary to the secondary stage.  
 
5.4 Discussion 
Results from the current study indicate that the ovarian follicles is a target tissue for 
DHEA, from the early preantral stage onward. Low dose DHEA supplementation supported 
follicle growth and survival, without impacting on oocyte quality. Increasing DHEA exposure 
reversed these beneficial effects and were detrimental for oocyte development, estradiol 
production and follicle growth.  
Employing the sex steroid precursor DHEA as steroid substrate for developing follicles, 
steroid metabolites could be detected for up to 3 enzymatic steps downstream of DHEA, and 
confirmed effective conversion to downstream androgens and oestrogens. Sex steroid 
production occurred earlier in DHEA-treated follicles compared with non-stimulated follicles, 
indicating that in the presence of steroid substrate, immature follicles are steroidogenically 
active and capable of major androgen synthesis. In women with PCOS adrenal DHEA and 
androstenedione production is clearly elevated (Mahesh and Greenblatt, 1962, Puurunen et al., 
2009, Bardin and Lipsett, 1967), Circulating androgen precursors are likely to be metabolized 
by the small preantral PCOS follicles, thereby contributing to the ovarian hyperandrogenism. 
On the other hand, circulating DHEAS levels decrease from the age of 30 years on (Orentreich 
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et al., 1984), and lead to reduced substrate availability, which could possibly play a role in the  
decreased fecundability observed during the third decade.  
Exposure to 100 nM DHEA had positive effects on follicle growth and survival, to a 
similar extent as those observed in the presence of 25 nM DHT, and these effects were mediated 
through the AR. Importantly, androgen treatment, at the lowest dose employed, did not impair 
oocyte development. These results contribute to the scientific foundation for DHEA pre-
treatment in poor responder women undergoing IVF, in order to improve the developmental 
quality of the maturing follicles. However, the dose and duration of androgen treatment to 
achieve the folliculotrophic effects remain to be examined in detail, and depend on baseline 
circulating androgen levels in the patients.  
When treating follicles with increasing concentrations of DHEA (200 and 500 nM), 
dysfunctional follicle development occurred, primarily characterised by a robust suppression 
of oocyte growth and maturation (in 200 nM DHEA conditions), and at higher doses (500 nM 
DHEA) accompanied by decreased aromatase enzyme activity, reduced oestrogen production, 
and follicular growth stagnation. The androgen-mediated downregulation of aromatase is in 
line with reported observations in granulosa (Yang et al., 2015a) and Leydig cells (Liu et al., 
2015, Maris et al., 2015). In rats, administration of DHT was accompanied by decreased 
granulosa cell proliferation (Pradeep et al., 2002), suppressed aromatase activity and reduced 
estradiol production (Conway et al., 1990), In primates, DHT administration resulted in reduced 
FSH-stimulated oestrogen synthesis (Zeleznik et al., 2004) Previous work has shown that 
follicular steroidogenesis is modulated by the oocyte throughout development (Vanderhyden 
and Macdonald, 1998) Impaired oocyte development, manifested by meiotic incompetence, 
was associated with dysfunctional granulosa cell steroidogenesis (Goldschmit et al., 1989). In 
this study increasing DHEA exposure altered the ability of the granulosa cell to accumulate 
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estradiol in the presence of abundant substrate and at the same time suppressed oocyte 
development. This observation might suggest that oocyte-derived factors or oocyte-dependant 
signalling pathways were responsible for the decreased oestrogen output and the reduced 
follicle growth. It is clear that additional factors are involved, such as kinetics related to the 
aromatase enzyme. In fact, the enzyme might be saturated at higher concentrations of DHEA 
(200 and 500 nM) (Sohl and Guengerich, 2010). 
Previous studies reported that in vitro supplementation of mouse follicles cultures with 
androstenedione, at doses > 200 nM (Romero and Smitz, 2010) or 10-5 M (Tarumi et al., 2012) 
was associated with decreased meiotic maturation and impaired spindle formation. The toxic 
effect on the oocyte was attributed to oestrogen-excess in one study (Tarumi et al., 2014), and 
inconclusive with regard to its androgen-mediated mechanism in the other study (Romero and 
Smitz, 2010). In my study, the detrimental oocyte phenotype in DHEA 200 and 500 nM treated 
follicles was clearly attributable to increased androgen provision to the follicle.  
Although it is difficult to translate the present findings, obtained with experimental 
androgen concentrations in murine follicles, to human pathological follicle development in 
hypo-or hyperandrogenic conditions, some general implications might hold true. As others have 
highlighted before (Ware, 1982, Prizant et al., 2014), the maturing follicle is subject to a 
delicate androgen homeostasis, with a clear threshold level, beyond which the beneficial effects 
become deleterious. This means that over- replacement of DHEA in assisted reproductive 
settings, might actually harm oocyte quality and become detrimental for follicle growth. This 
study clearly underlies the need for adequately powered randomised controlled trials on DHEA 
supplementation in women with low ovarian reserve undergoing fertility work-up, which take 
into account baseline levels of circulating androgens, and aim toward restoring physiological 
DHEA concentrations.  
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On the other hand, results from the present study might provide novel insight into the 
pathophysiological mechanisms underlying antral follicle arrest observed in PCOS. I describe 
a gradual, oocyte-centred process of follicle developmental arrest. From this, I extrapolate that 
local androgen excess negatively impacts on the oocyte quality in PCOS, which in turn co-
orchestrates antral follicle arrest. This statement is rendered plausible by the fact that PCOS 
oocytes have a decreased fertilization potential, indicative of compromised oocyte quality 
(Urman et al., 2004). Moreover, the cytoplasmic oocyte development is clearly altered in 
PCOS, and reflected by a distinctly abnormal gene expression profile (Wood et al., 2007). Also, 
the follicular fluid in PCOS, contains hallmarks of metabolic dysregulation, likely to  
contributing to the impaired oocyte quality, with elevated free androgen index (Niu et al., 2014).  
To conclude, DHEA treatment in the murine eIVFG system revealed dose-dependent 
androgen-related effects on follicle growth and survival, steroid and peptide hormone secretion, 
and on the capacity of the oocyte to resume meiosis following an ovulatory stimulus. These 
experiments illustrate the U-shaped curve of androgen actions in the follicle and highlight the 
delicate androgen homeostasis required for optimal follicle development and function.  
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6.1 Final conclusions 
Androgen homeostasis in the developing follicle is crucial to ensure optimal follicle 
growth, steroidogenesis and oocyte maturation. Androgen deficiency and androgen excess are 
both detrimental for female reproductive health. In this study we have investigated androgen 
synthesis, metabolism and action in the developing murine ovarian follicle. This work has 
resulted from a collaboration between Dr. Teresa Woodruff, follicle biologist at Northwestern 
University Chicago, and Prof.Wiebke Arlt, expert in steroid metabolism at the University of 
Birmingham. This collaboration has allowed me to spend 9 months of training in the Woodruff 
Lab in 2013, as well as to be enrolled in the Frontiers in Reproduction course at the Marine 
Biology Lab in Woods Hole, Massachusetts, in 2014. These training periods have permitted me 
to set up and validate the murine encapsulated in vitro follicle culture system at the University 
of Birmingham, as a platform to study the effects of androgens in the follicle.  
 
6.1.1 Endogenous steroid production and androgen metabolism in the developing 
follicle in culture 
In this study, we showed for the first time FSH-stimulated, endogenous dynamic 
production of androgens, oestrogens and progesterone by murine follicles in 3D-culture. These 
data were derived from the combination of two powerful techniques and the expertise of two 
leading research centres. LC-MS/MS is now considered the gold standard for all steroid 
hormone measurements, which avoids the methodological limitations of platform-based 
immunoassays, known for intrinsic problems of lower sensitivity, specificity, and cross-
reactivity in case of structurally linked steroid molecules. The 3D encapsulated follicle culture 
technique closely mimics the in vivo ovarian environment, and preserves the oocyte-somatic 
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architecture, communication and paracrine signalling. Both methods have been extensively 
validated by the research groups involved in this collaboration (Xu et al., 2006a, Kreeger et al., 
2006, West-Farrell et al., 2009, Hornick et al., 2013, Skory et al., 2015, O'Reilly et al., 2014, 
Idkowiak et al., 2016). Therefore, we believe that the hormonal secretion pattern presented in 
this study phenocopies the in vivo steroid production by murine follicles. 
The endogenous steroid production observed in basal conditions was modified when 
follicles were cultured in AR-modified conditions. The addition of exogenous DHT, a potent 
AR-agonist, resulted in reduced endogenous androgen secretion and reduced AR gene 
expression. Addition of enzalutamide (MDV), a selective AR-antagonist, abolished this effect 
and led to increased endogenous androgen production. These findings indicate that the ovarian 
follicle is equipped with a sensing mechanism, coupled to an autocrine feedback loop, aiming 
to maintain adequate AR-stimulation during follicular development. This regulatory 
mechanism occurred independent of pituitary stimulation, and was not accompanied by 
alterations in gene expression for steroidogenic enzymes or gonadotrophin receptors.   
After addition of DHEA, the universal sex steroid precursor, to the follicle culture 
medium, as substrate for androgen and oestrogen generation, we observed that small preantral 
follicles, steroidogenically inactive in basal conditions, were capable of achieving high 
androgen production. Increased supplementation of DHEA substrate led to decreased oestradiol 
production by the preovulatory follicles. This suggests that the androgen-generating capacity 
of the preantral follicle may contribute to the ovarian hyperandrogenism observed in PCOS 
women, who often exhibit increased adrenal DHEA production. 
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6.1.2 Effect of increasing androgen supplementation on follicle development and oocyte 
maturation 
It has been increasingly recognized that androgens are crucially required for optimal female 
fertility, but have dual effects on follicle development and ovulation (Walters, 2015, Prizant et 
al., 2014, Lebbe and Woodruff, 2013, Gleicher et al., 2011). In our system, we demonstrated a 
U-shaped curve of androgen action in normal folliculogenesis.  
In Enzalutamide (MDV)-treated follicles, AR signalling was antagonized, which 
resulted in reduced follicle growth and significantly less follicles reaching the antral stage. 
Lower dose DHT (25 nM) supplementation resulted in earlier preantral to antral follicle 
transition, with significantly more follicles reaching the antral stage. DHT 25nM treated 
follicles were growth-advanced, and a similar effect was observed when supplementing 
follicles with a lower dose of DHEA (100nM). Low dose androgen treated follicles were better 
protected from atresia during culture and ovulated meiotically competent oocytes, at the same 
rate as untreated follicles. 
Increased androgen provision (50 nM DHT and >200 nM DHEA) to the growing 
follicles caused a robust suppression of oocyte development, manifested by a decreased size 
and a reduced capacity to resume meiosis. At the highest dose of androgen exposure employed 
in this study (50 nM DHT and 500 nM DHEA), follicle growth was impaired, and 500nM 
DHEA also decreased estradiol production. 
These findings are in agreement with, and complement previously published reports on 
the effect of androgens on follicle development (Murray et al., 1998, Romero and Smitz, 2010, 
Wang et al., 2001, Sen et al., 2014, Rodrigues et al., 2015). This body of work provides support 
for the clinical use of androgen treatment in women with androgen insufficiency seeking 
fertility, or in low ovarian reserve patients undergoing assisted reproduction. The observations 
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presented in the current study highlight the need for adequate measurements of baseline and 
follow-up circulating androgen levels during androgen treatment. In fact, androgen over-
replacement is likely to provoke detrimental effects on follicle and oocyte.  
On the other hand, this study demonstrates the oocyte-toxic effect of increased androgen 
provision to the follicle. In PCOS, ovarian hyperandrogenism might directly impact on oocyte 
development, and oocyte-derived factors or oocyte-dependent signaling pathways may 
contribute to antral follicular arrest in an autocrine fashion, independent of gonadotrophin 
stimulation. Although an increase in FSH stimulation is capable of overriding the antral follicle 
arrest in PCOS, the fertilization potential of individual PCOS oocytes is compromised (Heijnen 
et al., 2006, Urman et al., 2004). Additional factors, such as the imbalance between androgens 
and FSH, are known contributors to follicular arrest in PCOS women  (Franks, 1995). 
 
6.2 Future directions 
6.2.1 Steroid analysis in murine target tissues of sex steroid hormones 
The promising steroid hormone data obtained in this study with LC-MS/MS now allows 
to finely dissect androgen synthesis and metabolism at murine target tissue level. Dr 
Woodruff’s laboratory has developed FemKUBE, an integrated ex vivo female reproductive 
tract, consisting of 3D culture of murine ovarian follicles, fallopian tube, uterus and cervix. In 
this bioengineered system, the ovarian follicles, cultured in a microfluidic system, are triggered, 
by addition of gonadotrophins, to produce steroid hormones in a pattern that mimics the human 
menstrual cycle. That way, the reproductive organs are exposed to cyclic levels of sex steroids, 
which will allow study of normal female reproductive biology in a first time, and become a tool 
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to explore pathophysiology and substance screening. LC-MS/MS measurements of steroid 
hormone levels across the different organs would represent a major addition to this technique. 
 
6.2.2 Steroid profiling in human follicles during in vitro alginate encapsulated growth  
The transfer of the present results to the human follicular physiological and 
pathophysiological development, is hindered by the use of a murine model. However, the 
eIVFG system was able to sustain human follicle growth, steroidogenesis and oocyte 
development (Xu et al., 2009). This methodology is a highly clinical relevant area of research, 
and developed as a fertility preserving tool for female cancer patients facing gonadotoxic 
treatments (Jeruss and Woodruff, 2009). Importantly, human ovarian follicles grown in vitro 
were capable of sustained steroid hormone production, in a pattern phenocopying the entire 
female menstrual cycle (Skory et al., 2015). Until present, all hormone measurements have been 
performed using immunoassays, and although important knowledge has been gained through 
this valuable studies, a modern mass spectrometry-based approach is warranted for this 
promising technique to excel.   
Also, in future experiments, ovarian tissue from healthy women, women with PCOS 
and patients with low ovarian reserve could be employed to unravel the role of androgens in 
human ovarian health and disease.  
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